* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download study of the human humoral immune response against rotavirus
Survey
Document related concepts
Vaccination wikipedia , lookup
DNA vaccination wikipedia , lookup
Immunocontraception wikipedia , lookup
Immune system wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Lymphopoiesis wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Adaptive immune system wikipedia , lookup
Molecular mimicry wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Innate immune system wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Transcript
STUDY OF THE HUMAN HUMORAL IMMUNE RESPONSE AGAINST ROTAVIRUS DANIEL FELIPE HERRERA RODRÍGUEZ THESIS Presented as a partial requirement to opt for the Doctoral degree in Biological Sciences Tutors Juana Ángel Manuel Antonio Franco Pontificia Universidad Javeriana School of Sciences Doctoral Program in Biological Sciences Bogotá, D.C. Colombia January 2014 NOTA DE ADVERTENCIA “La Universidad no se hace responsable por los conceptos emitidos por sus estudiantes en sus trabajos de tesis. Sólo velará porque no se publique nada contrario al dogma y a la moral católica y porque las tesis no contengan ataques personales contra persona alguna, antes bien que se vea en ellas anhelo de buscar la verdad y la justicia”. Artículo 23 de la Resolución No. 13 de julio de 1946. Study of the human humoral immune response against rotavirus Daniel Felipe Herrera Rodríguez APPROVED Manuel Antonio Franco Cortés, MD, PhD Tutor Juanita Ángel Uribe, MD, PhD Tutor John Mario González Escobar, MD, PhD Jury Carlos Narváez Rojas, MD, PhD Jury Gagandeep Kang, MBBS, MD, PhD Jury Gloria Vásquez Duque, MD, PhD Jury Deborah Dunn-Walters, PhD Jury Study of the human humoral immune response against rotavirus Daniel Felipe Herrera Rodríguez Ingrid Schuler, Biol, PhD Academic Dean School of Sciences Manuel Antonio Franco, MD, PhD Graduate Programs Director School of Sciences TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................... 10 2. BACKGROUND ................................................................................................. 14 2.1 ROTAVIRUS ................................................................................................ 14 2.1.1 Structure ................................................................................................ 14 2.1.2 Classification .......................................................................................... 15 2.1.3 Epidemiology ......................................................................................... 16 2.1.4 Life cycle ................................................................................................ 17 2.1.5 Clinical manifestations and pathophysiology in humans ........................ 19 2.2 IMMUNE RESPONSE AGAINST ROTAVIRUS ........................................... 20 2.2.1 Innate immunity ..................................................................................... 20 2.2.2 T cell response ...................................................................................... 21 2.2.3 B cell response ...................................................................................... 23 2.2.4 Correlates of protection after natural infection in children ...................... 23 2.2.5 Rotavirus vaccines ................................................................................. 24 2.2.6 Correlates of protection after RV vaccination in children ....................... 27 2.3 THE MUCOSAL IMMUNE SYSTEM ............................................................ 28 2.3.1 Induction of the mucosal immune response mediated by B cells in the intestine .......................................................................................................... 28 2.3.2 The polymeric immunoglobulin receptor ................................................ 29 2.3.3 Secretory IgA ......................................................................................... 31 2.3.4 RV secretory IgA (RV-SIgA) in serum .................................................... 32 2.4 B CELLS AND THE MAINTENANCE OF SEROLOGICAL MEMORY........ 33 2.4.1 Phenotype of circulating B cells and current controversies .................... 33 2.4.2 RV-specific B cells and how they are studied ........................................ 37 2.4.3 The serological memory and the theories of how it is maintained .......... 39 2.4.4 Rituximab and its effect on memory B cells and serological memory .... 40 3. HYPOTHESES .................................................................................................. 43 4. OBJECTIVES .................................................................................................... 43 5. MATERIALS AND METHODS .......................................................................... 44 6. JOURNAL ARTICLES ....................................................................................... 44 7. GENERAL DISCUSSION AND CONCLUSIONS .............................................. 48 8. PERSPECTIVES ............................................................................................... 56 9. APPENDIX......................................................................................................... 57 9.1 DETAILED MATERIALS AND METHODS .................................................. 57 9.1.1 Subjects and sample processing: children with gastroenteritis, children vaccinated with RIX4414, and placebo recipient children ............................... 57 9.1.2 ELISA for measuring plasma RV secretory immunoglobulin .................. 58 9.1.3 ELISA for measuring total plasma secretory IgA ................................... 59 9.1.4 ELISA for measuring plasma RV-IgM .................................................... 59 9.1.5 Recombinant human SC and competitive binding assays ..................... 59 9.1.6 Subjects, sample collection and processing: patients with autoimmune diseases and healthy volunteers ..................................................................... 60 9.1.7 Production of fluorescent virus like particles (VLPs) .............................. 61 9.1.8 Biotinylated - TT antigen ........................................................................ 61 9.1.9 Flow cytometry assays ........................................................................... 61 9.1.10 Measurement of total immunoglobulins (IgA, IgG and IgM) and IgM Rheumatoid Factor ......................................................................................... 63 9.1.11 ELISAs for detection of RV-specific IgA, IgG, and IgG1 and TT-specific IgG in plasma.................................................................................................. 63 9.1.12 Measurement of anti-CCP and anti-dsDNA autoantibodies (IgG isotype) ........................................................................................................................ 63 9.1.13 Statistical analyses .............................................................................. 64 9.2 Figure A1: Schematic representation of the ELISA for measuring plasma RV secretory immunoglobulin ........................................................... 65 9.3 Figure A2: Schematic representation of the ELISA for measuring total plasma secretory IgA ....................................................................................... 66 9.4 Relevant data not shown from the first article: “Rotavirus Specific Plasma Secretory Immunoglobulin in Children with Acute Gastroenteritis and Children Vaccinated with an Attenuated Human Rotavirus Vaccine” .. 67 9.5 Relevant data not shown from the second article: “Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab” ............................................ 68 9.6 Journal paper: “Circulating human rotavirus specific CD4 T cells identified with a class II tetramer express the intestinal homing receptors α4β7 and CCR9” ............................................................................................... 68 10. REFERENCES ................................................................................................ 69 ABSTRACT Rotavirus (RV) vaccines are less efficacious in countries with high mortality rates by this pathogen; the lack of a widely accepted immunological correlate of protection hinders the development of new RV vaccines. Secretory immunoglobulin (SIg) in serum has been proposed to indirectly measure intestinal Ig. Therefore, plasma RV-SIg was evaluated by ELISA in 50 children vaccinated with RIX4414 and 62 placebo recipients and correlated with protection when both groups were analyzed jointly. RV-SIg may serve as a valuable correlate of protection for RV vaccines. A thorough understanding of the relationship between memory B cells (mBc) and serological memory contributes to identify useful correlates of protection. RV-mBc are enriched in mBc subpopulations associated with certain autoimmune diseases pathogenesis. In patients treated with Rituximab (RTX), some autoantibodies (auto-Abs) decrease, but pathogen-specific IgG remain unchanged; thus, serological memory may depend on the type of antigen and/or Ab isotype evaluated. Circulating total, RV-, and tetanus toxoid (TT)-specific mBc and Abs, and some auto-Abs were evaluated in patients with autoimmunity before and after RTX therapy. Following treatment, total, RV-, and TT-mBc decreased significantly. Total IgM levels were significantly lower than total IgA and IgG levels, and the auto-Abs measured were significantly diminished. In contrast, RV- and TT-Abs remained unchanged. In conclusion, serological memory against RV and TT seem to be maintained by long-lived plasma cells (PC), not affected by RTX, and an important proportion of total IgM and serological memory against some autoantigens seem to be maintained by short-lived PC, dependent on mBc precursors depleted by RTX. RESUMEN Las vacunas contra RV son menos eficaces en países con una alta mortalidad por este patógeno; la falta de un correlato de protección inmunológico adecuado dificulta desarrollar nuevas vacunas. La inmunoglobulina secretora (SIg) circulante evalúa indirectamente la Ig intestinal. La RV-SIg sérica fue medida por ELISA en 50 niños vacunados con RIX4414 y 62 niños que recibieron placebo, y correlacionó con protección cuando los grupos se analizaron conjuntamente. La RV-SIg podría ser un correlato de protección valioso. Entender la relación entre las células B de memoria (cBm) y la memoria serológica contribuye a identificar correlatos de protección. Las RV-cBm están enriquecidas en subpoblaciones asociadas con algunas enfermedades autoinmunes. En pacientes tratados con Rituximab (RTX), ciertos autoanticuerpos (autoAcs) disminuyen, pero no la IgG específica de patógenos; entonces, la memoria serológica podría depender del antígeno y/o isotipo del Ac estudiado. Se evaluaron las cBm y los Acs totales y específicos de RV y toxoide tetánico (TT) circulantes y algunos autoAcs en pacientes con autoinmunidad antes y después de recibir RTX. Luego del tratamiento, las cBm totales y específicas de RV y TT disminuyeron significativamente. La IgM total se redujo significativamente más que la IgA e IgG total, así como los autoAcs evaluados, mientras que los Acs específicos de RV y TT permanecieron sin cambios. En conclusión, la memoria serológica contra RV y TT depende probablemente de células plasmáticas de larga vida; además, buena parte de la IgM total y la memoria serológica contra algunos autoantígenos es probablemente mantenida por células plasmáticas de corta vida dependientes de las cBm. Abbreviations RV SIg Ig RVmBc Bc RTX Abs TT PC GE CI WHO Dose 1 Dose 2 pIgR SC dsRNA VP NSP DLP TLP Ca++ ER ENS PAMPs PRRs IEC TLRs GALT CSR GC pIgs dsDNA RF rhSC PBMC Rotavirus Secretory immunoglobulin Immunoglobulin Rotavirus-specific Memory B cells B cells Rituximab Antibodies Tetanus toxoid Plasma cells Gastroenteritis Confidence interval World Health Organization D1 D2 Polymeric immunoglobulin receptor Secretory component Double-stranded RNA Viral protein Non-structural protein Double layered particle Triple layered particle Calcium Endoplasmic reticulum Enteric nervous system Pathogen-associated molecular patterns Pattern recognition receptors Intestinal epithelial cells Toll-like receptors Gut-associated lymphoid tissue Class-switch recombination Germinal center Polymeric immunoglobulins Double-stranded DNA Rheumatoid factor Recombinant human secretory component Peripheral blood mononuclear cells 1. INTRODUCTION RV is the main cause of severe gastroenteritis (GE) in young children. In 2008, before the introduction of routine immunization, it was estimated that RV GE caused 453,000 deaths (CI 95% 420,000 – 494,000) in children under the age of five, corresponding to 5% of children’s deaths of all causes and 37% of those attributable to GE yearly worldwide in this age group [1]. In Colombia it was estimated that without vaccination the annual number of medical visits and deaths by RV GE in children under 2 years would be 105,378 and 470 (CI 95% 295 - 560), respectively [2]. The burden of RV disease is not limited to the underdeveloped world; before implementation of the RV vaccine program in the United States, 50% of hospitalized children and 50% of those in the emergency department with acute GE were infected with RV [3]. This implied that the establishment of public health measures, such as improvements in water supply, hygiene, and sanitation, was insufficient and effective vaccines were necessary [4]. Two RV vaccines are commercially available and recommended for infants worldwide by the WHO [5]: RotarixTM (GlaxoSmithKline Biologicals) and RotaTeqTM (Merk and Co. Inc.). Nonetheless, both vaccines are less efficacious (39% to 77%) in some low-income countries in Africa and Asia [6], where 85% of worldwide mortality occurs [7]. This drawback and the difficulty, given by the cost, to include RV vaccines in the national immunization programs of the poorest countries make it necessary to improve them or to develop new RV vaccines [8, 9]. The achievement of this objective implies several difficulties, of which the lack of a widely accepted immunological correlate of protection is very important. In fact, all RV vaccine efficacy trials have had a clinical endpoint (protection against RVinduced moderate to severe diarrhea and/or mortality); these studies can be carried out in a limited array of settings and are very expensive. The use of a validated correlate of protection as a surrogate endpoint would contribute to the faster development of a new generation of RV vaccines and the assessment of its efficacy in a wider number of settings. It would also facilitate the evaluation of immune interference with other vaccines and support for guiding vaccination programs and regulatory decisions. With the present work we aimed to contribute to the correlates of protection for RV vaccines field in two ways: 1. We propose a new potential correlate of protection for RV vaccines. 2. In an effort to thoroughly understand the relationship between mBc and serological memory, we describe the association between RV-mBc and serological memory in humans, capitalizing the unique opportunity offered by 10 patients with autoimmune diseases treated with Rituximab (RTX). These findings are presented in two papers in the journal’s articles section. Currently, serum RV-specific IgA (RV-IgA) measured shortly after natural infection or vaccination represents the best practically measured correlate of protection against RV GE in humans [10, 11]. This is probably because serum RV-IgA transiently reflects the intestinal RV-IgA. Nevertheless, some vaccinees with serum RV-IgA develop mild RV GE, and protection provided by the vaccines can be higher or lower than the levels predicted by serum RV-IgA detected in vaccinees [12, 13]. RV induces an intestinal and systemic immune response, the latter most probably related to the antigenemia and viremia detected in acutely infected animals and children [14, 15]. Even so, RV preferentially replicates in the intestine, and local mucosal immunity is thought to be essential in human RV immunity [13]. In fact, during an acute RV infection in children, circulating IgD- RV-specific B cells (Bc) express intestinal-homing receptors (47+, CCR9+) and, as a result, probably reflect mucosal immunity [16]. Consistent with this finding, in a previous double blind trial of the attenuated RIX4414 human RV vaccine (which contains the same vaccine strain virus found in the Rotarix formulation), correlations between protection from disease and frequencies of RV-memory IgD-CD27+47+CCR9+ circulating Bc measured after dose 1 (D1) and levels of plasma RV-IgA after dose 2 (D2) were found. However, the correlation coefficients for both tests were low, suggesting that other factors are important in explaining protection from disease [17]. Moreover, it is generally accepted that neutralizing Abs against the RV infecting strain present in the intestine provide protection [18]; however, assessment of intestinal fluid after RV vaccination is impractical and measurement of RV-IgA in feces is subject to several problems [12]. SIg in serum has been proposed as an alternative method for indirectly measuring intestinal Ig [19]. Polymeric IgA and IgM are recognized by the polymeric immunoglobulin receptor (pIgR) on the basolateral membrane of the mucosal epithelial cells [20]. This complex is endocytosed and transcytosed to the apical membrane, where it is cleaved and part of it (the secretory component [SC]) remains attached to the Ig, forming SIg, which may retro-transcytose across epithelial cells and eventually enter the circulation [20]. RV-SIg has been detected in serum of children with acute RV infection [19, 21], and it correlated with the amounts detected in duodenal fluid one week after the infection [22]. Based on these precedents, we sought to confirm the presence of plasma RV-SIg in children with natural RV infection and to determine if circulating RV-SIg could reflect more precisely the intestinal protective immune response 11 induced by the RIX4414 RV vaccine, and be a better correlate of protection than circulating RV-IgA after vaccination. Recently, it was confirmed in an IgA deficient mouse model that this Ig is very important for the intestinal primary immune response against RV, and that it has a fundamental role in the protection against RV reinfection of the intestine. Even so, IgA has a minor role in the resolution of systemic primary RV infection and seems to be dispensable for clearance of antigenemia after reexposure to the virus. These results suggest that circulating RV- IgG and/or IgM are important in the clearance of the virus from the systemic compartment [23]. The observed pivotal role of Abs as mediators of protection against RV reinfection in mice [23, 24], and their correlation with protection in humans [11, 25-27], indicate that Bc are crucial for the immune response against RV infection. Bc are also important for the clearance of a primary RV infection in mice [24] and for the removal of the virus from the systemic circulation [28]. Furthermore, children with B and/or T immunodeficiencies become chronically infected with RV [29]. A better understanding of the frequencies of antigen-specific mBc subsets and their association with serological memory –defined as the persistence of Abs levels in the absence of the antigen [30]– is also important to identify valuable correlates of protection for vaccines [31, 32]. The mechanisms that lead to the maintenance of serological memory in healthy individuals are still unclear and, in general, have been studied only with regard to the IgG isotype and for a limited number of antigens. Pathogen-specific protective IgG levels following natural infection or vaccination can persist for decades, or in some cases for a lifetime, without any apparent role of the antigen [30]. In healthy adults, serological memory seems to be maintained by long-lived PC [30, 33], and it has been proposed that PC and mBc are independently regulated populations [34]. Nonetheless, under certain circumstances, such as autoimmunity, short-lived PC, which need to be constantly replenished by mBc, may also be a factor in the maintenance of serological memory [35]. Thus, in conditions where short-lived PC contribute to serological memory, a correlation between numbers of circulating antigen-specific mBc and levels of antigen-specific serological memory is expected [36]. Serological memory has been assessed in patients with autoimmunity and treated with RTX [37-40], an anti-CD20 monoclonal Ab that depletes Bc but does not affect PC. In such patients, some auto-Abs decrease after treatment [39], but other autoAbs [37] and pathogen specific IgG Abs [37, 38, 40] do not decrease. These findings suggest that the mechanism of maintenance of serological memory could depend on the type of antigen and/or Ab isotype evaluated, particularly in patients with autoimmune diseases. However, antigen-specific mBc and antigen-specific 12 Abs of different isotypes have not been simultaneously assessed in patients that received Bc depletion therapy with RTX. Circulating RV-specific Bc, compared to TT-specific Bc, seem to be peculiar because a subgroup of naïve Bc bind RV-virus like particles (VLPs) [41, 42], and because RV-mBc are enriched in the CD27+IgM+ and in the CD27-IgG+ mBc subsets [43, 44]. Additionally, CD27+IgA+ RV-mBc correlated positively with RV-IgA plasma levels, but a correlation between CD27+IgG+ RV-mBc and RV-IgG in plasma was absent. In contrast, CD27+IgG+ TT-mBc correlated with TT-IgG plasma levels [43]. Therefore, the relationship of RV-mBc with serological memory seems to be somewhat different from that of TT-mBc, making it a relevant model to study the association between mBc and serological memory. CD27+IgD+IgM+ mBc (IgM+ mBc) and CD27- mBc, the mBc subsets in which RVmBc are enriched, are relevant in autoimmune diseases pathogenesis. For example, IgM+ mBc are decreased in patients with systemic lupus erythematosus (SLE) [45], rheumatoid arthritis (RA) [46], and Sjögren’s Syndrome [47]. In fact, there is a negative correlation between the circulating number of IgM+ mBc and auto-Abs levels and disease activity in SLE patients [45]. In contrast, circulating CD27- mBc are increased in SLE patients and positively correlate with disease activity [48]. Given that RV-mBc are enriched in these subpopulations, we hypothesized that RV-mBc are distributed in a distinct manner in patients with autoimmune diseases and are therefore related to serological memory in a peculiar way, dissimilar from the proposed manner for pathogens studied thus far. 13 2. BACKGROUND 2.1 ROTAVIRUS 2.1.1 Structure RVs are non-enveloped double-stranded RNA (dsRNA) viruses that belong to the Reoviridae family, with a characteristic morphology of wheel-like particles (as seen by electron microscopy) from which their name is derived. The mature virus particle has icosahedral symmetry with a diameter of about 100 nm, including the spikes [49]. The viral genome is constituted by 11 segments of dsRNA encoding six structural proteins (VPs), which provide structural support and mediate cell entry, and six non-structural proteins (NSPs) (Figure 1), which are only produced by RVs in infected cells and are implicated in viral replication, morphogenesis, and evasion of the host immune response. Each segment encodes a single protein, except segment 11 that encodes two proteins (NSP5 and NSP6, in some viral strains) (Figure 1) [49]. The infective virion consists of three concentric protein layers that surround and cover its genome. The inner layer or core is constituted by 120 copies of VP2 (scaffolding protein), and anchored to each segment of dsRNA are VP1 (RNAdependent RNA-polymerase) and VP3 (guanylyltransferase and methylase), both proteins implicated in genome transcription. The middle layer surrounds the core and it is composed of VP6 organized as pentamers and hexamers, giving rise to 132 channels of three classes that play an important role in the entrance of compounds to the capsid and the export of newly formed mRNAs [50]. VP6 is the most abundant structural protein and it is assembled to form double layered particles (DLPs), which are non-infectious but transcriptionally active. The outermost layer, part of the entire infectious triple layered particle (TLP), is made up of the calcium-binding glycoprotein VP7, that forms the smooth surface of the virion, and the protease-sensitive VP4 spikes, involved in cellular attachment during infection. [51]. 14 Figure 1. Rotavirus genome and structure. a. SDS-PAGE showing rotavirus RNA segments and gene-protein designations. b. Surface of the mature rotavirus particle (TLP). Arrows denote the three types of aqueous channels labeled I, II and III. Three protein layers constitute the viral particle. The external layer is made up of VP7 (yellow) and VP4 (red), which are neutralization antigens and determine the G and P serotypes, respectively. c. Cut-away of the TLP structure showing the internal structural characteristics. The middle layer is made of VP6, which is the major structural protein (blue). The core surrounds the viral genome and contains the scaffolding protein VP2 (green), the RNA-dependent RNA polymerase VP1, and VP3 (red). Figure obtained from [49]. 2.1.2 Classification RV strains have a high genomic and antigenic diversity that can be classified into three different specificities: group, subgroup and serotype [12]. The VP6 protein, the major capsid viral protein, confers the group specificity; 7 groups (A-G) have been established according to antigenic properties and seroepidemiological studies. RVs belonging to groups A, B, and C are implicated in human and animal infections, whereas members of groups D-G have been found only in animal hosts. Group A viruses are certainly the most common in human infections; thus, this group is considered a relevant target for vaccination. Human group A RVs are subdivided into three distinct genogroups based on shared features among three prototype strains named Wa, DS-1, and AU-1. Cross-reactive antigenic epitopes also present in the VP6 protein confers this subgroup specificity: subgroups I, II, I/II, and non-I/non-II. G2 and G8 human RVs belong to subgroup I, whereas most G1, G3, G4, and G9 human RVs belong to subgroup II [52]. At present, this classification is less used. The serotype classification is based on the antigenic specificity of the outer capsid proteins VP7 and VP4. Given that the genes encoding these proteins can segregate independently, a dual nomenclature system was established in which the serotypes determined by the VP7 protein (termed G serotypes because VP7 is a glycoprotein) and the VP4 serotypes (designated P serotypes since VP4 is protease-sensitive) are considered. There are approximately 27 G and 14 P serotypes with G1, G2, G3, G4, and G9 comprising more than 90% of all human G serotypes detected in the world. The P1 serotype accounts for more than 91% of circulating human RV strains [12]. In addition to serotypes, nucleic acid sequence similarity analyses result in genotypes. A complete equivalence between G serotypes and genotypes has been described. In contrast, an absolute association between P serotypes and P genotypes does not exist. There are at least 35 P genotypes, and the nomenclature most frequently used denotes them in brackets. Of note, P[8] and P[4] genotypes correspond to two subtypes (P1A and P1B) of P1 serotype. In 15 summary, the rotavirus classification working group recommended the following nomenclature: first, the G serotype/genotype, “X” if it is unknown, followed by the P serotype, and finally the P genotype denoted in brackets [53]. The most common G and P type associations worldwide related with RV infection in humans are G1P1A[8], G2P1B[4], G3P1A[8], G4P1A[8] and G9P1A[8] [12]. The generation of new antigenic-distinct virus strains depends on point mutations, gene rearrangements, and reassortments generated when viruses of the same group co-infect the same cell [54]. 2.1.3 Epidemiology Historically, RV has been the dominant etiological agent of severe GE in children under 5 years of age worldwide. The United States Food and Drug Administration approved two live oral RV vaccines, RotarixTM and RotaTeqTM, in 2005 and 2008. Before the introduction of routine immunization with these vaccines, it was estimated that RV GE caused 453,000 deaths (CI 95% 420,000 – 494,000) in children under the age of five, corresponding to 5% of children’s deaths of all causes and 37% of those attributable to GE yearly worldwide in this age group. More than 50% of fatal cases attributable to RV occur in only five countries: India (22%), Nigeria (9%), Pakistan (9%), Democratic Republic of Congo (7%) and Ethiopia (6%) [1]. In the United States, norovirus has surpassed RV as the main cause of GE in medical visits after vaccine implementation [55]. Nevertheless, RV is still the most important etiological agent responsible for severe GE in developing countries that have not introduced RV vaccines [56]. In Colombia, approximately 1,300 children younger than 1 year die annually due to acute GE, which accounts for 10% of deaths in that age group [2]. A study conducted in Bogotá, Cali, and Barranquilla between December 2003 and November 2004 showed that in children under the age of 5 years RV infection caused 1 death per 2,000 children; 16 hospitalizations and 631 medical visits per 1,000 children [57]. Recently, it was estimated that without vaccination the annual number of medical visits and deaths by RV GE in children under 2 years would be 105,378 and 470 (CI 95% 295 - 560), respectively [2]. The pattern of RV transmission depends on the geographic zone considered. In tropical zones it has a year round pattern, although it seems to be higher in the cooler months. In temperate zones the rate of infections is higher in autumn and winter, and in the United States a traditional spatiotemporal dynamic of RV activity initiating in the southwest in late fall and ending in the northeast 3 months later was defined. However, it seems that vaccine implementation has changed this pattern, which will have a probable impact in epidemic dynamics [58, 59]. 16 RV strain distribution varies with time, season, and location. As mentioned above, the most frequent strains worldwide are G1P1A[8], G2P1B[4], G3P1A[8], G4P1A[8] and G9P1A[8], which account for more than 90% of RV disease burden [60]. In some areas of India, Brazil, and Africa, RV strains G9P[6], G5, and G8, respectively, are more prevalent than in other parts of the world [61]. However, the greatest variability is observed in Africa, where additional strains circulate with unusual G-P compositions and in some cases strains of a probable zoonotic origin [62]. RV transmission occurs through the fecal-oral route or the respiratory tract, by person-to-person contact or by contact with contaminated surfaces and objects. Highly infectious virus is excreted in high quantities in feces of infected people as early as 2 days before and up to 10 days after the onset of diarrhea. The inoculum required to infect a homologous host is, indeed, very small: 10 or less from the 1010 RV particles/gram of feces. In contrast, to infect a heterologous host a high concentration is required; the infection generates small amounts of progeny virus and is usually asymptomatic. Despite RV infection occurring in other mammals, transmission of animal RVs to humans is considered to be infrequent, due to hostrange restriction, and likely asymptomatic. Therefore, animals are improbable reservoirs for human viral strains [49]. 2.1.4 Life cycle RV infection depends on the recognition of specific receptors on the cell surface; therefore, the receptors define the viral tropism and pathogenesis. In vivo, RV replicates almost exclusively in mature enterocytes of intestinal villi tips of the small intestine. In contrast, in vitro RV seems to have a wider tissue tropism: cell lines from kidney, breast, stomach, bone, and lung, among others, are susceptible to RV infection [63]. RV strains have different cell-binding requirements. Some strains, usually from animals, rely on sialic acid for their initial attachment, whereas for most human strains it is unrequired. Thus, other cell surface proteins have been implicated as early attachment molecules, including GM1 and GM3 gangliosides, and the integrin 21, which binds to the VP5 fragment of VP4. After recognition of primary receptors, RVs bind to one or more secondary receptors, such as heat shock protein HSC70, or through VP7 to the integrins 42, 41, and V1. These initial recognition steps may occur within specific membrane microdomains enriched in cholesterol and sphingolipids, called rafts, which seem to be responsible for the susceptibility of a particular cell to RV infection. After attachment to the cell surface, RV enters the cell either via direct membrane penetration or endocytosis. Low Ca++ concentrations in the endosomes promote the loss of the outer protein layer, and transcriptionally active DLPs are then 17 released into the cytoplasm. This process requires the virus activation by trypsin cleavage of the VP4 protein into VP5 and VP8 polypeptide domains, which conduces to a productive infection. Non-trypsin activated RVs are endocytosed and transported to lysosomes, resulting in an abortive infection. In transcriptionally active DLPs, the dsRNA is used as template and the VP1 protein produces positive sense, capped, non-polyadenylated transcripts. These transcripts are used as templates for translation and for strand synthesis in the replication process to generate a complete set of eleven dsRNA genome segments. RNA molecules are ejected from DLPs into the cytoplasm through a series of channels. After translation, the structural proteins VP1, VP2, VP3, and VP6; the nonstructural proteins NSP2 and NSP5, and RNA molecules aggregate in viral inclusion bodies (viroplasms) located in the cytoplasm. In these viroplasms take place replication, RNA packaging, and DLPs assembly. Viral proteins VP4, VP7, NSP1, NSP3, and NSP4 are not present in the viroplasm but are necessary for other processes. NSP4 is attached to the endoplasmic reticulum (ER) membrane and binds VP6 in DLPs to facilitate its translocation to the intraluminal side of the ER. There, DLPs are covered with VP7 and VP4 (by an incompletely understood mechanism) to give rise to TLPs, which will be expulsed from the ER and subsequently from the cell before or during cell lysis (Figure 2) [64]. Figure 2. Schematic representation of the RV life cycle. During entry into the cell, the outermost protein layer is lost. Polymerase complexes in the core of the DLP produce viral mRNAs. Viral proteins and RNAs aggregate in viroplasms, where particle assembly is carried out. Interaction of newly formed polymerase complexes with the core capsid protein initiates genome replication, followed by addition of VP6. DLPs then enter the endoplasmic reticulum via NSP4 and obtain their outer capsid. After release through lysis or microvesicular trafficking, VP4 must be 18 cleaved by trypsin-like proteases in the intestinal lumen to activate the virus and start subsequent rounds of infection. Figure obtained from [65]. 2.1.5 Clinical manifestations and pathophysiology in humans After RV uptake, the incubation period lasts around 1 to 3 days prior to the onset of vomiting and diarrhea, the main symptoms of RV disease. The first clinical manifestation is usually vomiting, which appears abruptly and causes rapid dehydration and impedes oral rehydration. Diarrhea appears 1 to 2 days after vomiting, is usually self-limited, and lasts 4 to 8 days. Other clinical events related with RV infection include fever (in 30% of cases) and abdominal distress; these clinical symptoms are generally observed in children rather than in adults. Severe dehydration and electrolyte alterations are the most serious consequences of RV infection and occur more frequently in young children. They are responsible for the majority of fatal cases, which usually occur 1 to 3 days after onset of symptoms in conditions of poor access to medical attention [64]. Some reports also associate respiratory signs such as cough, pharyngitis, otitis media, and pneumonia with RV infection, but these findings require further study. In spite of the frequent RV antigenemia and viremia, extra-intestinal clinical manifestations are rare but include encephalitis and sterile meningitis, Kawasaki syndrome, sudden infant death syndrome, hepatic abscesses, exanthema, nonfebrile seizures, and pancreatitis [14]. Under particular conditions, RV infection can compromise the liver, lung, kidney, spleen, heart, and mesenteric lymph nodes [66, 67]. Recently, it has been reported that in immunocompetent children RV infection is frequently associated with elevated serum hepatic transaminases [68], pointing to a clinical significance of the frequently observed antigenemia and viremia [14]. The RV viral capsid structure makes it a very stable virus. This facilitates fecal-oral transmission and proper delivery into the small intestine, where it infects the nondividing mature enterocytes in the mid and upper part of the villi. Histopathological disturbances related with RV infection are almost restricted to this site and are characterized by shortening and atrophy of villi, augmented crypt depth, flattening of epithelial cells, distended ER, mitochondrial swelling, and increment of inflammatory cells in the lamina propria [69]. Likewise, postmortem studies on tissue specimens from children with RV illness showed degenerative changes in the epithelium, inflammatory infiltrates in the lamina propria, and hyperplasia of Peyer’s patches. Nevertheless, a direct relationship between histopathological findings and symptoms of disease is lacking [70]. The physiopathological explanation for RV-induced diarrhea is complex and still incompletely understood; multiple non-mutually exclusive mechanisms have been proposed: 1. Virus replication disturbs the metabolic functions of enterocyte membrane proteins, leading to malabsorptive diarrhea. 2. RV increases 19 intracellular Ca++ concentration, which alters the cytoskeleton and tight junctions augmenting cell permeability. 3. Virus replication induces NPS4, an enterotoxin that causes secretory non-cystic fibrosis transmembrane conductance regulator (CFTR)-mediated diarrhea [69]. NSP4 increases intracellular Ca++ concentration by activating a Ca++-dependent signaling pathway; this mobilizes Cl- from the endoplasmic reticulum and consequently induces water and electrolyte loss [49]. 4. RV stimulates the enteric nervous system (ENS) through NSP4 related serotonin secretion by enterochromaffin cells, inducing electrolyte secretion and intestinal fluid loss, in addition to increased intestinal motility [71]. In fact, pharmacological inhibitors of the ENS reduce RV induced diarrhea [72]. 5. Enterocyte death induces osmotic diarrhea [69]. Other undiscovered mechanisms of the RV-host interaction may also contribute to RV pathogenesis. Finally, the mechanisms of RV induced emesis have not been completely elucidated. Vomiting may be originated by an axis comprised of NSP4-Ca++ influxserotonin secretion and activation of the solitary tract (considered the center of vomit in the brain) by the vagus nerve [73]. 2.2 IMMUNE RESPONSE AGAINST ROTAVIRUS 2.2.1 Innate immunity The innate immune response constitutes the first line of host defense during infection and it plays a central role in the early recognition and subsequent induction of a proinflammatory response to invading pathogens. Innate immunity to RV seems to play a very important role: 40% of SCID mice (on a C57BL/6 background), which lack B and T lymphocytes, were able to resolve a primary RV infection [24]. Likewise, athymic BALB/c mice clear RV infection in the absence of specific antiviral Abs [74]. Moreover, RV infected children commonly recover during the first week of illness, before RV- T cells or Abs are entirely established in the small intestine [75]. The innate immune response relies on the recognition of pathogen-associated molecular patterns (PAMPs) through a restricted number of pattern recognition receptors (PRRs). Intestinal epithelial cells (IEC) may recognize RV via PRRs such as Toll-like receptors (TLRs), nucleotide oligomerization domain (NOD)-like receptors, and retinoic acid inducible gene 1 (RIG-I)-like receptors (RLRs), which recognize viral RNA. The engagement of PRRs results in the translocation of NFB and interferon regulatory factors that promote the expression of type I IFN. In turn, IFN stimulated genes mediate resistance of neighbor cells to viral infection [76]. RIG-I and melanoma differentiation associated protein-5 (MDA-5) receptors are also implicated in the recognition of RV replication products, given that the loss 20 of either of them significantly reduces the magnitude of IFN- induction and facilitates viral replication [77, 78]. RV recognition by PRRs may be cell type-specific. Thus, other membraneassociated or endosomal receptors such as TLR3, TLR7, and TLR9 have been implicated in triggering innate responses against RV infection [79, 80]. In this regard, age-dependent TLR3 expression has been inversely associated with susceptibility to RV infection, viral shedding, and histological damage in mice [80]. In contrast, other studies have shown that TLRs signaling adaptor proteins MyD88 and TRIFF are dispensable for IFN induction in IECs or myeloid dendritic cells (DC) following infection with murine RV [77, 81]. After MDA-5 engagement by viral dsRNA, the protein kinase (PKR)-dependent pathway seems important for IFN- induction. Nevertheless, during RV infection PKR does not appear to be committed in the early antiviral gene induction [78]. Therefore, the specific role of some PRRs in the innate response against RV infection is still controversial. IECs play a crucial role in the host immune response induction by producing cytokines and chemokines, which result in antigen-specific immunity through B and T cell responses. Nevertheless, the mechanism of immune modulation exerted by these cytokines against RV infection is poorly understood. Recently, a study conducted by our group revealed that RV infected Caco-2 cells released noninflammatory immune response mediators – IL-8, PG-E2, and TGF-1 – but not IL1, IL-6, IL-10, IL-12p70 or TNF- [82]. A subsequent study showed that DC treated with supernatants from Caco-2 RV infected cells generated a significantly lower Th1 response, mediated by TGF-1 [83]. These results may explain in part the poor T-cell immune response observed in blood samples after RV infection. 2.2.2 T cell response T cells are another important player in the immune response against RV. In mice, the induction of protective Abs depends on the presence of CD4 T cells [84], and CD8 T cells provide the first mechanism, although not the only one, to clear a primary RV infection [24]. In humans, CD4 T cells secrete antiviral cytokines such as IFN- that are crucial for the response against the pathogen [85, 86]. In fact, children with an ongoing RV-infection presenting emesis have lower IFN- levels than those without emetic episodes [87]. The RV-T cell response in humans has been mainly studied through proliferation, ELISPOT, and intracellular cytokine staining assays, both in children and adults. RV-lymphoproliferative responses in vitro are variable, but they have been confirmed to be antigen-specific, with some antigenic epitopes shared by bovine and human RVs recognized by T cells [88-91]. RV-lymphoproliferative activity seems to increase with age; in children less than 6 months of age it is almost 21 absent, but it is detected in 80% of individuals older than 5 years [90]. CD4 T cells seem to predominate over CD8 T cells in proliferation assays, at least 8 days after the stimulus [89]. Proliferative responses are transitory in children, being almost undetectable 12 months after an acute RV infection [91, 92]. These results suggest that children require multiple RV infections to develop a T cell response as the one observed in adults [92]. In relation to cytokine production profiles against RV, it was shown that RV infected DC promote a Th1 response [93]. In consequence, circulating RV-T cells in both healthy and acutely infected adults mostly produce IFN-, but not IL-2, IL-4, IL-13 or IL-17 [85, 94]. In healthy adults, a few CD4 T cells simultaneously produce IFN- and IL-2, but not solely IL-2 [94]. Considering that the frequencies of RV-T cells that produce IFN- are similar to those specific for several mucosal respiratory viruses [94], it seems that the RV-T cell response is not poor in terms of quantity but may be weak in terms of quality. The described phenotype suggests that the majority of RV-T cells are terminally differentiated effector cells, not able to provide long lasting immunity [95]. Likewise, in children RV-CD4 and CD8 T cells that only produce IFN- can be detected, but at very low frequencies [85, 86, 94]. In acutely infected adults RV-CD4 T cells that produce IL-10 are detectable, but in the convalescence phase this subset vanishes. This finding, along with the probably terminally differentiated RV-CD4 T cells and the barely detectable frequency of RV-T cells in children, suggests that the tolerogenic gut environment may substantially influence the T cell response against RV. In agreement with this hypothesis, after depletion of CD25+ T cells and/or the inhibition of the TGF- signaling pathway, in peripheral blood mononuclear cells (PBMC) from healthy adults, the frequency of RV-CD4 T cells that produce IFN- increases. Nevertheless, this mechanism does not seem to play a role in children. Furthermore, anergic cells could also be part of this population [94]. At present, we are preparing a manuscript in which the frequencies of RV-T cells producing IL-2, IFN-, and TNF- are compared to those specific for influenza virus and TT. Additionally, anergy inhibitors were used to assess the hypothesis of the presence of anergic T cells in the response against RV. Notably, regulatory T cells have been involved in mucosal IgA production through TGF-1 secretion, and in RV infected mice the numbers of FoxP3 + regulatory T cells are increased. Nevertheless, they do not seem to be essential for the response against RV, since their absence does not significantly affect RV clearance or Abs levels. Therefore, FoxP3+ regulatory T cells do not seem to importantly contribute to the early RV-IgA response in the intestine [96, 97]. Circulating RV-T cells preferentially express the intestinal homing receptor integrin 47 [86]. This and other studies have purified the homing receptors-expressing T cells before their detection in functional studies. This approach implies the risk to 22 change the T cells’ phenotype due to activation. Therefore, the use of MHC class II tetramers to characterize CD4 T cells without activating them has appeared as a new important tool to quantify and characterize the phenotype of antigen-specific T cells ex vivo. Such an approach has been already used for these purposes in several settings and viral models [98, 99]. Recently, we identified circulating RV epitope-specific CD4 T cells in healthy volunteers and vaccinated children, which expressed intestinal homing receptors (manuscript accepted for publication in Virology, see appendix 9.6). 2.2.3 B cell response Bc are probably the most important arm of the immune system in the response against RV. Bc deficient JHD knockout mice are unable to efficiently clear a primary RV infection and are susceptible to reinfection. Chronically RV infected mice are able to clear the virus after passively transferred with B cells that express intestinal, but not systemic, homing receptors [100]. More recently, it was shown that RV-Bc are determinant for the removal of the virus from the systemic circulation [28]. While in the RV mouse model intestinal IgG can protect, it is well known that IgA is crucial for protection against mucosal pathogens [101]. In agreement with this, it was recently confirmed in an IgA deficient mouse model that this Ig is very important for the intestinal primary immune response against RV, and that it has a fundamental role in the protection against intestinal RV reinfection [23]. In spite of this, IgA has a minor role in the resolution of systemic primary RV infection and does not seem to be needed for clearance of antigenemia after reexposure to the virus. These results suggest that circulating RV- IgG and/or IgM are important in the clearance of the virus from the systemic compartment [23, 102]. In humans, acute RV infection induces the secretion of RV-IgM in serum, which is subsequently replaced by RV-IgA and IgG. In the intestine, RV-IgM is also detected, followed by RV-IgA, and very low levels of IgG [103]. The importance of RV-specific systemic and intestinal Abs will be described in the next sections in the context of the correlates of protection after natural infection and vaccination, and in the mucosal immune system section. The RV-Bc phenotype and characteristics will also be discussed below. 2.2.4 Correlates of protection after natural infection in children It is generally accepted that neutralizing Abs against the RV infecting strain present in the intestine provide protection [18]. Nevertheless, assessment of intestinal fluid is impractical. In children, after natural RV infection, a serum RV-IgA titer > 1:800 confers a lower risk of infection and completely protects against moderate to 23 severe RV diarrhea. Children with a serum RV-IgG titer > 1:1,600 are protected against RV infection but not against RV diarrhea. These protective titers were reached after two successive RV infections either symptomatic or asymptomatic [11, 25]. In another study, total serum RV-IgA, but not total serum RV-IgG, correlated with milder disease [104]. It has been proposed that serum RV-IgA correlates with protection because it may transitorily reflect the intestinal immune response; serum RV-IgA correlates with serum RV-SIg [104], which in turn, at least one week after an acute RV infection, correlates with the RV-SIg in duodenal fluid [21]. Notably, serum RV-SIg could not be detected in serum later than 4 months after infection [104]. There is also evidence to support the importance of serum homotypic and heterotypic neutralizing Abs in protection against RV reinfection [12]. It seems that the first RV infections induce homotypic responses in children, but after successive infections occur, heterotypic Abs against a broader spectrum of G types appear, even though the real exposure had been to a restricted number of them. In conclusion, serum neutralizing Abs, and total serum RV-IgA appear to be better correlates of protection than total serum RV-IgG after natural infection in children [12]. Fecal RV-IgA has also been explored as a correlate of protection. However, its measurement is subject to several problems: 1. The intestinal proteolytic environment poses technical difficulties for its measurement. 2. The interference by maternal antibodies. 3. Although RV-IgA in stool has been reported to correlate with protection in studies performed in Australia [105] and the United States [106], some children that become reinfected have significant levels of RV-IgA in feces. These reasons explain why stool RV-IgA is an unfit correlate of protection in humans after natural infection [12]. 2.2.5 Rotavirus vaccines Due to the fact that RV does not induce sterilizing immunity, RV vaccines have been conceived to prevent severe disease in children, but not to eliminate infection. In other words, RV vaccines must simulate the effect of two natural RV infections, which, as mentioned earlier, provide complete protection against moderate to severe disease of any serotype. Nevertheless, this assumption diverges from recent results obtained in India, in a region where early infection is common (56% of children are infected by six months of age) and with high viral diversity. In that scenario, only after three natural RV infections a 79% protection against moderate or severe disease was reached [10, 107]. 24 In 1998, RotaShieldTM (Wyeth Lederle), a human-simian tetravalent RV vaccine, was licensed in the United States. But, 9 months after it became commercially available, it was withdrawn from the market because of a temporal association between vaccine administration and intestinal intussusception. The incidence of intussusception was particularly high when the first vaccine dose was administered in children more than 90 days old [108]. In 2006, two new RV vaccines (RotarixTM [GlaxoSmithKline Biologicals], a monovalent attenuated human vaccine, and RotaTeqTM [Merk and Co. Inc], a pentavalent human-bovine reassortant vaccine) were licensed in the United States after clinical trials with more than 60,000 children (for each vaccine) that assessed their safety and efficacy in the United States, Europe, and Latin America [109, 110]. RV vaccines were conceived with two different approaches in mind: on the one hand, Rotarix relies on the assumption that a single RV strain can induce a broadly cross-reactive neutralizing-Ab response and that a single natural RV infection in children can avoid a second severe infection [25]. In this case, the 89-12 strain was isolated from a child with RV GE and attenuated by multiple passages in cell cultures. This strain was selected because children symptomatically and asymptomatically infected with similar G1P1A[8] strains were 100% protected against RV GE in the next season. On the other hand, RotaTeq was formulated based on the mechanism of host range restriction attenuation and on the premise that homotypic protection is essential and, in consequence, the most common circulating human RV serotypes had to be included. Thus, RotaTeq is composed of five reassortant RV strains made of a parental WC3 strain and genes encoding VP7 or VP4 from RVs of human origin (G1, G2, G3, G4 and P1A[8]) [13] (Figure 3). Figure 3. The Rotarix and RotaTeq vaccines. a. Rotarix is an attenuated human rotavirus vaccine made of a tissue culture-adapted human G1P1A[8] strain. b. RotaTeq is a bovine (WC3)–human reassortant vaccine composed of five strains: four of them containing a human RV gene encoding the VP7 neutralizing protein 25 from different serotypes and the last one a human VP4 serotype. Figure obtained from [13]. Irrespective of their design, the efficacy of the RV vaccines has been similar in the different scenarios in which they have been tested so far. Therefore, in 2009, the WHO Strategic Advisory Group of Experts made a global recommendation that RV vaccines be included in national immunization programs worldwide [5] without any particular inclination for one of them. Early adopter countries of the vaccines against RV have shown a significant decrease in the number of medical visits, hospitalizations, and deaths related to RV GE. Specifically, studies in eight countries (United States, Australia, Belgium, Austria, Brazil, Mexico, Panama, and El Salvador) showed a 49% to 80% decline in hospitalizations of children under the age of five due to RV infection within two years of vaccine introduction [60]. Of note, hospitalizations for acute GE of any etiology decreased 17% to 55% after introduction of RV vaccination [60]. This suggests that the RV disease incidence was underestimated or that RV vaccines confer non-specific protection against other enteric pathogens. The effect of RV vaccination on the mortality related to GE of any etiology was particularly assessed in Mexico and Brazil, where deaths decreased by 35% and 22%, respectively [60]. The majority of countries that have implemented the vaccines against RV are of middle-to-high-income, and they account for less than 1% of the global deaths from RV before the introduction of vaccines. Unfortunately, the RV vaccines effectiveness is directly related to the per capita income of countries; RV vaccination provided 44% protection against severe RV GE in a low-income setting, approximately 76% in a low-to-middle-income setting, and greater than 80% in a number of middle-to-high-income settings [60]. These findings are in agreement with those reported in previous clinical trials. In Malawi and South Africa, the combined efficacy of Rotarix to prevent severe RV GE was 61.2% (49.4% in Malawi and 76.9% in South Africa), less than that observed in Europe (96.4%) and Latin America (84.8%) [111]. The efficacy studies for RotaTeq performed in Nicaragua (58%) [112], Bangladesh (42.7%), and Vietnam (63.9%) [113] also concluded that protection against severe RV GE is less than that reported in industrialized countries. Furthermore, in Africa [114], the efficacy between the first and second year after vaccination decreased from 64.2% to 19.6%. This finding also differs from the studies conducted in the United States and Europe [110, 115]. In conclusion, in spite of the great advance current RV vaccines have meant for the prevention of GE related mortality in children under the age of five, it is necessary to develop a new generation of RV vaccines that surpass current limitations regarding their efficacy in the settings where they are needed the most. To achieve this goal, research in the following areas need to be further addressed: the molecular basis of RV virulence and the mechanisms by which it induces GE, the 26 immune response elicited by RV infection, the genetic basis of virulence attenuation throughout serial cell culture passages and host range restriction, and, as mentioned earlier, the identification of an appropriate immunological correlate of protection [13]. 2.2.6 Correlates of protection after RV vaccination in children Two immune markers have been mainly used as correlates of protection after vaccination in children: RV-IgA, both in stool and serum, and serum RVneutralizing Abs. As mentioned earlier, measurement of stool RV-IgA is subject to several problems, and, for those reasons, it has been rarely used as a correlate of protection in vaccine studies. Notably, in the cited RIX4414 trial conducted by our group, only a minority (32.7%) of vaccinees presented RV-IgA coproconversion, indicating that this is not an optimal parameter to measure vaccine induced intestinal antibody responses [17]. Concerning serum RV-neutralizing Abs, in several studies its utility has been weak, which may be explained in part by the interference of maternal Abs [116]. Serum RV-IgA has been commonly measured in RV vaccine trials, used as an indicator of vaccine “take”, and associated with protection in some studies [10]. The rationale for its measurement is the same described above in the correlates of protection after natural RV infection. Compared with RV-IgG, RV-IgA seems to be more sensitive to evaluate vaccine immunogenicity [117]. Serum RV-IgA has been measured in RotaTeq trials and in many cases the RV-IgA seroresponse, a ≥3 fold rise in RV-IgA units between the preimmune sample and the sample taken after the last vaccine dose, surpassed the rates of protection against severe RV GE [12]. Regarding Rotarix, it was concluded that serum RV-IgA responses mirror the vaccine efficacy and that, in fact, vaccinees negative for RV-IgA are approximately 10 times more prone to suffer a RV GE in the next season than responders [118]. Recently, at the Tenth Rotavirus International Symposium the question if RV-IgA is really a suitable correlate of protection after vaccination was addressed. A study conducted in Africa by Dr. Htay Htay Han in vaccinated infants with Rotarix showed that a RV-IgA titer ≥ 20 U/mL correlated with protection against RV GE and that it was associated with a lower percentage of individuals with any or severe RV GE. However, a direct relationship between serum RV-IgA titers and the level of protection in seropositive children was lacking. Furthermore, vaccinated children with serum RV-IgA < 20 U/mL showed some level of protection compared to placebo recipients. Considering this study and the results from a meta-analysis of eight Rotarix efficacy studies in Europe, Asia, and South America (but not Africa), Dr. Han concluded that serum RV-IgA can be used as an epidemiological tool at the population level, but is unsuitable to predict individual protection [119, 120]. 27 Dr. Patel and his team showed an inverse relationship between RV-IgA titers and RV associated disease mortality. Moreover, RV-IgA correlated with vaccine efficacy for both vaccines; titers ≥ 90 U/mL correlated with higher protection and less waning of it than did titers < 90 U/mL. Countries with titers above 90 U/mL exhibit a two-year efficacy of 85% whereas those with titers below 90 U/mL display only a 44% [119, 121]. In conclusion, and as stated in the introduction, serum RV-IgA is currently the best, though imperfect, practically measured correlate of protection against RV GE [12, 13]. 2.3 THE MUCOSAL IMMUNE SYSTEM 2.3.1 Induction of the mucosal immune response mediated by B cells in the intestine In humans, antigen-specific mucosal immune responses initiate in the so-called inductive sites of the gut-associated lymphoid tissue (GALT), specifically Peyer’s patches (the principal site for the induction of antigen-specific responses) and isolated lymphoid follicles. These inductive sites are similar to lymph nodes in that they possess Bc follicles, T cell zones, and antigen-presenting cells such as macrophages and DC, but differ in that they lack afferent lymphatics [122]. Consequently, external stimuli must directly come from mucosal surfaces through the follicle-associated epithelium, which contains specialized epithelial M cells. These cells transport foreign macromolecules and microorganisms, via a vesicular transport system, to antigen-presenting cells within and under the epithelial barrier [123]. Another mechanism for intestinal antigen sampling consists of DC with the ability to sense the intestinal lumen by penetrating the epithelium with their processes. Induction of mucosal immunity can also take place in the gut-draining mesenteric lymph nodes, and, to some extent, at the effector sites (the lamina propria), home to activated B and T cells [124]. Payer’s patches also differ from lymph nodes in that the proportion of B to T cells is four to six times higher and are rich in cytokines important for IgA induction, such as TGF-, IL-4, IL-6, and IL-10. These cytokines are crucial for IgA class-switch recombination (CSR) of antigen-specific Bc in the germinal centers (GC), for expansion of IgA+ Bc, and for their differentiation to IgA secreting PC [125]. Once DC are loaded with the antigen, they migrate from the epithelial and subepithelial areas to the T cell-rich interfollicular regions of Peyer’s patches and initiate a polarized Th2 response, that in turn releases cytokines with Bc-activating properties. However, to exert this role, DC must be conditioned by epithelial cells via TGF- and thymic stromal lymphopoietin (TSLP), which stimulate DC to 28 produce IL-10, an IgA-inducing cytokine that additionally blocks the generation of a Th1 response by impeding DC’s production of IL-12 [126]. DC present in Peyer’s patches also secret retinoic acid (that promotes IgA CSR), IL-6 (that helps in the differentiation towards IgA secreting PC), and inducible nitric-oxide synthase (iNOS) (that promotes IgA CSR) to induce IgA responses. Additionally, retinoic acid is essential for the expression of 47 and CCR9 on IgA class-switched Bc, allowing them to recirculate through the thoracic duct and home to the gut lamina propria, their final destination as effector cells [127]. In the lamina propria, IgA+ plasmablasts terminally differentiate into IgA secreting PC. These PC also synthetize the joining (J) chain allowing the formation of IgA dimers. Particularly in humans, CD4 T cells provoke IgA1 class switching by activating Peyer’s patch IgM+IgD+ Bc via CD40L and TGF-. The resulting IgA1+ Bc migrate to the lamina propria and switch to IgA2 in response to a proliferationinducing ligand (APRIL) and IL-10 released by TLR-activated epithelial cells, especially in the distal intestine. Another IgM+IgD+ Bc may directly switch from IgM to IgA1 or IgA2 in response to B cell-activating factor of the TNF family (BAFF) or APRIL and IL-10 [127]. As previously mentioned, induction of an IgA response can also take place in the lamina propria, where residing DC also present antigens to Bc and may activate them via BAFF and APRIL. These mediators deliver CD40-independent IgA CSRinducing signals through transmembrane activator and calcium modulating cyclophilin-ligand interactor (TACI). Recent evidence showed that this could be the pathway for intestinal IgA production in a T cell-independent manner [128]. It has also been reported that human transitional T2 Bc have a high expression of the intestinal homing receptor 47 and indeed migrate towards the GALT, where they seem to be activated by the microbiota and could give rise to IgA secreting PC or marginal zone Bc with a prediversified repertoire. Another possibility is that activated immature Bc in the GALT die, thus constituting a checkpoint against autoimmunity [129]. 2.3.2 The polymeric immunoglobulin receptor Perhaps the most important factor in the mucosal immune system is the polymeric immunoglobulins (pIgs), particularly polymeric IgA (pIgA). At least 80% of the Ab production of the body takes place locally in the gut lamina propria. To be able to exert its protective effect pIgs must be extruded to the intestinal lumen. In fact, in an adult, it has been estimated that 3 g of dimeric IgA are translocated to the gut lumen everyday as SIgA, which is more than the total daily production of IgG in the body. Transcytosis is the process by which pIgs cross the epithelial cells from the basolateral membrane to the apical surface, and it is mediated by the pIgR [130]. 29 Indeed, this is the only identified receptor accounting for the epithelial export of IgA and IgM in mice deficient in it [131]. The pIgR is a transmembrane glycoprotein of approximately 100 kDa encoded by a single copy gene localized in chromosome 1, which is constitutively expressed by secretory epithelial cells in its basolateral membrane, mainly in the intestinal crypts. The upregulation of pIgR expression involves various proinflammatory cytokines, such as IFN-, IL-1, and TNF. The IL-4 has also been reported to synergistically increase the expression of pIgR in conjunction with IFN- [130]. Likely, PAMPs by means of TLRs can upregulate pIgR [132]. In mice, it was recently shown that microbiota-specific Th17 cells regulate intestinal pIgR expression and IgA secretion through IL-17, contributing to intestinal homeostasis [133]. After pIgR has recognized either dimeric IgA or pentameric IgM through the J chain (required for the high-affinity epithelial binding of pIgs), a clathrin-coated pit internalizes the complex. Notably, unoccupied pIgR is also continuously internalized. The molecules are then delivered to basolateral early endosomes and subsequently to common endosomes, where the complex is separated from other internalized molecules. The molecules are transported to the apical recycling endosomes underneath the apical membrane [134]. When the complex arrives at the apical surface, pIgR-IgA and pIgR-IgM are exocytosed after cleavage of the receptor, leaving behind the C-terminal segment for intracellular degradation. The extracellular portion of the pIgR is a piece of approximately 80 kDa particularly rich in carbohydrates, which is incorporated into the SIg molecules as bound SC in a modified conformational shape covering most of the J chain (Figure 4). SC endows particularly SIgA with resistance against proteolytic degradation [135]. Figure 4. Polymeric immunoglobulin receptor (pIgR) mediates the epithelial export of pIgA (mainly dimers) and pentameric IgM (not shown) to provide secretory 30 antibodies (SIgA and SIgM). SC is covalently attached to pIgA but not to pIgM. BBE, basolateral early endosome; CE, common endosome; ARE, apical recycling endosome. Left and right part of the figure obtained from [135, 136], respectively. Although human pentameric IgM has a higher affinity for free SC in vitro than does pIgA, the export of pIgA is privileged over that of pentameric IgM by a factor of approximately 5. This is probably explained by a diffusion restriction of the large IgM pentamers across the stromal matrix and basement membranes. Remarkably, it remains unknown how pIgs are directed from its local production site towards their diffusion through the stromal ground substance to reach the pIgR, instead of being drained by lymph to the peripheral circulation [135]. As previously stated, unbound pIgR is also internalized and released by proteolytic cleavage, originating free SC. Actually, around 50% of the exported pIgR ends up as free SC [137], which has innate immune functions such as neutralization of bacterial toxins and inhibition of epithelial adhesion of some Gram-negative bacteria. 2.3.3 Secretory IgA SIgA is the most abundant class of antibodies found in the human intestine and it is considered as a first line of defense in protecting the intestinal epithelium from enteric pathogens and toxins. Accurate differentiation between innocuous and harmful antigens is critical to guarantee local homeostasis in the gastrointestinal system. SIgA must, therefore, induce the dual properties of neutralization/protection and regulatory functions [136]. With regard to its protective immune function, SIgA combats microbial infections via mechanisms different from those used by antibodies in the systemic compartment because it exerts its functions mainly in an external environment. SIgA has the ability to block the adherence of pathogens and toxins to the intestinal epithelium [138]. One of the mechanisms that explain this blockade is steric hindrance, proposed as a way SIgA that interferes with cholera toxin binding to epithelial cells [139]. Another method consists in the direct attachment to receptor-binding domains, as has been shown in the reovirus type I Lang peroral challenge model in mice [138]. Probably one of the most recognized mechanisms of protection of SIgA is immune exclusion. It refers to its ability to prevent pathogens and toxins to gain access to the intestinal epithelium through a series of events: 1. Agglutination: Ab-mediated cross-linking via polyvalent surface antigens forms macroscopic clumps of bacteria (or viruses) that, depending on the epitope recognized, may have effects on bacterial physiology and gene expression, having in some cases direct effects on the pathogen virulence. 2. Mucus entrapment: SIgA facilitates the entrapment of bacterial pathogens in the mucus layer overlying the intestinal epithelium, probably 31 taking advantage of the association of oligosaccharide side chains of SC with mucus. 3. Agglutination and entrapment in mucus promote the clearance of bacteria through peristalsis. It is important to notice that it remains to be determined to what extent immune exclusion contributes to protective immunity against viruses [20]. SIgA protection against these and other pathogens may be mediated by two additional mechanisms: SIgA is capable of neutralizing pathogens intracellularly in its way to the apical surface and also can bind antigens in the lamina propria and promote their excretion, a process termed expulsion [20]. SIgA can also be considered part of the innate immune system. It has been proposed that given the high degree of similarity between the oligosaccharide side chains present on the heavy chain and SC of SIgA and those on the luminal side of the intestinal epithelium, SIgA can serve as a competitive inhibitor of pathogen attachment to the host cell. As suggested earlier, free SC may act as a decoy receptor for certain pathogens [140]. With respect to the regulatory role of SIgA, it is important as early as in the neonatal period. Natural and specific SIgA in breast milk bind commensal bacteria and are probably involved in the gradual and controlled establishment of the newborn’s microbiota, which in turn stimulates maturation of the GALT [141]. The control of commensal microorganisms is another important feature of SIgA. SIgAcommensal bacteria complexes promote their uptake by Peyer’s patch M cells, which seem to direct the complex towards local DC, that in turn induce local specific immune responses, preventing a systemic dissemination [142]. SIgA also has the ability to actively quench the capacity of certain antigens to evoke severe proinflammatory responses after uptake through Peyer’s patches M cells. Therefore, the retro-transport of antigen-SIgA complexes seems to be important to downregulate proinflammatory cytokines and preserve the integrity of the intestinal barrier. This mechanism also appears to be relevant for the maintenance of tolerance toward harmless proteins, including allergens [20]. Indeed, it was recently shown that both human and mouse SIgA induce tolerogenic DC, and that these DC in turn generate the expansion of regulatory T cells through IL-10 production. Furthermore, SIgA primed DC are capable of inhibiting autoimmune responses in mouse models of type 1 diabetes and multiple sclerosis [143]. Notably, a considerable proportion of IgA deficient patients are not only prone to develop mucosal infections, but also intestinal inflammation, allergic, autoimmune, and mucosal Bc lymphoproliferative disorders [144]. 2.3.4 RV secretory IgA (RV-SIgA) in serum SIgA and SIgM are normally detected in the systemic compartment of healthy individuals (1 – 91 years old), with a median of 10 mg/L and 14 mg/L, respectively [145-147]. The mechanism by which SIgA, produced at mucosal surfaces, is 32 transported to the circulation has not been elucidated. This “spillover” could be explained by leakage of SIgA or by active transport through the epithelial layer by a specific receptor still to be identified, since no known IgA receptor (pIgR, Fc receptor, FcRI or asialoglycoprotein receptor) seem to be involved in the process of uptake of SIgA by Peyer’s patches [148]. The transferrin receptor (CD71) has been proposed as an IgA receptor [149]. CD71 is abnormally expressed at the apical pole of enterocytes in patients with active celiac disease and evidence that SIgA mediates protected transport of pathogenic gliadin peptides through their binding to CD71 has been obtained [150]. Whether this is the case for pathogenspecific SIgA detected in serum remains to be determined. The first report of an ELISA assay to detect serum RV-SIg (RV-SIgA and/or RVSIgM) was published thirty years ago and showed that RV-SIg correlated very well with recent RV infection [19]. Subsequently, using a similar approach, RV-SIg was not detected in the serum of healthy breast-fed children, even though it was present in the stool and duodenal fluid of some of them and in their mothers’ milk and serum [151, 152]. In contrast, RV-SIg increased in serum of children with naturally acquired RV GE, and about one week after the acute phase of infection it correlated with the amounts detected in duodenal fluid, supporting the assumption that the RV-SIg in serum was derived from the local immune system in the intestine. Serum RV-IgA followed the same pattern, but, contrary to RV-SIg, remained elevated for at least six months [21]. A more detailed analysis of the RVSIg kinetics in serum showed that it peaks around 10 days (7 – 14 days) after the onset of GE and approximately a month later becomes undetectable. These results suggest that serum RV-SIg is frequently observed after RV infection and reflects intestinal Ig. However, a correlation between the amount of RV-SIg and the severity of disease was not found [22]. Finally, regarding the mechanism of protection exerted by RV-SIg, in mice anti-VP6 SIgA plays this role via intracellular neutralization, but not via immune exclusion [153]. In contrast, in humans a critical mechanism of protection is viral exclusion, since neutralizing Abs against VP4 and VP7 inhibit the infection and function as a barrier in the apical side of enterocytes. The importance of viral expulsion remains to be determined [12]. 2.4 B CELLS AND THE MAINTENANCE OF SEROLOGICAL MEMORY 2.4.1 Phenotype of circulating B cells and current controversies Bc in blood comprise three types: transitional Bc, mature naïve Bc, and mBc. Transitional Bc (approximately 14% of cord blood Bc and 2% of peripheral Bc) are early emigrants from the bone marrow that will complete their maturation process in the spleen and/or outside it, and are usually identified as CD19+CD24hiCD38hi 33 [154]. Naïve Bc are defined as cells that have not encountered their cognate antigen and, therefore, are inactivated and do not secrete antibodies. In contrast, mBc are antigen-experienced resting cells that can differentiate rapidly into effector cells after a subsequent encounter with its cognate antigen [155]. In terms of function, mBc express higher levels of co-stimulatory and activation molecules such as CD80, CD86, CD95, CD180, and TACI than naïve Bc [156, 157]. Moreover, proliferation and differentiation rates of naïve Bc and mBc in vitro resemble those of the primary and secondary immune responses in vivo, respectively, with a higher proportion of mBc that proliferate and differentiate into PC compared with naïve Bc [158]. The phenotype of the main circulating Bc populations in humans can be described by the differential expression of three markers: CD27, IgD, and IgM [159]: 1. Naïve Bc: CD27-IgD+IgM+, represent 60%-70% of the total Bc [160]. 2. IgM+ mBc: CD27+IgD+IgM+, constitute approximately 15% of circulating Bc [161]. 3. IgM+ only mBc: CD27+IgD-IgM+, represents around 1%-5% of circulating Bc [161, 162]. 4. IgD+ only mBc: CD27+IgD+IgM-, constitute less than 1% of Bc [163]. 5. Classswitched mBc: CD27+IgD-IgM-, which can be IgG+, IgA+ or IgE+, and comprise around 20% of Bc [160]. 6. CD27- mBc: CD27-IgD-, which can express IgM, IgA or IgG, and represent less than 5% of total Bc [164]. The rationale for the use of these markers comes from the various strategies that have been used to define mBc. It has been commonly accepted that after antigen encounter, Bc can further improve antigen-binding capacity by somatic hypermutation, a process that introduces point mutations in the variable regions of immunoglobulin loci; the selection of high-affinity mutants results in the affinity maturation of the Bc response [165]. In addition, the process of CSR permits adapting the antibody effector functions to the particular antigenic challenge, while conserving the specificity of the variable region, by changing the constant region from and to , , or . Both processes are accomplished by activation-induced cytidine deaminase (AID) [166] and the traditional concept was that they occurred in a sequential manner and exclusively in GCs, where the AID was activated [167]. Therefore, it was initially thought that the absence of IgM and IgD, accompanied by a considerable mutation load, was indicative of the memory status. However, the detection of CD27+IgM+ Bc capable of IgM secretion after polyclonal stimulation [168], and the finding of a significant population of IgM+IgD+ cells harboring mutations in their Ig genes [169, 170] were at odds with this conception. Consequently, CD27 was proposed as a universal marker of Bc memory given that its expression correlated with the capability of Bc to secrete immunoglobulins after polyclonal stimulation [171, 172], and with somatic hypermutation in IgM+IgD+ cells [162]. These studies allowed the identification of IgM+ mBc (CD27+IgD+IgM+) and IgM+ only mBc (CD27+IgD-IgM+). Besides the presence of somatic hypermutations, other evidences support the notion that these cells are indeed mBc: 1. They are scarce in children but increase with age [171]. 2. They are long-lived [173]. 3. 34 Similar to switched mBc, they respond to certain polyclonal stimuli generating PC [171, 174, 175]. 4. They respond in vitro to stimuli conventionally derived from T cells in a way that resembles switched mBc and is different from the naïve Bc response [158]. New concepts and controversies have emerged along with the description of IgM + mBc [176]. Their existence suggests that somatic hypermutation and CSR can occur independently in vivo, for which there is already some evidence in vitro [177]. Since it is thought that somatic hypermutation precedes CSR, it was proposed that IgM+ mBc are generated in GCs, but may be early emigrants (before CSR) from a T cell-dependent response. However, various findings suggest that IgM+ mBc cells are generated outside GCs: 1. These cells can be found in patients with X-linked hyper IgM syndrome (Hyper IgM type 1), who do not express a functional CD40L and therefore lack GCs, whereas IgM+ only and switched mBc are absent [178]. 2. AID expression has been identified in extrafollicular Bc, implying that the engagement in a GC reaction is not an absolute requisite for the induction of somatic hypermutations [179]. Nevertheless, mutations in the BCL6 gene, considered a genetic footprint of germinal center derivation, identified in IgM + mBc and IgM+ only mBc argue against a T cell-independent origin and support the hypothesis that these cells are indeed early emigrants from a GC reaction, produced by a conventional T cell-dependent response [161]. In mice, IgM+ mBc that belong to the B2 cell lineage seem to be part of two different subpopulations, defined by the differential expression of IgM and IgD. The first differentiates at the spleen periarteriolar lymphoid sheath area, expresses the markers IgMhiIgDlowCD21hiCD23−CD1dhi, and are called marginal zone Bc. The second expresses IgMlowIgDhiCD21intCD23+CD1dlow and are follicular Bc [180]. Furthermore, in humans it has been proposed that IgM+ mBc are the equivalent of mice marginal zone Bc, although with two important differences: in humans they recirculate and carry mutated immunoglobulin receptors, which suggests that these cells have a pre-diversified immunoglobulin repertoire, generated in the absence of an immune response against a particular antigen [181, 182]. IgM+ mBc also seem very important in T cell-independent responses, for instance in the protection against encapsulated bacteria like Streptococcus pneumoniae [183]. Thus, it is not surprising that Toll-like receptors (TLRs) take part in the ontogeny and homeostasis of these cells. It was recently shown that TLR9 activation generates somatically mutated mBc from a proportion of transitional Bc in vitro, and the mutation characteristics found in them resemble those of the same circulating mBc from Hyper IgM type 1 patients in vivo [184]. Furthermore, in patients deficient in MyD88 and IRAK4, the IgM+ mBc were significantly reduced, in the presence of normal switched mBc, and did not increase with age, which suggests that TLRs play an important role in the homeostasis of IgM+ mBc and not only in its ontogeny [185]. 35 A fraction of IgM+ mBc identified as CD20+CD27+CD43+CD70- has also been considered as the equivalent of B1 cells in humans because they accomplish three B1 cell fundamental functions described in mice: 1. Induction of allogeneic T cell proliferation. 2. Tonic intracellular signaling and 3. Spontaneous IgM secretion [186]. Nevertheless, some groups claim that these cells are really activated Bc on their way to PC differentiation [187-190]. Recent evidence supports the notion that the phenotype of “human B1 cells” actually corresponds to pre-plasmablasts [191]. To add even more debate to the question of what defines a mBc, class-switched and IgM+ CD27- mBc have been described [164, 192]. Therefore, it is not easy to clearly establish the origin and function of mBc just by their phenotype. The analysis of mutations present in the V(D)J exons of the immunoglobulin heavy and light chains, the study of the repertoire selection based on the V and J gene family usage, the analysis of clonal relationships, and the quantification of the number of cell cycles (replication history) have shed some light, but the panorama is still unclear. Based on these approaches, it has been recently proposed that CD27-IgG+ and IgM+ only mBc come from primary GC reactions, and switched mBc (IgA+/IgG+) arise from subsequent GC reactions. In contrast, IgM+ mBc (CD27+IgD+IgM+, termed “natural effector cells”) and CD27-IgA+ mBc, present in CD40L-deficient patients, seem to have a GC-independent origin, but with different tissue origins. At least in part, IgM+ mBc derive from the splenic marginal zone, whereas CD27 -IgA+ molecular characteristics mirror those of gut lamina propria derived IgA + Bc [193]. Concerning the relationship between circulating CD27- and CD27+ mBc, a recent study showed that mBc expressing IgM (either IgM+ only, “innate-like” CD27+IgD+IgM+, or CD27-IgD-IgM+) share unique characteristics, switched CD27+ and CD27- mBc use a similar IGHV repertoire and are distant from IgM + mBc, although IgG2 and IgA2 mBc have a more “innate-like” repertoire. Moreover, the expression of CD27 does not seem to be determined by a linear developmental pathway [194]. A summary of the conclusions of these and other studies using genetic approaches can be found in Table 1. In conclusion, multiple IgM+ mBc populations may exist in humans, each of them performing different functions related with diverse origins and in response to particular antigens. The road for further research on human mBc may have been opened by recent studies concerning different pathways of mBc generation in the mouse model. One of them showed that GC- dependent and independent mBc might proceed from a single CD38+GL7+ Bc precursor [195]. This multipotent cell produces GCindependent mBc at a very early time point in the primary immune response. These mBc are predominantly IgM+ and CD73-. GC-dependent mBc are generated later and are mainly switched mBc that, in contrast to GC-independent mBc, express CD73 [195]. In agreement with these findings, it was recently shown that CD73 induces CSR in an autonomous manner through the hydrolysis of ATP to adenosine [196]. A contemporary study utilizing a conditional ablation of BCL6 also 36 added convincing evidence that GC- dependent and independent mBc indeed coexist. Furthermore, GC-independent mBc are unmutated, long lived, IgM+ or IgG+, and, surprisingly, generated in a T-cell dependent manner in the absence of follicular T helper cells [197]. Furthermore, both mutated and unmutated mBc can optimally adapt to a secondary antigenic challenge throughout the accumulation of mutations and the development of a new Ab repertoire [198]. 2.4.2 RV-specific B cells and how they are studied There are few studies concerning antigen-specific Bc that use flow cytometry due to a paucity of model antigens that permit conducting them [199]. Our group and others developed a flow cytometry assay to characterize the phenotype of Bc that express surface RV-specific Ig (RV-sIg), based on an assay previously validated in mice [200, 201], in which a fluorescent RV antigen is specifically recognized by RV-sIg expressed on Bc. This antigen consists of recombinant virus-like particles (VLP) made up of VP6 and a fusion protein comprised of green fluorescent protein (GFP) coupled to the N-terminal end of VP2 devoid of its first 92 amino acids [202]. This construct was chosen as a RV model antigen given that an important proportion of cross-reactive RV-Abs recognize VP2 and VP6 and because VP6, in addition to being the most abundant structural RV protein, is recognized by the majority of Abs against RV in infected animals and humans [201, 203]. As mentioned earlier, RV-Abs are of critical importance to prevent reinfection in mice [23, 24], and correlate with protection in humans [11, 25-27]. This implies that Bc are very important for the immune response against RV infection; Bc are determinant for the clearance of a primary RV infection in mice [24] and for the removal of the virus from the systemic circulation [28]. One particularity of RV-Bc is that there is a fairly high frequency (around 1-2%) of RV-naïve Bc in newborns [41], which secrete low-affinity Abs against VP6 [42]. Curiously, children 2 months old have a high frequency of CD27+IgD+IgM+ RV-mBc regardless of the serum RV-IgA status, indicative of a previous RV infection [17]. It is still unclear whether these cells have been induced by symptomatic or asymptomatic RV infections and why they can be present in the absence of serum RV-IgA. RV infects almost every child from 2-6 months (when transplacentally transferred maternal IgG start waning) and 3 years of age, 50% of whom will have at least one symptomatic infection [7]. After an acute RV infection, RV-sIg Bc and RV-PC predominantly express the intestinal homing receptor 47 [204] and in consequence have the predicted phenotype of Bc stimulated in the Peyer’s patches [205]. The phenotype of RV-Bc changes from the acute to the convalescent phase of infection. Plasmablasts and PC characterize the primary RV-Bc response accompanied by the expression of intestinal homing receptors in 37 the great majority of them: CD38hiCD27hiCD138+/-CCR6-47+CCR9+CCR10+CLAL-selectinint/- and IgM+, IgG-, IgA+/-. In the convalescence phase, between one and two weeks after infection, the RV-Bc phenotype changes and corresponds to RVmBc with or without an intestinal homing migration pattern: CD38 int/-CD27int/CCR6+47+/-CCR9+/-CCR10-. Concurrently, RV-IgA and RV-IgM appear in serum [206] and stool [105]. One third of RV-mBc are most likely targeted to the small intestine because they express both 47 and CCR9, another third may be directed to other mucosal surfaces given that only express 47, and the last third is probably targeted to the systemic compartment [16]. This compartmentalized RV-mBc response in humans reflects the fact that, although RV replication in both animals and humans overall takes place in the intestinal tract, antigenemia and viremia are common features of RV infection [14, 15]. In an attempt to identify useful correlates of protection, circulating RV-mBc were characterized in healthy adults and its relation with serological memory was assessed as well [43]. Compared to TT-mBc, used as a model antigen, RV-Bc seem to be a distinctive subset, because they are enriched in the CD27+IgM+ (which includes the CD27+IgD+IgM+ subset) and in the CD27-IgG+ mBc subsets [43, 44]. Recently, this was confirmed and it was determined that RV-IgM+ mBc are significantly enriched in the IgMhiIgDlow subset. Moreover, human CD27+IgM+ RVmBc have a substantial ability to switch to IgG in vitro and in vivo, and to mediate a significant reduction of RV antigenemia and viremia in an adoptive transfer immunodeficient mice model [102]. Regarding the relationship between RV-mBc and serological memory, CD27+IgA+ RV-mBc correlated positively with RV-IgA plasma levels, but CD27+IgG+ RV-mBc did not correlate with RV-IgG in plasma. In contrast, CD27+IgG+ TT-mBc correlated with TT-IgG plasma levels. Therefore, the relation of RV-mBc with serological memory appears to be different from that of TT-mBc [43]. The Ig gene expression patterns in circulating RV-Bc have been analyzed as well. One of the first reports concluded that infant and adult human RV-Bc have common immunodominant variable gene repertoires since they share similar VH, D, JH, VL, and JL segment usage, degree of junctional diversity, and length of H chain CDR3 region [207]. This suggests that the Bc repertoire is not responsible for the poor quality of RV-Ab responses in children. Nevertheless, RV-Bc VH sequences from children with acute RV GE have a lower mutation load than the corresponding sequences in adults [208]. Furthermore, the mutations detected in the VH1-46 gene segment in adults, which is an immunodominant gene in RV-Bc of both children and adults, conferred functional advantages to VP6-specific Abs [42]. The Ig gene repertoire of VP6-Bc has been evaluated in circulating naïve Bc, IgM+ mBc, and switched mBc (including IgM+ only mBc given that this population was defined as CD27+IgD-) from healthy adults [44]. IgM+ RV-mBc had a shorter CD3 38 length compared to RV-naïve Bc and switched RV-mBc, probably explained by an increased TdT exonuclease activity. This study also reported that IgM+ and switched mBc share a predominant usage of the VH3 family, whereas the VH1 family is the most frequently used by naïve RV-Bc. In contrast, the same study reported that both naïve and the two subpopulations of mBc in total non-antigenspecific Bc predominantly use the VH3 family. Altogether, these results suggest that the dominant VH1-expressing naïve RV-Bc do not have an advantage in the selection processes that lead to IgM+ and switched RV-mBc [44]. Considering that RV-Bc are concentrated in the intestine, the genes used by these cells in healthy adults have been recently assessed in PC that bound RV-VLP and were isolated from the small bowel. The VH genes analyzed were highly mutated and preferentially expressed the VH4 family, which is not dominant among circulating RV-Bc [209]. Nevertheless, it was previously shown that both RV-IgDsystemic Bc and RV-IgD-47+ intestinal homing Bc preferentially use the VH1-46 gene segment, and that circulating RV-Bc 47+ were unmutated, as opposed to systemic RV-Bc [210]. In agreement with this, around 30% of IgA and IgG plasmablasts derived from the terminal ileum of healthy adults have been shown to secrete polyreactive Abs, and the majority of them recognize RV VLPs [211]. These apparent contradictions may reflect the lack of a direct comparison between circulating and intestinal derived RV-Bc. 2.4.3 The serological memory and the theories of how it is maintained Pathogen-specific protective IgG levels following natural infection or vaccination can persist for decades, or in some cases for a lifetime, in the apparent absence of the antigen [30]. This serological memory provides the host with a first line of defense against reinfection by many microorganisms [212], and critical pathogenspecific Ab titers that correlate with protection have been identified for several vaccines [213]. Additionally, in autoimmune diseases, auto-Abs of different isotypes have been associated with disease activity and pathogenesis [214] and in some cases predict disease severity [215-217]. The mechanisms that contribute to the maintenance of serological memory are still unclear and three main theories have been proposed, one dependent on mBc and the other two unrelated to them [218]. The first theory considers that serum Abs are secreted by short-lived PC, which are continuously replenished by mBc that become activated (proliferate and differentiate into Ab-secreting descendant cells) by non-antigen-specific polyclonal stimulation through TLR or bystander T-cells [35]. Thus, numbers of circulating antigen-specific mBc and levels of antigen-specific serological memory in healthy individuals should correlate [36]. However, this is not always the case. At present, it is considered that there is substantial evidence, at least in healthy volunteers, to discard this theory as the main mechanism to explain the maintenance of 39 serological memory [34, 218]. Furthermore, the existence of correlations between mBc and serological memory are thought to be an epiphenomenon in which both parts are equally stable but independently maintained, without implying a direct cause-and-effect relationship [30]. Nevertheless, in determined circumstances such as autoimmunity, given the existence of conditions that facilitate the rapid production of short-lived PC, this mechanism could have an important role [219221]. Therefore, in healthy adults, IgG serological memory seems to be maintained by long-lived PC, independently of mBc [30, 33]. Two non-mutually exclusive theories have been proposed to explain the survival of long-lived PC [218]: 1. Long-lived PC reside in a limited number of survival niches in the bone marrow or secondary lymphoid organs, and consequently do not require repopulation by mBc; however, there may be a competition for such niches between newly generated plasmablasts and older PC. Notably, this theory does not exclude the existence of short-lived PC, instead, it proposes that plasmablasts may or may not gain the competence to respond to survival signals, which will finally determine its lifespan [33, 222]. 2. PC and mBc represent independently regulated populations [34]. The lifespan of PC is related to the integrated signals through the B-cell receptor, which largely depend on the antigen’s repetitive nature, and signals obtained through CD4 T-cell help and, therefore, is imprinted at the time of the immune response induction [218]. 2.4.4 Rituximab and its effect on memory B cells and serological memory Autoimmune diseases are clinical syndromes caused by the activation of T or B cells, or both, in the absence of an ongoing infection or other discernible cause. They have a multifactorial origin and can cause organ-specific or systemic injury [223]. Auto-Abs are a typical feature in the majority of autoimmune diseases that can be used as autoimmunity diagnostic markers, which may or may not be implicated in disease pathogenesis. However, auto-Abs are only one of the many factors involved; it is considered that complex mechanisms including cells and molecules from both the innate and adaptive immune response play an important role. Thus, autoimmunity may be just the result from an over-activated immune system [224]. Recent evidence has shown that Bc have a central role in autoimmunity mediated by Ab-dependent or independent mechanisms. These include: antigen presentation, induction of CD4 helper T cells (Th 1, Th2, and Th17) and CD8 effector T cells, maintenance of T cell memory, inhibition of regulatory T cells, immune complexes formation, complement activation, pro-inflammatory cytokines secretion, chemokine production, and orchestration of tertiary lymphoid tissue generation [225]. Therefore, a reasonable therapeutic target in these patients 40 consists in the reduction of the number and activity of Bc, which can be accomplished by the use of biologic therapeutic agents such as RTX [226]. RTX is a chimeric monoclonal Ab directed against the transmembrane glycoprotein CD20 on Bc. The CD20 molecule is thought to be a Ca++ channel and to participate in Bc activation and proliferation. It appears from the pre-B maturation stage and disappears in terminally differentiated plasmablasts and PC. As a therapeutic target, CD20 has many advantages: it is not eliminated from the cell surface, it does not have a soluble form, and it is poorly internalized after Ab recognition [227]. The mechanism through which RTX diminishes or depletes mature Bc is not completely elucidated, but the most probable one depends on the expression of Fc receptors (FcRI y FcRIII), with monocytes as the principal effector cells, whereas T and natural killer cells do not seem to participate [228]. The activation of the complement system also seems to contribute [229]. RTX effectiveness has been demonstrated in many autoimmune diseases such as thrombocytopenic purpura [230], severe pemphigus [231], RA [232], SLE [233], and Sjögren’s syndrome [234], with an increasing use in pathologies for which its use was not initially conceived [235]. RTX causes a rapid and very significant reduction of circulating Bc subpopulations during 6 – 9 months after one cycle of therapy. Nevertheless, the variability of depletion seen in different individuals under the same conditions is a consistent finding [236]. The factors that influence the time at which repopulation initiates are not clearly established, but the magnitude of earlier depletion, drug clearance rate, and the capacity of the bone marrow to regenerate most probably determine it. Repopulation is comprised mainly of naïve Bc, with an increased frequency of transitional Bc, which resembles bone marrow transplantation [237]. Regarding Bc depletion in secondary lymphoid organs and other solid tissues in humans, the information is scarce. Studies in primates showed that higher doses are required to deplete bone marrow, spleen, and lymph nodes in this sequence [236]. With respect to the effect of RTX on serological memory, after Bc depletion with one cycle total IgA, IgG, IgM, and IgE levels significantly decrease, but within normal ranges [37]. In contrast, IgG Ab titers against pathogens such as measles [37], tetanus [38], and pneumococcal capsular polysaccharide [40] remain constant. In regard to auto-Abs, results differ: on the one hand, it has been reported that anti-double-stranded DNA (dsDNA) and anti-C1q [40], both of IgG isotype, and IgA-, IgG-, and IgM-class rheumatoid factors (RF) diminish significantly after RTX therapy [39]. On the other hand, auto-Abs against Ro52, Ro60, and La44, also of IgG isotype, remain unchanged after RTX therapy [37]. These results suggest that the mechanism of maintenance of serological memory could depend on the type of antigen and/or Ab isotype evaluated, particularly in patients with autoimmune diseases. Nevertheless, simultaneous assessment of antigen-specific mBc and antigen-specific Abs of different isotypes in patients that received B-cell depletion therapy with RTX is lacking. 41 Table 1. Genetic characteristics and proposed origin of different human B cell subsets Bc subset Phenotype Transitional Naïve CD38hiCD24hi CD38dimCD24dim CD27-IgM+ CD27+IgD+IgM+ IgM+ mBc IgM+ mBc Only CD27+IgDloIgMhi [180] CD27+IgDhiIgMlo [180] CD27+IgD-IgM+ IgD+ mBc Only CD27+IgD+IgM- Switched mBc CD27+IgG+ CD27+IgA+ CD27- mBc GC generation and possible tissue of origin [193] - IGH and/or IGL usage of V or J gene segments Number of cell cycles [193] SHM and subclass usage Clonal relationships IGHV4-34, IGHV4-59 [193] None 2 No No - GC/GCi. At least in part originate from the splenic marginal zone (GCi). >IGHJ4 and <IGHJ6 than naïve. >IGHV3 (IGHV3-23) and <IGHV1 usage than naïve. The opposite to Sw CD27+ mBc [194]. 7 (<GC) = GC, enriched for mutated IGKV3-20 [193]. <Sw CD27and CD27+. ?? ?? ?? ?? These cells seem not to be clonally related to Sw mBc [194, 238]. There is also evidence in both human GC and peripheral blood to support that Sw mBc are in part derived from IgM+ mBc [161, 239]. ?? ?? ?? ?? ?? ?? 9 (= GC) = GC in IGHV, higher in IGKV3-20 [193]. = CD27- mBc. GC, response probably driven by superantigens [240]. Consecutive GC responses. >IGHJ4 and <IGHJ6 than naïve Bc. >IGHV3 (IGHV3-23) and <IGHV1 usage than naïve [194]. Preferential Igλ usage. >IGHV3-23 and to a lesser extent >IGHJ6 than naïve and Sw CD27+ mBc [240]. ?? Due to the high SHM load it is expected to be high. High in IGH and IGL. >Sw CD27+ mBc [240]. They make large clones, unrelated to other populations [240]. >IGHJ4 and <IGHJ6 than naïve Bc. >IGHV1 than IgM+ mBc and naïve. However, IgG2 resembles the IGHV usage of IgM+ mBc. [194]. Ig+ (55%) [193]. >IGHJ4 and <IGHJ6 than naïve. >IGHV1 than IgM+ mBc and naïve [194]. 10 (>GC) High (IGHV and IGKV3) [193]. >CD27- mBc [194]. IGHG2 (51%) and IGHG1 (40%) [193]. 10 (>GC) = IGHJ4 and <IGHJ6 than naïve. >IGHV3 (IGHV3-23) and <IGHV1 usage than naïve [194]. >IGHJ4 and <IGHJ6 than naïve Bc. IGHV1 > IgM+ mBc and naïve [194]. ?? High (IGHV and IGKV3), >CD27+IgG+ [193]. >CD27mBc [194]. IGHA2 (19%) [193]. Similar to the other IgM+ subsets [194]. IgG1, IgG3, and IgA1 use more IGHV1 and lower IGHV3 than IgM+ mBc. IgG2 and IgA2 have a similar usage of IGHV1 and IGHV3 compared to IgM+ mBc, particularly IgG2 [194]. Primary responses. Consecutive responses. GC GC CD27-IgD-IgM+ CD27-IgD-IgG+ Primary responses. GC CD27-IgD-IgA+ 9 (= GC) GCi. Probably Ig+ (80%) [193]. >IGHJ4 and < 4 (<GC) generated locally at IGHJ6 than naïve Bc. IGHV1 > IgM+ the intestine. mBc and naïve [194]. All mBc populations had more transitions than transversion mutations and strand bias in the AT mutations [194]. GC: generated in a germinal center, GCi: generated independently from a germinal center. 42 = GC in IGHV, higher in IGKV3-20 [193]. >Naïve and IgM+ mBc [194]. IGHG1 (63%) and IGHG3 (31%) [193]. >GC in IGHV, = in IGKV3-20 [193]. >Naïve and IgM+ mBc [194]. IGHA2 (33%) [193]. All IgM+ mBc have a similar usage of IGHJ and IGHV families [194]. CD27- can precede CD27+ and vice –versa [194]. 3. HYPOTHESES 3.1 HYPOTHESIS 1: Circulating RV-SIg reflects more precisely the intestinal protective immune response induced by the vaccine RIX4414 and is, thus, a better correlate of protection than circulating RV-IgA. 3.2 HYPOTHESIS 2: RV-mBc are distributed in a different manner in patients with autoimmune diseases and contribute to RV-serological memory in a unique way. 4. OBJECTIVES General objectives are presented according to the two hypotheses assessed in this work, accompanied by their specific objectives. 3.1 To confirm that plasma RV-SIg can be detected in children after natural RV infection and to compare it to plasma RV-IgA as a correlate of protection in children vaccinated with RIX4414. 3.1.1 To determine if plasma RV-SIg is detected in children with RV-GE or GE from other etiology and in children vaccinated with RIX4414 and placebo recipients. 3.1.2 To assess the correlation of RV-SIg titers with circulating RV-mBc after vaccination and with the protection conferred by the vaccine against RV. 3.2 To explore the distribution of RV-mBc and their relationship with serological memory in patients with autoimmune diseases before and after treatment with RTX. 3.2.1 To compare circulating RV- and TT- mBc in healthy volunteers and patients with autoimmune diseases before and after RTX treatment. 3.2.2 To assess the relationship between RV-specific mBc and the corresponding plasma Abs in healthy volunteers and patients with autoimmune diseases. 3.2.3. To understand the contribution of some mBc subsets to the maintenance of serological memory, depending on the type of antigen and Ab isotype studied. 43 5. MATERIALS AND METHODS Materials and methods are described in each article. A more detailed version can be found in the appendices. 6. JOURNAL ARTICLES 6.1 Introduction to the article: Rotavirus specific plasma secretory immunoglobulin in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine Despite the great advance current RV vaccines have meant for the prevention of GE related mortality in children under the age of five, it is necessary to develop a new generation of RV vaccines that overcome current limitations regarding its efficacy, particularly in low-income countries. To achieve this goal, one of the definitive areas that must be addressed is the lack of an appropriate immunological correlate of protection [13]. At present, serum RV-IgA is the best, though imperfect, practically measured correlate of protection against RV GE [12, 13]. Recently, two cut-off points have been established for serum RV-IgA after vaccination, with different implications. On the one hand, after Rotarix vaccination a RV-IgA titer ≥ 20 U/mL correlates with protection against RV GE and is associated with a lower percentage of individuals with any or severe RV GE. Vaccinees with serum RV-IgA < 20 U/mL also show some level of protection compared to placebo recipients [119]. On the other hand, for both Rotarix and RotaTeq, serum RV-IgA titers ≥ 90 U/mL correlate with higher protection and less waning of it than titers < 90 U/mL [119, 121]. Nevertheless, serum RV-IgA can be used as an epidemiological tool at the population level, but does not permit predicting individual protection. Certainly, some vaccinees with serum RV-IgA develop mild RV GE, and protection provided by the vaccines can be higher or lower than the levels predicted by serum RV-IgA detected in vaccinees [12, 13]. Given that RV preferentially replicates in the intestine and local mucosal immunity is considered to be essential in human RV immunity [13], an adequate correlate of protection could be a marker able to precisely reflect the intestinal immune response induction. SIg in serum has been proposed as a method for indirectly measuring intestinal Ig [19]. RV-SIg has been detected in serum of children with acute RV infection [19, 21], and it correlated with the amounts detected in duodenal fluid one week after the infection [22]. Based on these precedents, we sought to confirm the presence of plasma RV-SIg in children with natural RV infection and to determine if circulating RV-SIg could reflect more precisely the intestinal protective immune response induced by the attenuated RIX4414 human 44 RV vaccine, and be a better correlate of protection than circulating RV-IgA after vaccination. We then evaluated total plasma SIgA and plasma RV-SIg by ELISA in children with RV-GE or GE from other etiology and in 50 vaccinated children and 62 placebo recipients. RV-SIg was only detected in children with evidence of previous RV infection or with acute RV gastroenteritis. We report, for the first time, that vaccinees had higher RV-SIg titers than placebo recipients after each applied dose, and that RV-SIg titers increased after the second vaccine dose. RV-SIg measured after the second dose correlated with protection when vaccinees and placebo recipients were analyzed jointly. We propose that plasma RV-SIg may serve as a valuable correlate of protection for RV vaccines. 45 Research Paper Research Paper Human Vaccines & Immunotherapeutics 9:11, 2409–2417; November 2013; © 2013 Landes Bioscience Rotavirus specific plasma secretory immunoglobulin in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine Instituto de Genética Humana; Facultad de Medicina; Pontificia Universidad Javeriana; Bogotá, Colombia; 2 R&D Laboratory; Division of Immunology and Allergy; University State Hospital; Lausanne, Switzerland 1 Keywords: rotavirus, vaccine, correlate of protection, secretory immunoglobulin Abbreviations: RV, rotavirus; SIg, secretory immunoglobulin; SIgA, secretory immunoglobulin A; SC, secretory component; GE, gastroenteritis; D1, dose 1; D2, dose 2; rhSC, recombinant human secretory component Rotavirus (RV)–specific secretory immunoglobulin (RV-SIg) has been previously detected in serum of naturally RV infected children and shown to reflect the intestinal Ig immune response. Total plasma SIgA and plasma RV-SIg were evaluated by ELISA in children with gastroenteritis due or not due to RV infection and in 50 children vaccinated with the attenuated RIX4414 human RV vaccine and 62 placebo recipients. RV-SIg was only detected in children with evidence of previous RV infection or with acute RV gastroenteritis. Vaccinees had higher RV-SIg titers than placebo recipients and RV-SIg titers increased after the second vaccine dose. RV-SIg measured after the second dose correlated with protection when vaccinees and placebo recipients were analyzed jointly. RV-SIg may serve as a valuable correlate of protection for RV vaccines. Introduction Rotavirus (RV) is the principal cause of severe gastroenteritis (GE) in young children, being responsible, before the introduction of routine immunization, for approximately 453,000 deaths annually worldwide.1 Two RV vaccines are available and recommended for infants worldwide by the WHO2 : Rotarix (GlaxoSmithKline Biologicals), an attenuated human RV vaccine, and Rotateq (Merck and Co. Inc.), a bovine-human reassortant vaccine. Both vaccines are less efficacious (39% to 77%) in some low-income countries in Africa and Asia,3 where 85% of worldwide mortality occurs.4 The improvement of these vaccines or the development of new RV vaccines is hindered by the lack of a widely accepted immunological correlate of protection. At present, serum RV-specific IgA (RV-IgA) measured shortly after natural infection or vaccination represents the best practically measured correlate of protection against RV GE.5 However, some vaccinees with serum RV-IgA develop mild RV GE, and protection provided by the vaccines can be higher or lower than the levels predicted by serum RV-IgA detected in vaccinees.6,7 RV preferentially replicates in the intestine, and local mucosal immunity is thought to be key in human RV immunity.7 During an acute RV infection in children, circulating IgD- RV-specific B cells express intestinal-homing receptors (α4β7+, CCR9+), and thus probably reflect mucosal immunity.8 In agreement with this finding, in our previous double blind trial of the attenuated RIX4414 human RV vaccine, correlations between protection from disease and frequencies of RV-memory IgD-, CD27+, α4β7+, CCR9+ circulating B cells measured after dose 1 (D1) and plasma RV-IgA after dose 2 (D2) were found. However, the correlation coefficients for both tests were low, suggesting that other factors are important in explaining protection from disease.9 In this trial, only a minority (32.7%) of vaccinees presented RV-IgA coproconversion, indicating that this is not an optimal parameter to measure vaccine-induced intestinal antibody responses.9 Secretory Ig (SIg) in serum has been proposed as an alternate method for indirectly measuring intestinal Ig.10 Polymeric IgA and IgM are transported across mucosal epithelial cells by the polymeric Ig receptor.11 At the epithelial surface the receptor is cleaved and part of it (the secretory component [SC]) remains attached to the Ig, forming SIg, which may retro-transcytose *Correspondence to: Juana Angel; Email: [email protected] Submitted: 03/08/2013; Revised: 05/30/2013; Accepted: 07/02/2013 http://dx.doi.org/10.4161/hv.25610 www.landesbioscience.comHuman Vaccines & Immunotherapeutics2409 ©2013 Landes Bioscience. Do not distribute. Daniel Herrera1, Camilo Vásquez1, Blaise Corthésy2, Manuel A Franco1, and Juana Angel1,* across epithelial cells and eventually enter the circulation.11 RV-SIg has been detected in serum of children with recent RV infection,10,12 but not in the serum of healthy breast-fed children, even though it was present in the stool and duodenal fluid of some of them and in their mothers’ milk and serum.13,14 Moreover, serum RV-SIg correlated with the amounts detected in duodenal fluid one week after the acute infection.15 These results suggest that serum RV-SIg is frequently observed after RV infection and reflects intestinal Ig. It is generally accepted that neutralizing antibodies against the RV infecting strain present in the intestine provide protection.16 However, assessment of intestinal fluid after RV vaccination is impractical and measurement of stool antibodies is subject to technical problems, including interference by maternal antibodies.9,17 Hence, circulating RV-SIg could reflect more precisely the intestinal protective immune response induced by the vaccine and be a better correlate of protection than circulating RV-IgA after vaccination. We here confirm the presence of plasma RV-SIg in children with natural RV infection, and further addressed its occurrence in children vaccinated with the attenuated human RV vaccine RIX4414. We report, for the first time, that vaccinees have higher RV-SIg titers than placebo recipients after each of the two administered doses, and that RV-SIg titers increased after D2. Furthermore, RV-SIg measured after D2 correlated with protection when vaccinees and placebo recipients were analyzed jointly. We propose that plasma RV-SIg may be a valuable correlate of protection for RV vaccines. Results Total plasma SIgA, RV-SIg and RV-IgM in children with acute GE Based on the presence of RV antigen or RNA in stools and RV-IgA in plasma, children with acute GE from prior studies (Table S1)18,19 were classified in 3 groups: group A: children without evidence of previous RV infection (RV-IgA-) and without RV GE (n = 5); group B: children with evidence of previous RV infection (RV-IgA+) but without RV GE (n = 20) and group C: children with acute RV GE with primary infection (RV-IgA-) (n = 7) or secondary infection (RV-IgA+) (n = 4). Umbilical cord blood samples taken from healthy full-term newborn infants, group D (n = 4), were used as controls. Plasma samples from 10 adult healthy volunteers were assessed in parallel. The mean concentration of total plasma SIgA for adult healthy volunteers was 12.27 μg/ml (6.73–25.8 μg/ml), which is comparable to values previously reported,20,21 and there was no significant difference when serum or plasma samples from these volunteers were evaluated (data not shown). Moreover, as previously shown,22,23 umbilical cord blood (group D) had significantly less total SIgA than any of the groups with acute GE (Fig. 1A). Group C (children with RV GE) had significantly less total plasma SIgA than group A (Fig. 1A) and than groups A and B analyzed jointly (children without RV GE, data not shown). Plasma RV-SIg was detected in children with previous RV infection and with current primary or secondary RV infection (groups B and C, respectively), but not in children without previous RV infection (group A) or in umbilical cord blood samples (group D, Fig. 1B). As expected,12 children with acute RV GE had significantly higher titers of plasma RV-SIg than children with previous RV infection but without an ongoing RV GE (group C vs. group B, Fig. 1B), and none of the 10 adult healthy volunteers had plasma RV-SIg (data not shown).24 The anti-human SC monoclonal antibody (mAb) used as a capture antibody in the ELISAs can recognize both SIgA and SIgM (Fig. 1A and data not shown). The ELISA protocol for total SIgA includes an anti-IgA antibody, and does not identify SIgM (data not shown); in contrast, the RV-SIg ELISA can detect both RV-SIgA and RV-SIgM. Therefore, we next explored RV-IgM responses in all groups of children (Fig. 1C) and potential correlations between RV-SIg and RV-IgA (Fig. 2A) and RV-IgM (Fig. 2B). Plasma RV-IgM was only detected in children with evidence of previous RV infection and those with acute RV GE, and was higher in the latter than the former (Fig. 1C). 2410Human Vaccines & Immunotherapeutics Volume 9 Issue 11 ©2013 Landes Bioscience. Do not distribute. Figure 1. Total plasma SIgA, RV-SIg and RV-IgM in children with acute GE. (A) The concentration of SIgA for each sample was determined based on a standard curve of plasma with a known SIgA concentration (14.6 μg/ml). The limit of detection was 4.8 ng/ml. (B) and (C) The reported values correspond to the log10 of the inverse titer measured by ELISA. The plasma RV-IgM for groups A and D is below the limit of detection. Lines and error bars denote the mean and SEM, respectively. Differences between groups were evaluated with the nonparametric Mann–Whitney test and all p values reported are 1-tailed. Groups of children: Group A: RV-IgA-, RV-GE-; group B: RV-IgA+, RV-GE-; group C: RV-IgA- (triangles) and RV-IgA+ (open squares) RV-GE+ and group D: umbilical cord blood samples taken from healthy full-term newborn infants. Correlation tests between RV-SIg and RV-IgA (group B and children from group C with secondary infection) or RV-IgM (groups B and C) were performed either separately or jointly. No correlation between RV-SIg and RV-IgA was observed in any case (Fig. 2A, and data not shown). In contrast, there was a significant correlation between RV-SIg and RV-IgM when groups B and C were analyzed jointly (children with evidence of RV infection) although with a low correlation coefficient (Fig. 2B). Thus, plasma RV-SIg seems to be induced independently of plasma RV-IgA and to a certain degree separately of plasma RV-IgM in children with natural RV infection. Competitive binding assays with rhSC To confirm anti-human SC mAb-mediated detection of total SIgA and RV-SIg in ELISAs, competitions with recombinant human secretory component (rhSC) were performed. As shown in Figure 3A, a 50% reduction in binding of colostral SIgA was obtained with 0.38 μg/ml rhSC, which corresponds to the naturally found 1:1 molar ratio occurring between rhSC and SIgA. As previously stated, the RV-SIg ELISA does not distinguish between RV-SIgA and RV-SIgM. Therefore, a plasma sample with presumably only RV-SIgA (RV-SIg+, RV-IgA+, RV-IgM-) and a plasma sample with presumably only RV-SIgM (RV-SIg+, RV-IgA-, RV-IgM+) were selected to compete with rhSC for the binding to the anti-human SC mAb. As shown in Figure 3B and C, the same concentration of rhSC (0.38 μg/ml) inhibited approximately 50% of the maximum signal observed for both types of samples. Thus, detection of either total SIgA or RV-SIg strictly relies on the binding of SIg to the anti-human SC mAb. Total plasma SIgA and RV-SIg in children vaccinated with the attenuated RIX4414 human RV vaccine In our previous trial of the RIX4414 human RV vaccine, children received the “all-in-one” vaccine formulation, in which the calcium carbonate buffer is lyophilized with the virus and the powder is reconstituted with water before vaccination. This formulation induced lower RV-IgA seroconversion rates25 ; however, it contains the same vaccine strain virus found in the Rotarix formulation and protected at similar levels against any RV GE and severe RV GE.9 There were no significant differences for total plasma SIgA among study groups (Fig. 4A). As shown in Figure 4B, vaccinees had higher RV-SIg titers than placebo recipients, both after D1 and D2. Titers of RV-SIg in vaccinees were significantly higher after D2 than after D1 (Fig. 4B), suggesting a boost effect of the second dose. Figure 3. Effect of competing rhSC on measurement of purified colostral SIgA and RV-SIg. Reported values are optical density units (OD, 450 nm) (Y axis) and the log10 of the rhSC concentration in μg/μl (X Axis) used to compete the binding of: (A) purified colostral SIgA (0.076 μg/ml); (B) a plasma sample from a child in which RV-SIg was presumably only RV-SIgA (RV-IgA+, RV-IgM-); and (C) a plasma sample from a child in which RV-SIg was presumably only RV-SIgM (RV-IgA-, RV-IgM+). Open dots in graphics show the concentration of rhSC inducing approximately 50% of inhibition and the dashed lines correspond to the signal observed when samples were competed with albumin at the same concentrations as for rhSC. www.landesbioscience.comHuman Vaccines & Immunotherapeutics2411 ©2013 Landes Bioscience. Do not distribute. Figure 2. Correlations of RV-SIg with RV-IgA and RV-IgM. (A) Correlation (Spearman one-tailed test) between plasma RV-SIg and plasma RV-IgA titers of children from group B (RV-IgA+, RV-GE-) and children from group C with secondary infection (RV-IgA+, RV-GE+) analyzed jointly. (B) Correlation (Spearman one-tailed test) between plasma RV-SIg and plasma RV-IgM titers of children from groups B and C analyzed jointly. In an attempt to establish the relationship between RV-IgA and RV-SIg after vaccination, the distribution of RV-SIg was analyzed in children with and without RV-IgA (RV-IgA + vs. RV-IgA-, Table 1). The frequency of RV-SIg+ children was significantly higher in RV-IgA+ vaccinees than in RV-IgA- vaccinees after D2 (16/25 vs. 8/25, chi-square test p < 0.05, Table 1). Moreover, the frequency of placebo recipients with RV-SIg+ was significantly higher in children RV-IgA+ than in those RV-IgAafter D2 (4/5 vs. 12/57, Fisher exact probability test p < 0.05, Table 1). In addition, a significant correlation was found between RV-IgA and RV-SIg in all study groups, except for vaccinees after D1 (data not shown); however, in all cases the correlation coefficients were low (Spearman test rho < 0.4). The frequency of RV-SIg+ children was significantly higher in RV-IgA- vaccinees than in RV-IgA- placebo recipients after D1 and/or D2 (20/23 vs. 21/54, chi-square test p < 0.05, Table 1). These results suggest that plasma RV-IgA and RV-SIg partially overlap, but depict different antibody responses. Next, the relationship between RV-SIg titers and protection was assessed. First, as shown in Table 2, the protection rates for vaccinees, as well as for placebo recipients, increased as a function of RV-SIg titers detected after D2. Second, when vaccinees and placebo recipients were analyzed jointly there was a correlation between protection and RV-SIg titers measured after D2 (Spearman test p < 0.05, rho = 0.22). Third, the frequency of protected children was significantly higher in RV-SIg+ children (titers ≥ 1:100) than in those RV-SIg- (titer < 1:100) (37/40 vs. 55/72, chi-square test p < 0.05) and the presence of RV-SIg conferred an almost four times increase in the probability to be protected against any RV GE (OR: 3.81, CI 95%: 1.04–13.93). Finally, protected children had significantly higher RV-SIg titers than non-protected children after D2 (Fig. 4C). In contrast, analysis of samples after D1 did not show any statistically significant correlation or difference between study groups. Altogether, these results suggest that RV-SIg is related to protection both after vaccination and natural RV infection. Additionally, no correlations were found between any RV-specific B cells subset previously studied, including RV-specific IgD + CD27+α4β7+ CCR9+ and IgD-CD27+α4β7+ CCR9+, and plasma RV-SIg (data not shown).9 Finally, we addressed the possibility that plasma RV-IgG could correlate with protection after vaccination with RIX4414. Although vaccinees had higher RV-IgG titers than placebo recipients after D2 (Fig. S1A), RV-IgG did not correlate with protection in any case (Table S3, Spearman test p = 0.38, rho = 0.026, when vaccinees and placebo recipients were analyzed jointly). Furthermore, there was no difference in RV-IgG titers between protected and non-protected children (Fig. S1B). Discussion We confirmed12,15 that RV-SIg can be detected in blood of naturally infected children (Fig. 1B), and showed that children vaccinated with the attenuated RIX4414 human RV vaccine have higher RV-SIg titers than placebo recipients, both after D1 and D2, and in vaccinees higher titers were observed after D2 than after D1 (Fig. 4B). Furthermore, RV-SIg measured after D2 correlated with protection in vaccinees and placebo recipients analyzed jointly (Table 2). The lack of correlation of RV-SIg with protection in vaccinees is probably related to the low number (five) of vaccine failures in these children.9 To our knowledge, this is the first study in which plasma antigen specific SIg has been evaluated as a correlate of protection after vaccination. Unexpectedly,12 children with acute RV GE (group C) had less total SIgA than children with acute GE of a different etiology (groups A and B analyzed jointly). Considering that plasma SIgA may be short-lived, similar to circulating IgA (4–6 d),26 and that the mean time of blood drawing after onset of diarrhea was 4.2 d, this result suggests that acute RV GE may disrupt the intestine epithelial barrier to a greater extent than other pathogenic conditions, affecting the mechanism by which total SIgA is selectively retro-transcytosed from the intestinal lumen. 2412Human Vaccines & Immunotherapeutics Volume 9 Issue 11 ©2013 Landes Bioscience. Do not distribute. Figure 4. Total plasma SIgA and RV-SIg in vaccinees and placebo recipients. Data for 50 vaccinees and 62 placebo recipients after dose 1 (D1) or dose 2 (D2) are shown. Lines and error bars denote the mean and SEM, respectively. Differences between vaccinees and placebo recipients, as well as between protected and non-protected children, were evaluated with the Mann–Whitney test and between vaccinees after D1 and D2 with the Wilcoxon test. All p values reported are 1-tailed. (A) The reported values correspond to μg/ml interpolated from a plasma pool with a known SIgA concentration (14.6 μg/ ml). (B and C) The reported values correspond to the log10 of the inverse titer measured by ELISA. Table 1. Number of vaccinees and placebo recipients with/without (+/−) plasma RV-IgA with plasma RV-Sig. Vaccinees n = 50 Placebo recipients n = 62 RV-IgA RV-IgA RV-IgA+ RV-IgA- (RV-SIg+) (RV-SIg+) (RV-SIg+) (RV-SIg+) After D1 13 (6) 37 (14) 4 (2) 58 (13) After D2 25 (16) 25 (8) 5 (4) 57 (12)b After D1 and/or D2c 27 (18) 23 (20) 8 (6) 54 (21) + - a Statistically significant difference between the subgroups with RV-IgA and without RV-IgA for vaccine and placebo recipients (chi-square test and Fischer exact probability test p < 0.05, respectively). cStatistically significant difference between the subgroups of vaccinees and placebo recipients without RV-IgA (chi-square test p < 0.05). RV-SIg has been reported to appear as early as 3–4 d after the onset of RV diarrhea, with the number of individuals positive for serum RV-SIg increasing significantly around day 10, and becoming undetectable approximately a month later.15 The transient nature of RV-SIg is probably one of the reasons why its measurement has not been implemented for evaluating vaccine immunogenicity.27 We used a labeled avidin-biotin ELISA protocol, which is expected to be more sensitive than the one available in previous reports, and detected RV-SIg in 17 out of 20 children with evidence of previous RV infection without an ongoing RV GE. This result challenges the notion that plasma RV-SIg can only be transitorily detected. Nonetheless, RV-SIg was transiently observed in some vaccinated children, since only half of vaccinees with RV-SIg after D1 also had RV-SIg after D2. Of 15 placebo recipients with RV-SIg after D1 only 4 had it after D2. This potential divergence in plasma RV-SIg persistence between naturally infected and vaccinated and placebo recipient children could be explained by differences in the mean age (14.2 vs. 4 mo, respectively), by the number of RV infections in the children, and by differences between the effects of wild type virus and the vaccine virus on the plasma RV-SIg positivity rates. Further studies are necessary to determine the kinetics of RV-SIg in blood after RV vaccination. Both RV-SIgA and RV-SIgM are probably measured in our RV-SIg ELISA, because RV-SIg can be identified both in children without RV-IgA (children with primary RV infection from group C) and in children with low levels or no RV-IgM (group B). Moreover, plasma RV-SIg is probably produced with a different kinetics than plasma RV-IgA, since there was no significant correlation between RV-SIg and RV-IgA in children with evidence of previous RV infection (Fig. 2A) that were analyzed 2–10 d after the onset of diarrhea. Likewise, RV-SIg is probably produced independently of RV-IgM, because in children with primary RV infection RV-SIg and RV-IgM exhibit no correlation (data not shown). Nonetheless, some of the RV-SIg may include RV-SIgM, due to the fact that there is a significant correlation between RV-SIg and RV-IgM when groups B and C are analyzed jointly, although the correlation coefficient was low (Spearman test rho = 0.33). Thus, RV-SIg induced after natural infection is most probably composed of both RV-SIgA and RV-SIgM, and these Igs are independently produced from RV-IgA and RV-IgM, supporting the hypothesis that plasma RV-SIg is generated in the intestinal compartment. Correlations were found between RV-SIg and RV-IgA in vaccinees after D2 and placebo recipients after D1 and D2 (data not shown), but not in vaccinees after D1, or in children with evidence of previous RV natural infection (Fig. 2A). This may be explained by differences between these groups: children with evidence of previous RV infection were older (mean age 14.2 mo) than vaccinees (4 mo old) and may have been more exposed to RV infections. Thus, age and history of RV infections seem to be important determinants of RV-SIg responses and will need to be further investigated. In children that received Rotarix, the main effect of the second dose was to provide a “catch-up’ immunization.7,9,28 Our results for RV-IgA and RV-SIg are in agreement with this finding: RV-IgA was detected in 13 vaccinees after D1 and it was detected in 14 more children after D2. RV-SIg was detected in 20 vaccinees after D1, and it was detected in 14 more children after D2. However, a detectable boost (4-fold increase in preexisting plasma RV-SIg) for RV-SIg was observed in three children whereas for RV-IgA it was detected only in one child. In addition, a significant difference between vaccinees and placebo recipients’ titers was observed for plasma RV-SIg (Fig. 4B) but not for RV-IgA.9 In our trial plasma RV-SIg seems to be a better correlate of protection than plasma RV-IgA, because although RV-IgA also correlated with protection when vaccinees and placebo recipients were analyzed jointly after D2 (Table S2, Spearman test p = 0.05, rho = 0.152),9 in contrast to RV-SIg (Table 2), the frequency of protected children was not significantly higher in RV-IgA + children (titers ≥ 1:100) than in those RV-IgA- (titer < 1:100) (Table S2, Chi-square test p > 0.05,). Moreover, the frequency of protected children was significantly higher in RV-IgA- (titer < 1:100) vaccinees compared with RV-IgA- placebo recipients (Table S2), which implies that other factors, aside from RV-IgA, are important in explaining protection from disease in vaccinees. The lack of correlation between RV-SIg detected after vaccination and any RV-memory B cells subsets analyzed may be explained by the fact that RV-SIg detected is probably a mixture of SIgM and SIgA. Since naturally acquired serum RV-IgG has been correlated with protection against RV infection in children,29 and passively transferred serum RV-IgG mediated mucosal immunity against RV infection in a macaque model,30 we assessed RV-IgG titers in plasma samples of vaccinees and placebo recipients after D2. www.landesbioscience.comHuman Vaccines & Immunotherapeutics2413 ©2013 Landes Bioscience. Do not distribute. a, b Table 2. Correlation between RV-SIg titers after D2 and protection against any RV GE RV-SIg Titers after D2 Vaccinees* (%) Placebo recipients* (%) < 100 22/26 (84.61) 33/46 (71.73) 100 10/11 (90.90) 8/10 (80) 18/21 (85.71)b ≥ 200 13/13 (100) 6/6 (100) 19/19 (100)c a Vaccinees+placebo recipients* (%) 55/72 (76.39) Although RV-IgG titers were significantly higher in vaccinees than placebo recipients (Fig. S1A), RV-IgG did not correlate with protection (Table S3). This lack of correlation is most probably due to the presence of variable amounts of maternal RV-IgG antibodies, transferred via the placenta, when the second vaccine dose was administered (4 mo old). Human antigen-specific SIg has been quantified in secretions,31-33 as well as in serum,34-36 both after natural infection or vaccination with multiple pathogens and antigens. Mucosal priming seems to be required for induction of SIg, but immunization at a given mucosal surface may induce a response at multiple mucosal sites.37 Although SIg in serum may potentially come from colostrum,38 this is unlikely in our study, because the children studied were older than two months of age, and very few (7%) of the placebo recipients had RV-SIg while almost all of them (> 96%) were breast fed.9 The mechanism by which SIgA produced at mucosal surfaces is transported to the circulation has not been clearly established: passive leakage of SIgA or active transport mediated by an unknown receptor could be involved.11,39 The transferrin receptor (CD71) has been proposed as an IgA receptor.40 CD71 is abnormally expressed at the apical pole of enterocytes in patients with active celiac disease and evidence that polymeric/ secretory IgA mediates protected transport of pathogenic gliadin peptides through their binding to CD71 has been obtained.41 Whether this is the case for pathogen-specific SIg detected in serum remains to be determined. Although some RV-SIg could be retro-transcytosed bound to the viral antigen during acute infection, it seems that several months after the virus has disappeared RV-SIg continues to be retro-transcytosed (Fig. 1B). Frequent RV infections have been associated with celiac disease in genetically predisposed children.42 Thus, further studies associating RV infection with celiac disease and IgA nephropathy (in which abnormally localized SIg may play a pathogenic role)36,43 are required. Since present RV vaccines are less efficacious in countries where they are most needed, new vaccine formulations are being tested. For this reason, the RV’s field would greatly benefit of the use of a correlate of protection to accelerate this process. Our results suggest that RV-SIg could be complementary to RV-IgA in evaluating vaccine immunogenicity and could be a valuable correlate of protection for RV vaccines. However, because of our lack of preimmune plasma samples, our study does not demonstrate vaccine induced RV-SIg. In addition, due to the fact that children received an “all-in-one” vaccine formulation, which is less immunogenic than the final RIX4414 formulation, the correlation of RV-SIg with protection may be underestimated. In fact, the Rotarix commercial formulation induces higher RV-IgA seroconversion rates than the RIX4414 formulation used in the present study, and this may also be the case for RV-SIg.28 Hence, further studies are needed to assess plasma RV-SIg kinetics in vaccinees, and to properly determine its value as a RV correlate of protection for existing vaccines. Materials and Methods Ethics statement Written informed consent was obtained from each volunteer or infant’s parents or legal guardian. Studies were approved by the Ethics Committee of the San Ignacio Hospital and Pontificia Universidad Javeriana and conducted in accordance with the guidelines of the Helsinki Declaration. Subjects and sample processing We studied plasma samples from 36 children with acute GE from prior published studies.18,19 These children (14 females and 22 males; mean age: 13.5 mo, range: 6–22; 20 breast fed and 16 not breast fed) were admitted with gastroenteritis to the pediatric emergency service or were hospitalized at the moment of sample collection. Demographic and clinical data of the children are presented in Table S1 arranged in the 3 groups described in the results section. The mean time of blood drawing after onset of diarrhea was 5 d (range: 1–12). Plasma and serum samples were obtained from 10 healthy adult volunteers (7 females and 3 males; mean age: 28 y, range: 25–38), without any gastrointestinal symptoms, during the month previous to the blood drawing. Additionally, 4 umbilical cord blood samples taken from healthy full-term newborn infants were also included. In our previous double-blind randomized controlled study,9 children received two doses of either placebo (n = 160) or 106.7 focus-forming units of the attenuated RIX4414 human RV vaccine (n = 159). Vaccine and placebo groups were very similar in terms of the median age at the time of the first and second vaccination (60 and 122 d, respectively), gender (M/F 85/74 and 84/76, respectively), and percentage of breast fed at dose 1 and dose 2 (96.9% and 95%, 88.6% and 88.1%, respectively). 2414Human Vaccines & Immunotherapeutics Volume 9 Issue 11 ©2013 Landes Bioscience. Do not distribute. *Shown is the number of protected vaccinees, placebo recipients or vaccinees and placebo recipients analyzed jointly / the total number of children in each population for each RV-SIg titer. aThe frequency of protected children was similar in RV-SIg- (titer < 1:100) vaccinees and placebo recipients (chi-square test p > 0.05). bThe frequency of protected children was significantly higher in RV-SIg+ children (titers ≥ 1:100) than in those RV-SIg- (titer < 1:100) when vaccinees and placebo recipients were analyzed jointly (chi-square test p < 0.05). cCorrelation between RV-SIg titers and protection (Spearman test p < 0.05, rho = 0.22) when vaccinees and placebo recipients were analyzed jointly. No. 16-10-01) (70 μl of 1/1,000 dilution), SP, and plates were developed and analyzed as described above. The concentration of total SIgA in the plasma pool, used as a positive control, was interpolated from a standard curve generated with purified SIgA from human colostrum (AbD Serotec, Cat. No. PHP133). The corresponding concentration for each plasma sample tested was in turn interpolated from the plasma pool curve using a fourparameter logistic-log function.46 ELISA for measuring plasma RV-IgM RV-IgM ELISA was performed as previously described,24 with minor modifications. Briefly, 96-well Immulon 2 microtiter ELISA plates (Dynex Technologies) were coated overnight at 4°C with Goat F(ab’)2 anti-human IgM (Invitrogen, Cat. No. AHI1601) (70 μl of 1/500 dilution). The plates were then blocked and incubated with plasma samples diluted in 5% blotto. The remaining steps of the assay are as described for plasma RV-SIg ELISA. Samples were considered as positive using the same criteria previously described. ELISA for measuring plasma RV-IgG Briefly, and as previously described with minor modifications,24 plates were coated with either a supernatant from RF virus-infected MA104 cells or the supernatant of mock-infected cells (negative control) and incubated overnight at 4°C. After blocking, serial dilutions of plasma samples were deposited in each well. After incubation, the following sequence of reagents was added: biotin-labeled goat anti-human IgG (KPL, Cat. No. 16-10-06) (70 μl of 1/1000 dilution), SP, and plates were developed and analyzed as described. Serial dilutions of a pool of plasmas from children with RV-IgG was used as a positive control and a plasma from a child without evidence of previous RV infection (RV-IgA-) and without RV-IgG from placental transfer of maternal IgG antibodies was used as a negative control. Recombinant human SC and competitive binding assays Recombinant human secretory component (rhSC) was obtained as previously described,47 and was used to ensure the activity of the capture antibody in the SIg ELISAS. Bovine serum albumin (Merck, 1120180100) (used as a negative control) or rhSC was added in 1/2 serial dilutions (starting from 6.1 μg/ml onwards) after the blocking step, and incubated for 10 min at 37°C. Next, purified SIgA was added at a concentration of 0.076 μg/ml (the concentration of SIgA present in a 1/200 dilution of the positive control plasma pool), plates were incubated for 2 h and the assay continued as described above. A similar strategy was used for RV-SIg, using a dilution of plasma (1/200) that gave a sub-saturating signal in the ELISA. Statistical analyses Analysis was performed with SPSS software version 20.0 (IBM Inc.) and with GraphPad Prism version 6 for Mac. Differences between groups were evaluated with nonparametric Wilcoxon, Mann–Whitney, Fisher exact probability or chi-square tests, as required. Correlations were evaluated using Spearman’s test. Significance was established if p ≤ 0.05, in 1 tailed tests. Disclosure of Potential Conflicts of Interest JA and MF were co-principal investigators for a trial of the RIX4414 rotavirus vaccine (the precursor to the Rotarix vaccine) www.landesbioscience.comHuman Vaccines & Immunotherapeutics2415 ©2013 Landes Bioscience. Do not distribute. Details about the vaccine trial and the strategy for clinical evaluation of protection were previously published.9 Briefly, from the moment infants received their second dose of vaccine/placebo, they were contacted every 2 weeks until they were 13 mo old to identify cases of GE. Of the 319 children who received two doses of vaccine/placebo, a subgroup of 119 was randomly selected for immunological assessments (50 vaccinees and 69 placebo recipients). Plasma samples from all these children, except seven placebo recipients (children in whom the informed consent form did not authorize further studies), were included in the present studies. Plasma samples were collected 14–16 d after receiving each dose of RIX4414 or placebo. All plasma samples from previous studies,9,18,19 which had been stored at -80°C, were thawed, diluted in 50% glycerol and preserved at -20°C for use. All assays, except competitive binding assays, were blinded experiments. ELISA for measuring plasma RV secretory immunoglobulin 96-well vinyl microtiter ELISA plates (Thermo Electron Corporation, Cat. No. 2401) were coated with an anti-human SC mAb (clone GA-1) (Sigma-Aldrich, Cat. No. I 6635) (70 μl of 1/10,000 dilution) and incubated overnight at 4°C. After blocking with 5% blotto, serial dilutions of plasma samples in 2.5% blotto were deposited in each well. After incubation, samples were discarded and 1/10 dilutions of a supernatant from RF (Bovine RV strain P6[1]G6, 107 focus forming units/ml) virus-infected MA104 cells or the supernatant of mock-infected cells (negative control) were added. Of note, most antibodies detected with this antigen are specific for the major capsid protein VP6, which contains group- and subgroup-specific antigenic determinants and exhibits a high level of sequence conservation.44,45 Then, the following sequence of reagents was added: guinea pig anti-rhesus RV hyperimmune serum (70 μl of 1/4000 dilution); biotinylated goat anti-guinea pig serum (Vector Laboratories, Cat. No. BA-7000) (70 μl of 1/2,000 dilution); peroxidase-labeled streptavidin (SP) (Kirkegaard and Perry Laboratories [KPL], Cat. No. 14-30-00) (70 μl of 1/1,000 dilution) and tetramethyl benzidine substrate (SigmaAldrich, Cat. No. 50-76-00). The reaction was stopped by the addition of 17.5 μl 2 M sulfuric acid. Absorbance was read at a wavelength of 450 nm on an ELISA plate reader (Multiskan EX; Thermo Labsystems). Serial dilutions of a pool of plasmas from children with RV-SIg was used as a positive control and a plasma from a child without evidence of previous RV infection (RV-IgA-) was used as a negative control in each plate. Samples were considered positive if the optical density in the experimental wells was > 0.1 units and 2-fold greater than the optical density in the corresponding negative control wells. To be accepted for analysis, the titer of the positive control plasma could not differ by more than one dilution from plate to plate. ELISA for measuring total plasma secretory IgA To detect total SIgA, a sandwich ELISA was developed using a previously described approach.43 Briefly, plates were coated with the anti-human SC mAb or PBS (Gibco, Cat. No. 21600-069) (negative control). After blocking, serial dilutions of plasma samples were applied in each well. The following sequence of reagents was then added: biotin-labeled goat anti-human IgA (KPL, Cat. Acknowledgments This publication was financed by the Pontificia Universidad Javeriana (ID4215). We thank the subjects who participated in the previous studies for their generosity, the personnel of the Pediatrics Department of the San Ignacio Hospital for their help References 1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD; WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136-41; PMID:22030330; http://dx.doi. org/10.1016/S1473-3099(11)70253-5 2. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009--Conclusions and recommendations. Biologicals 2010; 38:170-7; PMID:20093043; http://dx.doi.org/10.1016/j.biologicals.2009.12.007 3. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011; 30(Suppl):S1-5; PMID:21183833; http://dx.doi.org/10.1097/ INF.0b013e3181fefa1f 4. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 2009; 200(Suppl 1):S39-48; PMID:19817613; http://dx.doi.org/10.1086/605035 5. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol 2012; 2:419-25; PMID:22677178; http://dx.doi.org/10.1016/j.coviro.2012.05.003 6. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006; 24:2718-31; PMID:16446014; http://dx.doi. org/10.1016/j.vaccine.2005.12.048 7. Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol 2007; 5:529-39; PMID:17571094; http://dx.doi.org/10.1038/nrmicro1692 8. Jaimes MC, Rojas OL, Kunkel EJ, Lazarus NH, Soler D, Butcher EC, et al. Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 2004; 78:10967-76; PMID:15452217; http://dx.doi. org/10.1128/JVI.78.20.10967-10976.2004 9. Rojas OL, Caicedo L, Guzmán C, Rodríguez LS, Castañeda J, Uribe L, et al. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Viral Immunol 2007; 20:300-11; PMID:17603846; http://dx.doi.org/10.1089/vim.2006.0105 10. Grauballe PC, Hjelt K, Krasilnikoff PA, Schiøtz PO. ELISA for rotavirus-specific secretory IgA in human sera. Lancet 1981; 2:588-9; PMID:6116034; http:// dx.doi.org/10.1016/S0140-6736(81)90981-8 11. Mantis NJ, Rol N, Corthésy B. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011; 4:60311; PMID:21975936; http://dx.doi.org/10.1038/ mi.2011.41 12. Hjelt K, Grauballe PC, Schiøtz PO, Andersen L, Krasilnikoff PA. Intestinal and serum immune response to a naturally acquired rotavirus gastroenteritis in children. J Pediatr Gastroenterol Nutr 1985; 4:60-6; PMID:2984402; http://dx.doi. org/10.1097/00005176-198502000-00012 in identifying children with diarrhea, Luz-Stella Rodríguez and Olga L Rojas for their support, Harry B Greenberg and Peter Burrows for reading the manuscript and Marisol Machetá for help in administrating the research projects. Supplemental Materials Supplemental materials may be found here: www.landesbioscience.com/journals/vaccines/article/25610 13. Hjelt K, Grauballe PC, Nielsen OH, Schiøtz PO, Krasilnikoff PA. Rotavirus antibodies in the mother and her breast-fed infant. J Pediatr Gastroenterol Nutr 1985; 4:414-20; PMID:2991489; http://dx.doi. org/10.1097/00005176-198506000-00016 14. Rahman MM, Yamauchi M, Hanada N, Nishikawa K, Morishima T. Local production of rotavirus specific IgA in breast tissue and transfer to neonates. Arch Dis Child 1987; 62:401-5; PMID:3036019; http://dx.doi.org/10.1136/adc.62.4.401 15.Hjelt K, Grauballe PC, Andersen L, Schiøtz PO, Howitz P, Krasilnikoff PA. Antibody response in serum and intestine in children up to six months after a naturally acquired rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1986; 5:74-80; PMID:3944746; http://dx.doi. org/10.1097/00005176-198601000-00014 16.Ward RL, Clark HF, Offit PA. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 2010; 202(Suppl):S72-9; PMID:20684721; http://dx.doi. org/10.1086/653549 17. Wood D; WHO Informal Consultative Group. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005. Vaccine 2005; 23:5478-87; PMID:16129525; http:// dx.doi.org/10.1016/j.vaccine.2005.07.035 18. Mesa MC, Rodríguez LS, Franco MA, Angel J. Interaction of rotavirus with human peripheral blood mononuclear cells: plasmacytoid dendritic cells play a role in stimulating memory rotavirus specific T cells in vitro. Virology 2007; 366:174-84; PMID:17499331; http://dx.doi.org/10.1016/j.virol.2007.04.007 19. Mesa MC, Gutiérrez L, Duarte-Rey C, Angel J, Franco MA. A TGF-beta mediated regulatory mechanism modulates the T cell immune response to rotavirus in adults but not in children. Virology 2010; 399:77-86; PMID:20096911; http://dx.doi. org/10.1016/j.virol.2009.12.016 20. Kvale D, Brandtzaeg P. An enzyme-linked immunosorbent assay for differential quantitation of secretory immunoglobulins of the A and M isotypes in human serum. J Immunol Methods 1986; 86:107-14; PMID:3944464; http://dx.doi. org/10.1016/0022-1759(86)90272-3 21. Zhang JJ, Xu LX, Liu G, Zhao MH, Wang HY. The level of serum secretory IgA of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Nephrol Dial Transplant 2008; 23:207-12; PMID:17938148; http://dx.doi. org/10.1093/ndt/gfm492 22. van Furth R, Schuit HR, Hijmans W. The immunological development of the human fetus. J Exp Med 1965; 122:1173-88; PMID:4159036; http://dx.doi. org/10.1084/jem.122.6.1173 23. Cleveland MG, Bakos MA, Pyron DL, Rajaraman S, Goldblum RM. Characterization of secretory component in amniotic fluid. Identification of new forms of secretory IgA. J Immunol 1991; 147:181-8; PMID:2051019 24. Rojas OL, Narváez CF, Greenberg HB, Angel J, Franco MA. Characterization of rotavirus specific B cells and their relation with serological memory. Virology 2008; 380:234-42; PMID:18789807; http://dx.doi.org/10.1016/j.virol.2008.08.004 2416Human Vaccines & Immunotherapeutics 25. Zaman KSD, Yunus MD, Arifeen SE, Azim T. Podder G, Faruque ASG, Karim S, Luby S, and Breiman RF. Rotavirus vaccine trials in Bangladesh: past, present, and future. VIIIth Commonwealth Association of Paediatric Gastroenterology and Nutrition [CAPGAN] Congress on Diarrhea and Malnutrition, 2006. 26.Morell A, Skvaril F, Noseda G, Barandun S. Metabolic properties of human IgA subclasses. Clin Exp Immunol 1973; 13:521-8; PMID:4717094 27. Grimwood K, Lund JC, Coulson BS, Hudson IL, Bishop RF, Barnes GL. Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children. J Clin Microbiol 1988; 26:732-8; PMID:2835391 28. Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-16; PMID:16148848; http://dx.doi.org/10.1097/01. inf.0000178294.13954.a1 29. Velázquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-9; PMID:11069230; http://dx.doi.org/10.1086/317619 30. Westerman LE, McClure HM, Jiang B, Almond JW, Glass RI. Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci U S A 2005; 102:7268-73; PMID:15883382; http://dx.doi. org/10.1073/pnas.0502437102 31. Fox PD, Khaw PT, McBride BW, McGill JI, Ward KA. Tear and serum antibody levels in ocular herpetic infection: diagnostic precision of secretory IgA. Br J Ophthalmol 1986; 70:584-8; PMID:3741822; http://dx.doi.org/10.1136/bjo.70.8.584 32. Rocha-Zavaleta L, Pereira-Suarez AL, Yescas G, CruzMimiaga RM, Garcia-Carranca A, Cruz-Talonia F. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology. Viral Immunol 2003; 16:159-68; PMID:12828867; http://dx.doi. org/10.1089/088282403322017893 33. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566-74; PMID:12077289 34. Herremans MM, van Loon AM, Reimerink JH, Rümke HC, van der Avoort HG, Kimman TG, et al. Poliovirus-specific immunoglobulin A in persons vaccinated with inactivated poliovirus vaccine in The Netherlands. Clin Diagn Lab Immunol 1997; 4:499503; PMID:9302194 35. Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999; 162:5011-8; PMID:10202050 Volume 9 Issue 11 ©2013 Landes Bioscience. Do not distribute. between October 2002 and October 2003, which was partially funded by GlaxoSmithKline. 41. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Ménard S, Candalh C, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008; 205:143-54; PMID:18166587; http://dx.doi.org/10.1084/jem.20071204 42. Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006; 101:2333-40; PMID:17032199; http://dx.doi.org/10.1111/j.1572-0241.2006.00741.x 43. Oortwijn BD, van der Boog PJM, Roos A, van der Geest RN, de Fijter JW, Daha MR, et al. A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int 2006; 69:1131-8; PMID:16395264; http://dx.doi. org/10.1038/sj.ki.5000074 44. Youngman KR, Franco MA, Kuklin NA, Rott LS, Butcher EC, Greenberg HB. Correlation of tissue distribution, developmental phenotype, and intestinal homing receptor expression of antigen-specific B cells during the murine anti-rotavirus immune response. J Immunol 2002; 168:2173-81; PMID:11859103 45. Tang B, Gilbert JM, Matsui SM, Greenberg HB. Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis. Virology 1997; 237:89-96; PMID:9344910; http://dx.doi.org/10.1006/viro.1997.8762 46. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM. Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol 1991; 29:1439-46; PMID:1909345 47. Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthésy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity 2002; 17:107-15; PMID:12150896; http://dx.doi.org/10.1016/ S1074-7613(02)00341-2 www.landesbioscience.comHuman Vaccines & Immunotherapeutics2417 ©2013 Landes Bioscience. Do not distribute. 36. Eijgenraam JW, Oortwijn BD, Kamerling SWA, de Fijter JW, van den Wall Bake AWL, Daha MR, et al. Secretory immunoglobulin A (IgA) responses in IgA nephropathy patients after mucosal immunization, as part of a polymeric IgA response. Clin Exp Immunol 2008; 152:227-32; PMID:18336594; http://dx.doi. org/10.1111/j.1365-2249.2008.03616.x 37. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 2009; 183:6883-92; PMID:19923474; http://dx.doi. org/10.4049/jimmunol.0901466 38. Ogra SS, Weintraub D, Ogra PL. Immunologic aspects of human colostrum and milk. III. Fate and absorption of cellular and soluble components in the gastrointestinal tract of the newborn. J Immunol 1977; 119:245-8; PMID:577500 39. Corthésy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J Immunol 2007; 178:27-32; PMID:17182536 40.Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194:417-25; PMID:11514599; http:// dx.doi.org/10.1084/jem.194.4.417 Landes Bioscience www.landesbioscience.com Supplemental Material to: Daniel Herrera, Camilo Vásquez, Blaise Corthésy, Manuel A Franco, and Juana Angel Rotavirus specific plasma secretory immunoglobulin in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine 2013; 9(11) http://dx.doi.org/10.4161/hv.25610 www.landesbioscience.com/journals/vaccines/article/25610 Supplementary Figure 1. RV-IgG in vaccinees and placebo recipients Data for 50 vaccinees and 62 placebo recipients after dose 2 (D2) are shown. Lines and error bars denote the mean and SEM, respectively. Differences between vaccinees and placebo recipients, as well as between protected and non-protected children, were evaluated with the Mann–Whitney test. All p values reported are 1-tailed. A. and B. The reported values correspond to the log10 of the inverse titer measured by ELISA. 1 Table S1. Demographic and clinical data from children with acute GE (n = 36). Group Gender Agea Breast Diarrheab RV feeding - RV Agd RV IgAc Feces Plasma Genotype A M 9 No 7 Neg Neg Neg Neg A F 6 Yes 5 Neg Neg Neg Neg A F 13 Yes 3 Neg Neg Neg Neg A M 14 Yes 5 Neg Neg Neg Neg A M 7 No 8 Neg Neg Neg Neg B M 13 Yes 8 100 Neg Neg Neg B M 10 No 10 100 Neg Neg Neg B F 21 No 5 100 Neg Neg Neg B F 22 Yes 4 400 Neg Neg Neg B M 16 No 5 800 Neg Neg Neg B F 8 No 4 200 Neg Neg Neg B M 16 Yes 4 800 Neg Neg Neg B F 10 Yes 4 100 Neg Neg Neg B M 14 Yes 8 3200 Neg Neg Neg B M 15 No 5 400 Neg Neg Neg B M 15 No 5 200 Neg Neg Neg B M 11 Yes 12 3200 Neg Neg Neg B M 14 Yes 7 51200 Neg Neg Neg B M 20 No 4 50 Neg Neg Neg B F 11 No 3 3200 Neg Neg Neg P 1 B F 15 Yes 4 800 Neg Neg Neg B M 17 No 2 3200 Neg Neg Neg B F 14 Yes 10 800 Neg Neg Neg B M 14 Yes 3 400 Neg Neg Neg B M 8 Yes 4 200 Neg Neg Neg C M 11 No 3 Neg 39 Neg P[6] C F 15 Yes 2 Neg 166.5 73.9 P[8] C F 21 No 2 Neg 87.8 90 P[4] C F 20 No 10 Neg 108.2 112.6 P[4] C M 6 Yes 3 Neg 104 23.8 P[8] C M 11 Yes 2 Neg 100 48.3 P[8] C M 14 Yes 7 Neg 103.4 33 P[8] C F 12 Yes 1.25 800 19 Neg P[8] C M 14 No 10 1600 87 Neg P[8] C M 21 Yes 3 200 94.4 Neg P[4] Ce F 10 No 3 100 87.4 Neg P[8] 2 a 3 respectively: 9.8 (1.59); 14.2 (0.87); 14.09 (1.46)]. b Days after onset of diarrhea at 4 the time of blood drawing [Mean and (SEM) for groups A, B and, C, respectively: 5 5.6 (0.87); 5.55 (0.6); 4.2 (0.97)]. c Inverse of RV-IgA titer. d % of positive control. 6 Neg: negative. 7 RV infection (RV-IgA+). Age of the children in months [Mean and (SEM) for groups A, B and, C, e The last four children of group C are individuals with secondary 8 9 2 10 Table S2. Correlation between RV-IgA titers after D2 and protection against 11 any RV GE RV-IgA Titers Vaccinees* (%) after D2 Placebo Vaccinees+placebo recipients* (%) recipients* (%) <100 23/25 (92) 44/64 (68.75)a 67/89 (75.28) 100 9/10 (90) 1/1 (100) 10/11 (90.90)b 200 7/8 (87.5) 1/1 (100) 8/9 (88.88) 400 3/3 (100) 1/1 (100) 4/4 (100) 800 2/3 (66.66) 1/1 (100) 3/4 (75) ≥1600 1/1 (100) 1/1 (100) 2/2 (100)c 12 *Shown is the number of protected vaccinees, placebo recipients or vaccinees and 13 placebo recipients analyzed jointly / the total number of children in each population 14 for each RV-IgA titer. 15 a 16 vaccinees than in RV-IgA- placebo recipients (Fischer exact probability test p < 17 0.05). 18 b 19 children (titers ≥ 1:100) than in those RV-IgA- (titer < 1:100) when vaccinees and 20 placebo recipients were analyzed jointly (chi-square test p > 0.05). 21 c 22 0.152) when vaccinees and placebo recipients were analyzed jointly. 23 Data are from reference 8 and include the seven placebo recipient children not 24 analyzed for RV-SIg. Similar results are obtained if they are excluded. The frequency of protected children is significantly higher in RV-IgA- (titer <100) The frequency of protected children was not significantly higher in RV-IgA+ Correlation between RV-IgA titers and protection (Spearman test p = 0.05, rho = 3 25 Table S3. Correlation between RV-IgG titers after D2 and protection against 26 any RV GE RV-IgG Titers Vaccinees* (%) after D2 Placebo Vaccinees+placebo recipients* (%) recipients* (%) 800 0/0 2/3 (66.66) 2/3 (66.66) 1600 3/3 (100) 12/14 (85.71) 15/17 (88.23) 3200 7/7 (100) 8/12 (66.66) 15/19 (78.94) 6400 19/21 (90.47) 12/18 (66.66) 31/39 (79.48) 12800 13/15 (86.66) 10/12 (83.33) 23/27 (85.18) 51200 2/3 (66.66) 2/2 (100) 4/5 (80) 102400 0/0 1/1 (100) 1/1 (100) 204800 1/1 (100) 0/0 1/1 (100) 27 *Shown is the number of protected vaccinees, placebo recipients or vaccinees and 28 placebo recipients analyzed jointly / the total number of children in each population 29 for each RV-IgG titer. 30 Plasma samples are the same analyzed for RV-SIg. 4 6.2 Introduction to the article: Simultaneous Assessment of RotavirusSpecific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab RV viremia is directly related to antigenemia, which is a common finding in acutely infected children with RV, independent from the existence of diarrhea. This appears to be very important because antigen load is inversely related to serum RV-IgA and RV-IgG titers [15]. Moreover, it was recently shown that RV infected children with RV RNA and RV antigen in both stool and serum were more susceptible to have severe symptoms [241]. Also, it was concluded that RV infection is occasionally accompanied by mild hepatitis [67] and frequently by a detectable increase of hepatic transaminases [68]. Immune mediators of RV clearance from the systemic compartment in humans have not been thoroughly identified. In mice, both T and B cells are important, but none of them is absolutely required. Nevertheless, serum RV-Abs alone are effective to delay RV antigenemia appearance, and they are sufficient to temporarily reduce antigenemia in chronically infected SCID mice [28]. Therefore, although local mucosal immunity is crucial in the human immune response against RV [13], the involvement of the systemic compartment by RV infection suggests that the systemic immune response could also be very important. In this regard, the study of circulating RV-mBc and their relation with serological memory seems relevant to better understand the immune response against RV, and thus improve the basis for finding better correlates of protection after vaccination [31, 32]. Patients with autoimmune diseases treated with RTX constitute a unique opportunity to evaluate the relation of antigen-specific mBc with antigen-specific serological memory in humans. It provides the case in which one of the components, circulating mBc, is temporarily absent, so its effect on the other component, serological memory, can be assessed. Additionally, autoimmunity is a condition in which short-lived PC seem to be important for the maintenance of serological memory [35], in contrast to what is considered in healthy adults [30, 33]. Even though pathogen-specific IgG Abs and auto-Abs of different isotypes have been evaluated in patients with autoimmunity treated with RTX [37-40], antigen-specific mBc and antigen-specific Abs of different isotypes have not been simultaneously assessed. Furthermore, RV has several distinguishing features that make it a relevant model to study the relationship between mBc and serological memory: 1. It is one of the few models with tools that permit the characterization of antigen-specific mBc in humans. 2. Circulating RV-specific Bc seem to be peculiar: a group of naïve Bc bind RV- VLPs [41, 42], and RV-mBc are enriched in the CD27+IgM+ and in the CD27-IgG+ mBc subsets [43, 44], subpopulations important in autoimmune 46 diseases pathogenesis [45-48]. 3. The relationship between RV-mBc and serological memory appears to be somewhat different from that of TT-mBc, one of the most studied antigens concerning the maintenance serological memory [43]. We, thus, hypothesized that RV-mBc are distributed in a distinct manner in patients with autoimmune diseases and are, therefore, related to serological memory in a peculiar way, dissimilar from the proposed manner for pathogens studied thus far. To evaluate this hypothesis, circulating total, RV- and TT-mBc and Abs, and some auto-Abs, were evaluated in patients with autoimmunity before and after RTX therapy, and in sex and age-matched healthy adults. We found that the relative contribution of each mBc subset to RV-mBc was, overall, comparable between healthy volunteers and patients before RTX treatment. We also present direct evidence that in the absence of circulating TTand RV-mBc the corresponding antigen-specific serological memory remains steady, irrespective of the Ab isotype and subclass studied here and, therefore, seems to be maintained by long-lived PC unaffected by RTX. In contrast, shortlived PC seem to maintain at least a fraction of IgM-RF, IgG-anti-CCP, and IgGanti-dsDNA auto-Abs, as well as a high proportion of the total IgM pool, which are probably in equilibrium with auto-Ag-specific mBc depleted by RTX. 47 PLOS ONE Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab --Manuscript Draft-Manuscript Number: PONE-D-13-48893 Article Type: Research Article Full Title: Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab Short Title: RV-Serological Memory after Rituximab Theraphy Corresponding Author: Manuel Antonio Franco, M.D. Ph.D. Pontificia Universidad Javeriana Bogota, COLOMBIA Keywords: serological memory; memory B cells; Rituximab; autoimmune diseases; rotavirus Abstract: The mechanisms that contribute to the maintenance of serological memory are still unclear. Rotavirus (RV) memory B cells (mBc) are enriched in IgM+ and CD27subpopulations, which are associated with autoimmune diseases pathogenesis. In patients with autoimmune diseases treated with Rituximab (RTX), some autoantibodies (auto-Abs) decrease after treatment, but other auto-Abs and pathogen-specific IgG Abs remain unchanged. Thus, maintenance of autoimmune and pathogen-specific serological memory may depend on the type of antigen and/or Ab isotype evaluated. Antigen-specific mBc and antigen-specific Abs of different isotypes have not been simultaneously assessed in patients after RTX treatment. To study the relationship between mBc subpopulations and serological memory we characterized total, RV- and tetanus toxoid (TT)-specific mBc by flow cytometry in patients with autoimmune diseases before and after treatment with RTX. We also measured total, RV- and TTAbs, and some auto-Abs by kinetic nephelometry, ELISA, and EliA tests, respectively. Minor differences were observed between the relative frequencies of RV-mBc in healthy controls and patients with autoimmune disease. After RTX treatment, naïve Bc and total, RV- and TT-specific mBc [IgM+, switched (IgA+/IgG+), IgM+ only, IgD+ only, and CD27- (IgA+/IgG+/IgM+)] were significantly diminished. An important decrease in total plasma IgM and minor decreases in total IgG and IgA levels were also observed. IgM rheumatoid factor, IgG anti-CCP, and IgG anti-dsDNA were significantly diminished. In contrast, RV-IgA, RV-IgG and RV-IgG1, and TT-IgG titers remained stable. In conclusion, serological memory against RV and TT seem to be maintained by longlived plasma cells, unaffected by RTX, and an important proportion of total IgM and serological memory against some auto-antigens seem to be maintained by short-lived plasma cells, dependent on mBc precursors depleted by RTX. Order of Authors: Daniel Herrera Olga Lucía Rojas Carolina Duarte Rubén Darío Mantilla Juana Ángel Manuel Antonio Franco, M.D. Ph.D. Suggested Reviewers: Jennifer H Anolik, MD, PhD University of Rochester Medical Center, School of Medicine and Dentistry [email protected] Her research interests include the role of B cells in the pathophysiology of human systemic lupus. She has been one of the pioneers in the use of B-cell depletion for the therapy of autoimmune diseases and investigation of the effects of B cell depletion on immune function in SLE patients. Baoming Jiang, D.V.M, PhD Centers for Disease Control and Prevention Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation Simultaneous Assessment of Rotavirus-Specific Memory B Cells and 1 2 Serological Memory after B Cell Depletion Therapy with Rituximab 3 4 Daniel Herrera1, Olga L. Rojas2, Carolina Duarte-Rey3, Rubén D. Mantilla3, 5 Juana Ángel1 and Manuel A. Franco1*. 7 1 6 8 9 Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia. 2Unidad de Inmunología, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia. 3Riesgo de 10 Fractura S.A. - CAYRE I.P.S, Bogotá, Colombia. 12 *Correspondence to: Dr. Manuel A. Franco, Instituto de Genética Humana, 14 Phone: 57-1-3208320 Ext 4077. Fax: 57-1-2850356. 11 13 Pontificia Universidad Javeriana, Carrera 7 # 40-62, Bogotá, Colombia. 15 1 16 ABSTRACT 18 still unclear. Rotavirus (RV) memory B cells (mBc) are enriched in IgM+ and 17 The mechanisms that contribute to the maintenance of serological memory are 19 CD27- subpopulations, which are associated with autoimmune diseases 21 (RTX), some autoantibodies (auto-Abs) decrease after treatment, but other 23 maintenance of autoimmune and pathogen-specific serological memory may 20 pathogenesis. In patients with autoimmune diseases treated with Rituximab 22 auto-Abs and pathogen-specific IgG Abs remain unchanged. Thus, 24 depend on the type of antigen and/or Ab isotype evaluated. Antigen-specific 26 simultaneously assessed in patients after RTX treatment. To study the 25 mBc and antigen-specific Abs of different isotypes have not been 27 relationship between mBc subpopulations and serological memory we 29 in patients with autoimmune diseases before and after treatment with RTX. We 31 nephelometry, ELISA, and EliA tests, respectively. Minor differences were 33 patients with autoimmune disease. After RTX treatment, naïve Bc and total, RV- 35 CD27- (IgA+/IgG+/IgM+)] were significantly diminished. An important decrease in 37 observed. IgM rheumatoid factor, IgG anti-CCP, and IgG anti-dsDNA were 39 titers remained stable. 28 characterized total, RV- and tetanus toxoid (TT)-specific mBc by flow cytometry 30 also measured total, RV- and TT-Abs, and some auto-Abs by kinetic 32 34 observed between the relative frequencies of RV-mBc in healthy controls and and TT-specific mBc [IgM+, switched (IgA+/IgG+), IgM+ only, IgD+ only, and 36 total plasma IgM and minor decreases in total IgG and IgA levels were also 38 significantly diminished. In contrast, RV-IgA, RV-IgG and RV-IgG1, and TT-IgG 2 40 In conclusion, serological memory against RV and TT seem to be maintained 42 total IgM and serological memory against some auto-antigens seem to be 44 by RTX. 41 43 by long-lived plasma cells, unaffected by RTX, and an important proportion of maintained by short-lived plasma cells, dependent on mBc precursors depleted 45 3 46 Introduction 48 can persist for decades, or in some cases for a lifetime, in the apparent 50 first line of defense against reinfection by many microorganisms [2], and critical 52 identified for several vaccines [3]. Additionally, in autoimmune diseases, 54 activity and pathogenesis [4] and in some cases predict disease severity [5-7]. 47 Pathogen-specific protective IgG levels following natural infection or vaccination 49 absence of the antigen [1]. This serological memory provides the host with a 51 pathogen-specific antibody (Ab) titers that correlate with protection have been 53 55 autoantibodies (auto-Abs) of different isotypes are associated with disease The mechanisms that contribute to the maintenance of serological memory in 56 healthy individuals are still unclear and, in general, have been studied only with 58 adults, IgG serological memory seems to be maintained by long-lived plasma 57 respect to the IgG isotype and for a limited number of antigens. In healthy 59 cells (PC), independently of memory B cells (mBc) [1,8]. Two non-mutually 61 [9]: 1) long-lived PC reside in a limited number of survival niches in the bone 63 competence to respond to survival signals of these niches, which will finally 65 lifespan of PC is related to the integrated signals through the B-cell receptor, 67 through CD4 T-cell help, and therefore, is imprinted at the time of the immune 69 independently regulated populations [11]. 60 exclusive theories have been proposed to explain the survival of long-lived PC 62 marrow or secondary lymphoid organs. Plasmablasts may or may not gain the 64 determine their lifespan as long-lived PC or short-lived PC [8,10]. 2) The 66 which largely depend on the antigen repetitive nature, and signals obtained 68 response induction [9]. This theory proposes that PC and mBc represent 4 70 However, under certain circumstances, such as autoimmunity, short-lived PC, 71 which need to be continuously replenished by mBc, may also contribute to 73 PC contribute to serological memory, a correlation is expected between 75 serological memory [13]. 77 treated with B-cell depletion therapy using Rituximab® (RTX), an anti-CD20 72 maintain serological memory (see below) [12]. In conditions where short-lived 74 numbers of circulating antigen-specific mBc and levels of antigen-specific 76 Serological memory has been evaluated in patients with autoimmune diseases 78 monoclonal Ab that depletes circulating Bc and leaves PC unaffected. After Bc 80 decrease, but within normal ranges [14]. In contrast, IgG Ab titers against 82 polysaccharide [16] remain constant. In regard to auto-Abs results differ: on the 84 anti-C1q [16], both of IgG isotype, and IgA-, IgG-, and IgM-class rheumatoid 86 auto-Abs against Ro52, Ro60, and La44, also of IgG isotype, remain 88 of maintenance of serological memory could depend on the type of antigen 79 depletion with one RTX cycle total IgA, IgG, IgM, and IgE levels significantly 81 pathogens such as measles [14], tetanus [15], and pneumococcal capsular 83 one hand, it has been reported that anti-double-stranded DNA (dsDNA) and 85 factors (RF) diminish significantly after RTX therapy [17]. On the other hand, 87 unchanged after RTX therapy [14]. These results suggest that the mechanism 89 and/or Ab isotype evaluated, particularly in patients with autoimmune disease. 91 have not been simultaneously assessed in patients that received B-cell 93 In a recent study, we characterized circulating RV-specific B cells (RV-Bc 90 However, antigen-specific mBc and antigen-specific Abs of different isotypes 92 depletion therapy with RTX. 94 identified by their capacity to bind GFP-coupled virus like particles [VLPs]) and 5 95 tetanus toxoid-specific B cells (TT-Bc identified by their capacity to bind biotin 97 volunteers [18]. Compared with TT-Bc, RV-Bc seem to be peculiar because a 99 CD27+IgM+ (which includes the CD27+IgD+IgM+ subset) and in the CD27-IgG+ 101 RV-IgA plasma levels, but a correlation between CD27+IgG+ RV-mBc and RV- 96 labeled TT) and assessed their relation with serological memory in healthy 98 group of naïve Bc bind RV-VLPs [19,20], and RV-mBc are enriched in the 100 mBc subsets [18,21]. In addition, CD27+IgA+ RV-mBc correlated positively with 102 IgG was absent. In contrast, CD27+IgG+ TT-mBc correlated with TT-IgG plasma 104 seems to be somewhat different from that of TT-mBc, making it a relevant 106 CD27+IgD+IgM+ mBc (IgM+ mBc) and CD27- mBc, the mBc subsets in which 108 mBc have been shown to be decreased in patients with systemic lupus 110 Syndrome [24]. Moreover, there is a negative correlation between the 112 patients [22]. In RA patients IgM+ mBc seem to migrate to the synovial 103 levels. Therefore, the association between RV-mBc and serological memory 105 model to study the relationship between mBc and serological memory. 107 RV-mBc are enriched, are relevant in autoimmune diseases pathogenesis. IgM+ 109 erythematosus (SLE) [22], rheumatoid arthritis (RA) [23], and Sjögren’s 111 circulating number of IgM+ mBc and auto-Abs levels and disease activity in SLE 113 membrane in a tumour necrosis factor dependent manner [23]. In contrast, 115 with disease activity [25]. Since RV-mBc are enriched in these subsets, such 114 circulating CD27- mBc are increased in SLE patients and positively correlate 116 cells could be related to serological memory in a unique manner and we 118 autoimmunity. 117 hypothesized they could be distributed in a peculiar manner in patients with 6 119 Here, total, RV- and TT-specific B-cell subsets were characterized in patients 121 and in healthy individuals. Total immunoglobulins (Igs), RV- and TT-Abs, and 120 with autoimmune diseases before and after B-cell depletion therapy with RTX, 122 some auto-Abs were also measured in the same timeframes. Titers of RV-IgA, 124 In contrast, IgM RF, IgG against cyclic cytrullinated peptide (CCP), and IgG 123 RV-IgG, and RV-IgG1, as well as TT-IgG, remained stable after RTX treatment. 125 against dsDNA were significantly diminished, as well as total Igs, especially 127 by long-lived PC, unaffected by RTX, and an important proportion of total IgM 129 short-lived PC, dependent on mBc depleted by RTX. 131 Materials and Methods 133 Written informed consent was obtained from each adult volunteer. Studies were 135 Universidad Javeriana and conducted in accordance with the guidelines of the 137 Pools of plasma samples from children enrolled in prior published studies [26- 126 128 130 total IgM. Thus, serological memory against RV and TT seem to be maintained and serological memory against some auto-antigens seem to be maintained by 132 Ethics Statement 134 approved by the Ethics Committee of the San Ignacio Hospital and Pontificia 136 Helsinki Declaration. 138 28] in whom the informed consent form (also approved by the Ethics Committee 140 their use in unrelated research studies were used as positive controls in some 139 of the San Ignacio Hospital and Pontificia Universidad Javeriana) authorized 141 experiments. 143 Subjects 142 7 144 Fourteen patients, twelve females and two males, nine of them diagnosed with 145 RA and five with SLE according to the American College of Rheumatology 147 disease activity, despite treatment with disease-modifying anti-rheumatic drugs 149 score of 28 joint counts (DAS28) or SLE Disease Activity Index (SLEDAI), 151 selected to receive RTX by their treating rheumatologist. Additional clinical 153 included: lupus nephritis (n = 2), autoimmune thrombocytopenia (n = 1), overlap 155 regimen included two infusions of intravenous RTX (1,000 mg), 14 days apart, 157 median age at RTX treatment was 46 years (range 26 – 69) and the median 159 patients had been diagnosed (within three years or less). Clinical follow up 146 international criteria [29,30] were included. All patients had moderate or high 148 or standard immunosuppressive therapy, measured by the disease activity 150 respectively. Given the failure to standard treatment regimens, they were 152 manifestations considered to use RTX as the treatment of choice in patients 154 of RA and SLE (n = 4), and antiphospholipid syndrome (n = 2). The treatment 156 in combination with intravenous methylprednisolone (100-250 mg) [31,32]. The 158 disease duration to the time of RTX treatment was 3 years (range 1 – 30); eight 160 could be done in eleven patients within the following six months post B-cell 162 clinical improvement. Supplementary Table S1 describes accompanying 164 treatment, baseline disease activity, and clinical follow up. Ten age and sex 161 depletion therapy. Out of these, seven patients showed subjective and objective 163 autoimmune diagnoses, concomitant and relevant previous pharmacologic 165 matched healthy volunteers were used as controls. 167 Sample collection and processing 166 8 168 Peripheral blood mononuclear cells (PBMC) were isolated by LymphoSep (MP 170 samples from ten of the fourteen patients, described above, immediately before 172 samples were only available after RTX treatment), and from ten age and sex 174 volunteer after each blood draw, and plasma was collected and stored at −80 176 measurement. 178 Production of fluorescent virus like particles (VLPs) 180 using baculovirus expression vectors, as previously described [33]. Briefly, Sf9 182 infection greater than 5 PFU/cell. One baculovirus expressed RF (bovine RV) 184 fused to the N terminus of RF VP2 deleted in the first 92 amino acids. Infected 186 gradient centrifugation in CsCl. The optimal concentration of the RV VLPs for 188 Of note, RV VP6 is an immunodominant protein, and the majority of human RV- 190 infected animals and humans recognize the VP6 protein on the outer shell of 169 Biomedicals, Solon, OH) density-gradient centrifugation from heparinized 171 and four to six months after RTX infusion (in the remaining four patients PBMC 173 matched healthy controls. A complete blood count test was performed for each 175 °C for subsequent total and antigen-specific Igs assessment and auto-Abs 177 179 Fluorescent RV VLPs were a kind gift of Annie Charpilienne and were produced 181 cells were co-infected with 2 recombinant baculoviruses at a multiplicity of 183 VP6 and the other a fusion protein consisting of green fluorescent protein (GFP) 185 cultures were collected five to seven days post infection and purified by density 187 labeling of specific mBc was determined using PBMC from healthy volunteers. 189 specific B cells bind to VP6 [34]. Additionally, the majority of RV antibodies in 191 the VLPs [35]. 192 9 193 Biotinylated - TT antigen 195 biotinylated using the EZ-Link Photoactivatable Biotin kit (Pierce Biotechnology, 197 [18], with minor modifications. A total of 750 µg of TT protein was incubated 199 under a UV (365 nm) lamp, and then dialyzed against PBS for 18 hours, to 201 Pierce, Illkirch, France). The optimal concentration of the biotinylated TT for 203 TT vaccinated volunteers, and the specificity of binding was evaluated with a 194 Tetanus Toxoid (Statens Serum Institute, Denmark) for in vitro tests was 196 Rockford, IL) according to manufacturer's instructions, as previously described 198 with biotin at a molar ratio of 20 mol of dye per mole of protein, for 20 min on ice 200 remove excess biotin, using a Slide-A-Lyzer dialysis cassette (Thermo Scientific 202 labeling of specific mBc was determined using PBMC from healthy and recently 204 competition assay using non-biotinylated TT (data not shown). 206 Flow cytometry assays 208 Gaithersburg, MD) and incubated with the GFP labeled VLPs (0.9 µg/test) or 210 temperature (RT). The cells were then washed with PBS – 1% bovine serum 212 Chemicals, Paris, KY) (staining buffer), and surface stained with Abs against 214 Jose, CA), IgD-HorizonTM V450 (IA6-2 clone; BD), CD27- phycoerythrin (PE)- 205 207 Fresh PBMC, 4 to 6 x 106, were washed twice with PBS (Gibco-BRL, 209 without this reagent (negative control) for 45 minutes in the dark, at room 211 albumin (Merck, Darmstadt, Germany), 0.02% sodium azide (Mallinckrodt 213 CD19-allophycocyanin (APC)-H7 (SJ25C1 clone; Becton Dickinson [BD], San 215 Cy7 (M-T271 clone; BD), goat anti-IgA-R-PE (Jackson ImmunoResearch, West 217 700 (145-8 clone; BD). Biotinylated-TT, or no reagent, was also added at this 216 Grove, PA), IgG-APC (G18-145 clone; BD) and custom-made IgM-Alexa Fluor 10 218 step and incubated for 30 minutes in the dark, at RT. Cells were then washed 220 peridinin chlorophyll protein (PerCP) (BD). Streptavidin-PerCP was also added 222 this reagent (negative control). After staining, the cells were washed and 224 window, were acquired on a FACSAria (BD) or LSRFortessa (BD) flow 226 intensity values among experiments run on different days and regardless of the 228 the cut-off between positive and negative cell populations for each marker [36]. 219 with staining buffer and the biotinylated-TT was detected using streptavidin- 221 to the PBMCs without biotinylated-TT to assess the background generated by 223 resuspended in staining buffer. At least 200,000 B cells, gated on a CD19+ 225 cytometer. Application settings were used to obtain constant fluorescence 227 flow cytometer used. Fluorescence minus one controls were used to determine 229 Of note, Abs against CD3/CD14-HorizonTM V500 (UCHT1 and M5E2 clones, 230 respectively; BD) were used as a dump channel in samples taken from patients 232 use, the dump channel was disregarded in the final analyses. 234 of CD19+ B cells/mL, calculated after background subtraction, based on the 236 Evaluable total B cell subpopulations were defined as those with ≥10 acquired 238 calculated considering the median CD19+ events acquired after RTX treatment, 231 after RTX treatment. However, since conclusions were similar with or without its 233 Results for total and antigen-specific mBc were expressed as absolute numbers 235 total lymphocyte numbers in the patient's complete blood count test results. 237 events [37]. The frequency, in terms of CD19+ B cells, of those 10 events was 239 and multiplied by the median absolute B cell count after RTX treatment. This 240 241 242 value, 3.5 CD19+ B cells/mL, corresponds to the dotted lines present in each total B cell subpopulation of Figure 2 and represents the flow cytometry detection limit for total B cell subpopulations. A common detection limit could 11 243 not be determined for antigen-specific mBc subsets due to the variable 245 mBc subsets with ≥10 acquired events, and at least two-fold greater than the 247 Flow cytometry analysis was performed using FlowJo software version 9.6.2 for 244 background. Nevertheless, the reported values correspond to antigen-specific 246 observed background. 248 Mac (Treestar, Ashland, OR). 250 Measurement of total immunoglobulins (IgA, IgG and IgM) and IgM 252 Plasma samples were thawed and simultaneously assessed by kinetic 254 Fullerton, CA), following the manufacturer’s instructions. Measuring ranges are 256 mg/dL); IgG: 200 – 3600 mg/dL (normal reference range values: 751 – 1560 249 251 Rheumatoid Factor 253 nephelometry on an IMMAGE® immunochemistry system (Beckman Coulter, 255 as follows: IgA: 40 – 700 mg/dL (normal reference range values: 82 – 453 257 mg/dL); IgM: 25 – 400 mg/dL (normal reference range values: 46 – 304 mg/dL); 258 and IgM rheumatoid factor (RF): 20 – 800 IU/mL (negative cut off value: <20 260 70-75%. 262 ELISAs for detection of RV-specific IgA, IgG, and IgG1 and TT-specific IgG 259 261 IU/mL), with a sensitivity level in RA patients reported by the manufacturer of 263 in plasma 265 modifications [18]: 96-well vinyl microtiter ELISA plates (Thermo Electron 267 infected MA104 cells or the supernatant of mock-infected cells (negative 264 RV and TT antibodies were assessed as previously described with minor 266 Corporation, Milford, MA) were coated with either a supernatant from RF virus- 12 268 control), for RV-specific ELISAs, or 0.5 µg/mL of TT or PBS (negative control), 270 dilutions of plasma samples were deposited in each well. After incubation, the 272 or IgG (Kirkegaard & Perry Laboratories [KPL], Gaithersburg, MD) or, biotin- 274 peroxidase (KPL) and tetramethyl benzidine substrate (KPL). Pools of plasma 276 were used as positive controls. Plasmas from a child without evidence of 278 used as negative controls. Samples were considered positive if the optical 280 optical density in the corresponding negative control wells. To be accepted for 282 one dilution from plate to plate. 284 Measurement of anti-CCP and anti-dsDNA autoantibodies (IgG isotype) 286 immunoassay (EliA test), following the manufacturer’s instructions, on a Phadia 288 has a measuring range of 0.4 to at least 340 U/mL, a negative cut off value of < 290 U/mL; the manufacturer’s reported clinical sensitivity and specificity are 87.8% 292 range of 0.5 to at least 400 IU/mL, a negative cut off value of < 10 IU/mL, an 269 for TT-specific IgG ELISA, and incubated overnight at 4°C. After blocking, serial 271 following sequence of reagents was added: biotin-labeled goat anti-human IgA 273 labeled mouse anti-human IgG1 (Sigma-Aldrich, St. Louis, MO); streptavidin- 275 samples from children with RV-IgA, or RV-IgG, and from adults with TT-IgG 277 previous RV infection (RV-IgA-) and from an adult negative for TT-IgG were 279 density in the experimental wells was > 0.1 units and two-fold greater than the 281 analysis, the titer of the positive control plasma could not differ by more than 283 285 Plasma samples were simultaneously assessed by a fluorescence enzyme 287 ImmunoCAP 100 system (Phadia AB, Uppsala, Sweden). The anti-CCP test 289 7 U/mL, an equivocal range of 7 – 10 U/mL, and a positive cut off value of > 10 291 and 96.7%, respectively, in RA patients. The anti-dsDNA test has a measuring 13 293 equivocal range of 10 – 15 IU/mL, and a positive cut off value of > 15 IU/mL; the 295 specificity of 93.2%. 297 Statistical analyses 299 GraphPad Prism version 6. Differences between groups were evaluated with 301 were evaluated with Spearman's test. When data followed a normal distribution, 302 303 tailed tests. 304 305 Results 307 and patients 309 CD27- mBc subpopulations [22,23,25], in which RV-mBc are enriched, we 311 volunteers (HV) and patients prior RTX treatment (prior-RTX) by flow cytometry 313 enrichment of RV-mBc was found in the IgMhiIgDlow subset in HV and patients 294 296 manufacturer’s reported sensitivity for active SLE is 70.8% and clinical 298 Analysis was performed with SPSS software version 20.0 (IBM Inc.) and with 300 nonparametric Mann–Whitney and Wilcoxon tests, as required. Correlations 306 a Student’s t-test was applied. Significance was established if p < 0.05, in 2 RV-mBc are enriched in the circulating IgM+ mBc subsets in both controls 308 Since patients with RA and SLE show altered frequencies in the IgM+ mBc and 310 compared the relative frequencies of total and RV-Bc subsets in healthy adult 312 (see analysis strategy in Supplementary Figure S1A). As expected [34], an 314 prior-RTX (Figure 1A and 1B, respectively). Additionally, an enrichment of RV- 315 mBc was also found in the IgMlowIgDhi mBc subset in both HV and patients 317 enrichment of RV-naïve Bc was observed in patients prior-RTX (Figure 1B). 316 prior-RTX, and in the IgM+ only mBc subset in HV (Figure 1A). An apparent 14 318 An enrichment of RV-mBc was not detected in the CD27- mBc subset in HV and 319 patients prior-RTX (Figure 1A and 1B, respectively). However, in agreement 321 mBc, RV-mBc were enriched in the CD27-IgG+ subset in HV, but not in patients 320 with previous results [18], when the analysis was done in terms of the CD27- 322 prior-RTX (data not shown). 323 324 similar between HV and patients prior-RTX. 325 326 Total and antigen-specific Bc subsets are significantly decreased after B- 328 Patients with autoimmune diseases treated with RTX represent a unique 330 humans, because it provides a scenario in which one of the components, 332 serological memory, can be evaluated. Therefore, we compared the absolute 334 and ten patients before and after RTX treatment (see analysis strategy in Thus, the relative contribution of each mBc subset to RV-mBc was, in general, 327 cell depletion therapy with RTX 329 opportunity to assess the relation between mBc and serological memory in 331 circulating mBc, is temporarily absent, so its effect on the other component, 333 numbers (CD19+ B cells/mL) of total, RV- and TT-specific Bc subsets in ten HV 335 Supplementary Figure S1B). 337 prior-RTX. As shown in Figure 2, IgM+ mBc, IgM+ only mBc, and switched IgG+ 339 same was observed for IgM+ mBc IgMhiIgDlow and IgMlowIgDhi, IgD+ only mBc, 336 First, we compared circulating total mBc subsets present in HV and patients 338 mBc were significantly decreased in patients prior-RTX, compared with HV. The 340 and switched IgA+ mBc (see Supplementary Figure S2). 342 and after-RTX. After RTX treatment, six of the ten patients studied had clinical 341 Second, we compared circulating total mBc subsets present in patients before 15 343 peripheral Bc depletion (less than 5,000 CD19+ cells/mL) (Figure 2). The four 345 peripheral Bc depletion (data not shown). In patients after-RTX a significant 347 Figure S2). The median decrease in all subsets, with respect to the 349 IgG+ mBc, which had a median decrease of 87% (data not shown). 351 patients before and after-RTX. RV-IgM+ mBc, RV-IgM+ only mBc, RV-switched 344 patients assessed by flow cytometry only after RTX treatment also had clinical 346 decrease in all total Bc subsets was observed (Figure 2 and Supplementary 348 pretreatment values, was above 96%, except for switched IgA+ and switched 350 Third, we compared circulating antigen-specific mBc subsets present in HV and 352 IgA+ mBc, and RV-switched IgG+ mBc were significantly decreased in patients 354 and IgMlowIgDhi, and RV-IgD+ only mBc were also significantly diminished (see 353 prior-RTX, compared with HV (Figure 3). In addition, RV-IgM+ mBc IgMhiIgDlow 355 Supplementary Figure S3). In patients after-RTX a significant decrease in all 357 Figure S3). The median decrease in all subsets, respect to the baseline values, 359 which had a median decrease of 92% and 93%, respectively. 361 antigen-specific-mBc subsets decreased in similar proportions. Of note, we 363 switched mBc [22,38]. In patients after-RTX both total and antigen-specific Bc 356 RV- and TT-specific Bc subsets was observed (Figure 3 and Supplementary 358 was above 98%, except for RV-switched IgA+ and RV-switched IgG+ mBc, 360 Taken together, these results showed that in patients prior-RTX total and 362 confirmed that patients prior-RTX have decreased IgM+ mBc subsets and 364 subsets are significantly diminished at similar levels. 366 Total plasma immunoglobulins and auto-Abs, unlike RV- and TT-Abs, are 365 367 significantly decreased after B-cell depletion therapy with RTX 16 368 To determine the effect of B-cell depletion therapy with RTX on the total 370 by kinetic nephelometry (Figure 4). Levels of total plasma Igs in patients prior- 372 patients prior-RTX (2-tailed Mann-Whitney’s test, p = 0.0578). As expected [14], 374 remained within normal ranges (Figure 4). Two patients had an increase in the 376 increase in the IgG level. Of note, excluding the patients who showed an 378 respect to the pretreatment values, was significantly greater than the 380 and p = 0.0093, respectively) (data not shown). 382 serological memory, we assessed IgM-RF and IgG-anti-CCP levels (relevant 369 serological memory, we measured the levels of total plasma IgA, IgG, and IgM 371 RTX and HV were similar; nevertheless, total IgM tended to be higher in 373 after RTX treatment total plasma Igs were significantly decreased, although 375 IgA level, one of them also in the IgM level, and another patient showed an 377 increase after RTX treatment, the total plasma IgM percentage decrease, 379 percentage decrease for total IgA and IgG (2-tailed Student’s t-test, p = 0.0031 381 To evaluate the effect of B-cell depletion therapy with RTX on autoimmune 383 auto-Abs in RA) and IgG-anti-dsDNA levels (relevant auto-Ab in SLE) in 385 in HV as controls. In four HV the levels of RF were just above the negative cut 387 (Figure 5B), and in two levels of anti-dsDNA were positive (Figure 5C). 389 dsDNA auto-Abs levels (Figure 5A, 5B, and 5C, respectively). Following RTX 391 In order to contrast the effect of B-cell depletion therapy on the levels of 384 patients with the corresponding diagnoses before and after RTX treatment, and 386 off value (Figure 5A), in all of them levels of anti-CCP auto-Abs were negative 388 Compared with HV, patients prior-RTX had higher RF, anti-CCP, and anti- 390 treatment, all auto-Abs levels were significantly diminished (Figure 5). 392 individual auto-Abs and their respective isotype of total plasma Ig, data after 17 393 RTX treatment were expressed as the percentage decrease respect to the 395 analyzed. The percentage drop in IgG-anti-dsDNA and IgG-anti-CCP was 397 0.0001 and p = 0.0378, respectively). There was no significant difference 399 As expected [15], and in contrast to the effect of B-cell depletion therapy on 401 constant after RTX treatment (Figure 6A). Similarly, RV-IgA (Figure 6B) and 403 titers because CD27-IgG+ mBc predominantly express the IgG1 and IgG3 405 seems to be a predominant RV-IgG subclass [40]. Plasma RV-IgG1 titers in 407 In conclusion, B-cell depletion therapy with RTX did not have an effect on 409 significantly decreased the auto-Abs assessed and the total plasma Igs, 394 pretreatment values. Only patients with an abnormal pretreatment value were 396 significantly higher than that in total plasma IgG (2-tailed Student’s t-test, p < 398 between the percentage drop in IgM-RF and total plasma IgM (data not shown). 400 total plasma Igs and the auto-Abs evaluated, plasma TT-IgG titers remained 402 RV-IgG (Figure 6C) remained unchanged. We further assessed the RV-IgG1 404 subclasses [39], RV-mBc are enriched in the CD27-IgG+ subset, and RV-IgG1 406 patients before and after RTX treatment were similar (Figure 6D). 408 pathogen-specific serological memory, irrespective of the isotype evaluated, but 410 especially total IgM. 412 Correlations between mBc subsets and serological memory 414 auto-Abs or Ag-specific Abs. All IgM+ mBc subsets correlated with total plasma 411 413 We next set to determine if selected mBc subsets could correlate with total Igs, 415 IgM (Table 1) only when data before and after RTX treatment in all patients 417 total switched IgG+ and CD27-IgG+ mBc correlated with anti-dsDNA levels. 416 were analyzed jointly. Likewise, in patients with SLE as their principal diagnosis, 18 418 TT-switched IgG+ mBc correlated with plasma TT-IgG titers in HV; in contrast, 420 plasma RV-IgA or RV-IgG titers were absent in HV and in patients (Table 2 and 419 correlations between RV-switched IgA+ and IgG+ mBc and their corresponding 421 data not shown). 423 Discussion 425 specific mBc after B-cell depletion therapy with RTX (Figure 3 and 427 6). In contrast, the auto-Abs measured were significantly diminished (Figure 5). 429 IgG (Figure 4 and data not shown). Moreover, when data before and after RTX 431 correlated (Table 1). To the best of our knowledge, this is the first time that 433 isotypes are determined in patients receiving B-cell depletion therapy with RTX, 435 plasma IgM is described in patients with autoimmunity. 422 424 Here, we show that despite a significant decrease of circulating RV- and TT- 426 Supplementary Figure S3), plasma RV- and TT- Abs remained constant (Figure 428 Similarly, total IgM decreased at significantly higher levels than total IgA and 430 treatment were analyzed jointly, IgM+ mBc subsets and total plasma IgM 432 circulating antigen-specific mBc and antigen-specific Abs of the IgA and IgG1 434 and the first time that a correlation between several IgM+ mBc subsets and total 436 The results presented here advance our knowledge of RV-mBc. We confirmed 438 that RV-mBc were also significantly enriched in the IgMlowIgDhi and IgM+ only 437 [18,21,34] that in HV RV-mBc are enriched in the IgMhiIgDlow subset and found 439 mBc subsets (Figure 1A), a tendency previously observed [34]. In contrast, in 441 1B) was absent, possibly because this subset was significantly decreased 440 patients prior-RTX enrichment of RV-mBc in the IgM+ only mBc subset (Figure 442 compared with HV (Figure 3). An enrichment of RV-naïve Bc was observed in 19 443 patients prior-RTX (Figure 1B). However, this may be simply because total and 445 compared with HV (Figure 2), or because naïve autoreactive B cells in patients 447 antigens (due to a deficiency in negative selection) [41]. 449 mBc are heterogeneous: the IgMhiIgDlow subset resembles the spleen marginal 451 “innate” Ig responses to pathogens [42]. However, other IgM+ mBc subsets 444 446 448 RV-IgM+ mBc subsets were significantly diminished in patients prior-RTX with autoimmune diseases may be more susceptible to cross-react with other The enrichment of RV-mBc in all IgM+ mBc subsets in HV is intriguing. IgM+ 450 zone B cells, may use a prediversified subset of Ig genes and participates in 452 seem to behave as “true” antigen selected mBc [43]. Similarly, the enrichment 453 of RV-mBc in the IgM+ only subset (at the expense of switched IgA+ or IgG+ 455 mBc have undergone a less extensive maturation in germinal centers than 457 mice model, human CD27+IgM+ RV-mBc switch to IgG in vitro and in vivo, and 454 mBc), which has a lower frequency of somatic mutations [21], suggests that RV- 456 other mBc subpopulations. Besides, in an adoptive transfer immunodeficient 458 significantly reduce RV antigenemia and viremia [34]. Thus, further studies are 460 The response to RTX treatment is variable; it usually induces a very significant 462 of therapy [44]. Ten of the fourteen patients studied had clinical peripheral Bc 464 other four patients were also significantly diminished (Figure 2). Blood samples 466 respectively. Therefore, it is possible that RTX therapy had failed to completely 459 required to understand the repertoire of IgM+ RV-mBc. 461 reduction of circulating Bc subpopulations for six to nine months after one cycle 463 depletion by RTX (Figure 2 and data not shown). Levels of circulating Bc in the 465 from two of these four patients were taken 5 and 6 months after RTX treatment, 467 deplete them of circulating Bc or that they were already in the repopulation 20 468 phase post treatment. Regardless of the case, our conclusions are unaffected 469 by these findings. 471 subset of IgM-RF, IgG-anti-CCP, and IgG-anti-dsDNA auto-Abs are mainly 473 specific mBc depleted by RTX. In contrast, long-lived PC, unaffected by RTX 475 and RV, regardless of the antigen-specific isotype and subclass studied here. 477 probably reflects its differential effect on both auto-Abs and Abs against 479 Here, we present direct evidence that in the absence of circulating TT- and RV- 481 and therefore seems to be maintained by long-lived PC unaffected by RTX. In 483 memory is maintained by long-lived PC [45-47]. These and other findings 485 maintenance of serological memory in healthy individuals [12]. The existence of 487 been put forward to support this model [12]. However, antigen-specific mBc 489 these correlations do not necessarily imply a cause-and-effect relationship 491 switched IgG+ mBc correlated with plasma TT-IgG titers in HV (Table 2), these 470 Concerning serological memory, altogether our results suggest that at least a 472 maintained by short-lived PC, which are probably in equilibrium with auto-Ag- 474 treatment, probably maintain serological memory against pathogens, like TT 476 The small effect of B-cell depletion therapy on total IgA and IgG (Figure 4) 478 pathogens. 480 mBc the corresponding antigen-specific serological memory remains steady, 482 agreement with this finding, in some mouse models antigen-specific serological 484 [11,48,49] are at odds with the mBc bystander activation model of the 486 correlations between mBc and serological memory in healthy individuals has 488 correlate with serum antigen-specific Ab levels only in some cases [1], and 490 between the mBc and the corresponding Abs. Accordingly, although TT- 21 492 titers were stable after RTX treatment; thus, the latter correlation may simply 494 The lack of correlation between RV-Abs and RV-mBc may be related to the fact 496 repetitive nature and high avidity, can detect low affinity Bc [21] that produce 493 reflect equally stable but independently maintained parameters [1,11]. 495 that the GFP-VLPs used to measure the RV-mBc, because of their antigen 497 antibodies undetected in the RV-ELISAs. Furthermore, a lack of correlation 499 maintenance of serological memory by long-lived PC. In our patients with 501 PC, but only a correlation between switched IgG+ mBc and CD27- IgG+ mBc 503 last correlation, and the lack of other expected correlations, must be analyzed 505 corresponding auto-Abs is lacking. 507 that the percentage drops in IgG-anti-dsDNA and IgG-anti-CCP were 509 suggest a differential effect of B-cell depletion therapy with RTX on the various 498 between mBc and serological memory does not necessarily indicate 500 autoimmunity, all auto-Abs studied seem to be mainly maintained by short-lived 502 with anti-ds-DNA auto-Abs in SLE patients was found (Table 2). However, this 504 with caution, because direct assessment of auto-antigen-specific mBc and the 506 As previously shown for IgG-RF and IgG-anti-CCP auto-Abs [17], we observed 508 significantly higher than the percentage drops in total plasma IgG. These results 510 types of IgG serological memory. Similarly, when IgA-RF and total IgA were 512 was significantly greater than that in total serum IgA [17]. 514 pool may depend on short-lived PC, because the decrease effect of B-cell 511 assessed after B-cell depletion therapy with RTX, the decrease of the IgA-RF 513 In contrast to circulating total IgG and IgA, a high proportion of the total IgM 515 depletion therapy with RTX on IgM-RF and total plasma IgM was similar in this 516 and prior studies [17]. Accordingly, all IgM+ mBc subsets correlated with total 22 517 plasma IgM when data before and after RTX treatment were analyzed jointly 519 rapidly than total IgA and IgG after B-cell depletion therapy with RTX [14]. Of 518 (Table 1). Furthermore, total IgM levels have been reported to decrease more 520 note, in patients with autoimmune diseases the total IgM pool may be enriched 522 CD154, detected in some patients, have been associated to a rapid PC 524 in all volunteers (data not shown); thus, the effect of B-cell depletion therapy on 521 in Abs produced by short-lived PC, since the overexpression of IL-10 and 523 differentiation and auto-Ab production [50-52]. Plasma RV-IgM was undetected 525 pathogen-specific plasma IgM remains undetermined. 527 Mann-Whitney’s test, p = 0.0578) (Figure 4) all IgM+ mBc subsets were 529 S2). Even so, IgM+ mBc subsets correlated with total plasma IgM when data 526 Although total plasma IgM tended to be higher in patients prior-RTX (2-tailed 528 significantly diminished compared with HV (Figure 2 and Supplementary Figure 530 before and after RTX treatment were analyzed jointly (Table 1). Thus, it is 532 structures, may be related to circulating IgM+ mBc subsets and account for an 531 possible that PC producing autoimmune IgM, localized in ectopic lymphoid 533 important proportion of the total circulating IgM Abs. In support of this 535 patients [23], and its decreased frequency negatively correlates with auto-Abs 537 transgenic mouse model of RA, pathogenic B cells accumulate in lymph nodes 534 hypothesis, IgM+ mBc (CD27+IgD+IgM+) seem to migrate to the synovium in RA 536 levels and disease activity in SLE patients [22]. Moreover, in a human TNF 538 draining arthritic joints and are eliminated after B-cell depletion therapy with 539 RTX, with a concomitant disease improvement [53]. 540 541 Conclusions 23 542 Serological memory against TT and RV, irrespective of the isotype and 544 B-cell depletion therapy with RTX. In contrast, short-lived PC, continuously 546 proportion of IgM Abs. 548 Acknowledgements 550 generosity, Elisa Navas for her help in contacting the patients, Maria Consuelo 552 Camilo Vásquez for assistance with Figure 1, and Marlee Neel for reviewing the 554 (ID3867). 543 545 547 subclass studied here, seems to be maintained by long-lived PC, unaffected by replenished by mBc, seem to maintain some auto-Abs and an important 549 We thank the patients and healthy volunteers who participated for their 551 Romero for her assistance with the measurement of total Igs and auto-Abs, 553 manuscript. This work was supported by Pontificia Universidad Javeriana 555 24 556 REFERENCES 557 1. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to 559 2. Ahmed R, Gray D (1996) Immunological memory and protective immunity: 561 3. Dunning AJ (2006) A model for immunological correlates of protection. Stat 563 4. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, et al. (2009) Polyreactive 558 560 562 common viral and vaccine antigens. N Engl J Med 357: 1903-1915. understanding their relation. Science 272: 54-60. Med 25: 1485-1497. 564 autoantibodies in systemic lupus erythematosus have pathogenic 566 5. Uysal H, Nandakumar KS, Kessel C, Haag S, Carlsen S, et al. (2010) 565 potential. J Autoimmun 33: 270-274. 567 Antibodies to citrullinated proteins: molecular interactions and 569 6. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmström V, et al. (2010) 568 arthritogenicity. Immunol Rev 233: 9-33. Autoimmunity to specific citrullinated proteins gives the first clues to the 570 571 572 etiology of rheumatoid arthritis. Immunol Rev 233: 34-54. 7. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM (2009) Residual 573 inflammation after rituximab treatment is associated with sustained 575 Rheum Dis 68: 1011-1016. 574 synovial plasma cell infiltration and enhanced B cell repopulation. Ann 576 8. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A (2010) Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 10: 577 578 579 193-200. 9. Amanna IJ, Slifka MK (2010) Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 236: 125-138. 580 25 581 10. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KGC, et al. (2006) Competence and competition: the challenge of becoming a long- 582 583 584 lived plasma cell. Nat Rev Immunol 6: 741-750. 11. Amanna IJ, Hammarlund E, Lewis MW, Slifka MK (2012) Impact of infection or vaccination on pre-existing serological memory. Hum Immunol 73: 585 586 587 1082-1086. 12. Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. 588 589 590 Science 298: 2199-2202. 13. Traggiai E, Puzone R, Lanzavecchia A (2003) Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 21 591 592 593 Suppl 2: S35-37. 14. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, et al. 594 (2007) Treatment with rituximab affects both the cellular and the humoral 596 74. arm of the immune system in patients with SLE. Clin Immunol 122: 62- 595 597 15. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, 599 in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581. Emery P, et al. (2004) Efficacy of B-cell-targeted therapy with rituximab 598 600 16. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, et al. 601 (2006) B cell depletion therapy in systemic lupus erythematosus: effect 603 3612-3622. on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54: 602 26 604 17. Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein MR, Salden M, et al. (2003) Serologic changes following B lymphocyte depletion therapy for 605 606 607 rheumatoid arthritis. Arthritis Rheum 48: 2146-2154. 18. Rojas OL, Narváez CF, Greenberg HB, Angel J, Franco MA (2008) 608 Characterization of rotavirus specific B cells and their relation with 610 19. Parez N, Garbarg-Chenon A, Fourgeux C, Le Deist F, Servant-Delmas A, et 609 serological memory. Virology 380: 234-242. 611 al. (2004) The VP6 protein of rotavirus interacts with a large fraction of 613 12496. 612 human naive B cells via surface immunoglobulins. J Virol 78: 12489- 614 20. Kallewaard NL, McKinney BA, Gu Y, Chen A, Prasad BVV, et al. (2008) 615 Functional maturation of the human antibody response to rotavirus. J 617 21. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, et al. 616 Immunol 180: 3980-3989. 618 (2008) Immunodominance of the VH1-46 antibody gene segment in the 620 memory compartment through somatic mutation of nondominant clones. primary repertoire of human rotavirus-specific B cells is reduced in the 619 621 J Immunol 180: 3279-3288. 622 22. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas J, Rodriguez C, 624 CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic 623 Brieva JA (2010) Decreased frequency and activated phenotype of blood 625 lupus erythematosus patients. Arthritis Res Ther 12: R108. 626 23. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, et al. (2009) Alterations in peripheral blood memory B cells in patients with 627 27 active rheumatoid arthritis are dependent on the action of tumour 628 629 necrosis factor. Arthritis Res Ther 11: R84. 630 24. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, et al. (2002) 632 memory B cells in the salivary glands of patients with Sjogren's 631 Diminished peripheral blood memory B cells and accumulation of 633 syndrome. Arthritis Rheum 46: 2160-2171. 634 25. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, et al. (2007) A new 635 population of cells lacking expression of CD27 represents a notable 637 erythematosus. J Immunol 178: 6624-6633. component of the B cell memory compartment in systemic lupus 636 638 26. Rojas OL, Caicedo L, Guzmán C, Rodríguez L-S, Castañeda J, et al. (2007) 639 Evaluation of circulating intestinally committed memory B cells in children 641 300-311. vaccinated with attenuated human rotavirus vaccine. Viral Immunol 20: 640 642 27. Mesa MC, Rodriguez LS, Franco MA, Angel J (2007) Interaction of rotavirus 643 with human peripheral blood mononuclear cells: plasmacytoid dendritic 645 Virology 366: 174-184. 644 cells play a role in stimulating memory rotavirus specific T cells in vitro. 646 28. Mesa MC, Gutierrez L, Duarte-Rey C, Angel J, Franco MA (2010) A TGF- 648 response to rotavirus in adults but not in children. Virology 399: 77-86. beta mediated regulatory mechanism modulates the T cell immune 647 649 29. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) 2010 650 Rheumatoid arthritis classification criteria: an American College of 652 initiative. Ann Rheum Dis 69: 1580-1588. Rheumatology/European League Against Rheumatism collaborative 651 28 653 30. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. 654 655 656 Arthritis Rheum 40: 1725. 31. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, et al. (2012) 2012 657 Update of the 2008 American College of Rheumatology 659 and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care 661 32. Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, et al. (2008) 658 recommendations for the use of disease-modifying antirheumatic drugs 660 Res 64: 625-639. 662 EULAR recommendations for the management of systemic lupus 664 Committee for International Clinical Studies Including Therapeutics. Ann 663 erythematosus. Report of a Task Force of the EULAR Standing 665 Rheum Dis 67: 195-205. 666 33. Charpilienne A, Nejmeddine M, Berois M, Parez N, Neumann E, et al. 667 (2001) Individual rotavirus-like particles containing 120 molecules of 669 29367. fluorescent protein are visible in living cells. J Biol Chem 276: 29361- 668 670 34. Narvaez CF, Feng N, Vasquez C, Sen A, Angel J, et al. (2012) Human 671 Rotavirus-Specific IgM Memory B Cells Have Differential Cloning 673 In Vivo. J Virol 86: 10829-10840. Efficiencies and Switch Capacities and Play a Role in Antiviral Immunity 672 674 35. Youngman KR, Franco MA, Kuklin NA, Rott LS, Butcher EC, et al. (2002) 676 intestinal homing receptor expression of antigen-specific B cells during 675 Correlation of tissue distribution, developmental phenotype, and 677 the murine anti-rotavirus immune response. J Immunol 168: 2173-2181. 29 678 36. Perfetto SP, Chattopadhyay PK, Roederer M (2004) Seventeen-colour flow 680 37. Campana D (2009) Role of Minimal Residual Disease Monitoring in Adult 679 cytometry: unravelling the immune system. Nat Rev Immunol 4: 648-655. 681 and Pediatric Acute Lymphoblastic Leukemia. Hematol Oncol Clin North 683 38. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I (2009) Insights into the 682 Am 23: 1083-1098. heterogeneity of human B cells: diverse functions, roles in autoimmunity, 684 685 686 and use as therapeutic targets. Immunol Res 45: 144-158. 39. Fecteau JF, Côté G, Néron S (2006) A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency 687 688 689 of somatic mutation. J Immunol 177: 3728-3736. 40. Grauballe PC, Hornsleth A, Hjelt K, Krasilnikoff PA (1986) Detection by ELISA of immunoglobulin G subclass-specific antibody responses in 690 691 692 rotavirus infections in children. J Med Virol 18: 277-281. 41. Keenan RA, De Riva A, Corleis B, Hepburn L, Licence S, et al. (2008) Censoring of autoreactive B cell development by the pre-B cell receptor. 693 694 695 Science 321: 696-699. 42. Reynaud C-A, Descatoire M, Dogan I, Huetz F, Weller S, et al. (2012) IgM memory B cells: a mouse/human paradox. Cell Mol Life Sci 69: 1625- 696 697 698 1634. 43. Seifert M, Kuppers R (2009) Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of 699 memory B cell generation. J Exp Med 206: 2659-2669. 700 30 701 44. Leandro MJ (2013) B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis 702 703 704 Res Ther 15 Suppl 1: S3. 45. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, et al. (2008) 705 Maintenance of long-lived plasma cells and serological memory despite 707 mice. J Immunol 180: 361-371. mature and memory B cell depletion during CD20 immunotherapy in 706 708 46. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ (2008) Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci 709 710 711 USA 105: 4802-4807. 47. Huang H, Benoist C, Mathis D (2010) Rituximab specifically depletes shortlived autoreactive plasma cells in a mouse model of inflammatory 712 713 714 arthritis. Proc Natl Acad Sci U S A 107: 4658-4663. 48. Genova GD (2006) Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine 715 716 717 specific. Blood 107: 2806-2813. 49. Richard K, Pierce SK, Song W (2008) The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in 718 719 720 vitro but not in vivo. J Immunol 181: 1746-1752. 50. Tangye SG, Avery DT, Hodgkin PD (2003) A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J 721 722 723 Immunol 170: 261-269. 51. Peng H, Wang W, Zhou M, Li R, Pan HF, et al. (2013) Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin 724 Rheumatol 32: 1255-1266. 725 31 726 52. Peters AL, Stunz LL, Bishop GA (2009) CD40 and autoimmunity: the dark 728 53. Li J, Kuzin I, Moshkani S, Proulx ST, Xing L, et al. (2010) Expanded 727 side of a great activator. Semin Immunol 21: 293-300. 729 CD23+/CD21hi B Cells in Inflamed Lymph Nodes Are Associated with 731 Are Targets of Anti-CD20 Therapy. J Immunol 184: 6142-6150. the Onset of Inflammatory-Erosive Arthritis in TNF-Transgenic Mice and 730 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 32 751 FIGURE LEGENDS 753 only mBc subsets. 755 multiparametric flow cytometry. All p values reported are 2-tailed (p < 0.05, 757 respectively. A. Healthy volunteers (n = 10). B. Patients (n = 10) with 759 Figure 2. Comparison of selected total B cell subpopulations among the 761 Healthy volunteers (HV) (n = 10), patients before RTX treatment (prior-RTX) (n 763 cells, the dashed line represents the clinical depletion limit after RTX treatment 765 cytometry detection limit of 3.5 CD19+ B cells/mL. Solid lines and error bars 767 HV and patients prior-RTX were evaluated with Mann–Whitney tests and 769 values reported are 2-tailed. 771 study groups. 773 respectively. Differences between HV (n = 10) and patients prior-RTX (n = 10) 752 Figure 1. RV-mBc are enriched in the IgMhiIgDlow, IgMlowIgDhi, and IgM+ 754 Summary of the frequencies of seven subsets of total and RV-mBc assessed by 756 Wilcoxon test). Lines and error bars denote the median and interquartile range, 758 autoimmune diseases before RTX treatment. 760 study groups. 762 = 10) and patients after RTX treatment (after-RTX) (n = 10). For total CD19+ B 764 (less than 5,000 CD19+ cells/mL). The dotted lines represent the estimated flow 766 denote the median and interquartile range, respectively. Differences between 768 between patients prior-RTX and patients after-RTX with Wilcoxon tests. All p 770 Figure 3. Comparison of RV-specific B cell subpopulations among the 772 Solid lines and error bars denote the median and interquartile range, 774 were evaluated with Mann–Whitney tests and between patients prior-RTX and 33 775 patients after-RTX (n = 10) with Wilcoxon tests. All p values reported are 2- 777 Figure 4. Comparison of total immunoglobulins in plasma among the 779 Levels of total IgA (A), IgG (B) and IgM (C) in plasma determined by kinetic 781 normal reference range (IgA: 82 – 453 mg/dL; IgG: 751 – 1560 mg/dL; IgM: 46 783 range, respectively. Differences between HV (n = 10) and patients prior-RTX (n 776 tailed. 778 study groups. 780 nephelometry. The dotted lines represent the lower and upper values of the 782 – 304 mg/dL). Solid lines and error bars denote the median and interquartile 784 = 14) were evaluated with Mann–Whitney tests and between patients prior-RTX 786 tailed. 788 levels in plasma among the study groups. 785 and patients after-RTX (n = 14) with Wilcoxon tests. All p values reported are 2- 787 Figure 5. Comparison of RF, anti-CCP and anti-dsDNA autoantibodies 789 Levels of rheumatoid factor (RF) determined by kinetic nephelometry (A), anti- 791 dsDNA) (C) determined by a fluorescence enzyme immunoassay (EliA test) in 793 patients had both diagnoses). Solid lines and error bars denote the median and 795 limits below which a sample is considered negative according to the technique 797 IU/mL). Differences between HV and patients prior-RTX were evaluated with 799 with Wilcoxon tests. All p values reported are 2-tailed. 790 cyclic citrullinated peptide (anti-CCP) (B) and anti-doubled stranded DNA (anti- 792 patients diagnosed with RA (A and B) (n = 11) or with SLE (C) (n = 7) (some 794 interquartile range, respectively. The dotted lines correspond to the clinical 796 used for its detection (RF: <20 IU/mL, anti-CCP: <7 U/mL and anti-dsDNA: <10 798 Mann–Whitney tests and between patients prior-RTX and patients after-RTX 34 800 Figure 6. Comparison of RV- and TT-specific immunoglobulins titers in 802 Titers of TT-IgG (A), RV-IgA (B), RV-IgG (C) and RV-IgG1 (D) in plasma 804 interquartile range, respectively. Differences between HV (n = 10) and patients 801 plasma among the study groups. 803 determined by ELISA. Solid lines and error bars denote the median and 805 prior-RTX (n = 14) were evaluated with Mann–Whitney tests and between 806 patients prior-RTX and patients after-RTX (n = 14) with Wilcoxon tests. 807 35 808 809 810 Table 1. Memory B cell subsets that correlate with total immunoglobulins. Cell subseta P Valueb Rho Pt. IgM+ Only mBc with total plasma IgM 0.0013 0.6687 Pt. IgM+ mBc with total plasma IgM 0.0305 0.4842 Pt. IgM+ mBc IgMhi IgDlow with total plasma IgM 0.0148 0.5361 Pt. IgM+ mBc IgMlow IgDhi with total plasma IgM 0.0306 0.484 Pt. CD27- IgM+ mBc with total plasma IgM 0.0364 0.4702 a All correlations for patients (Pt.) were established when data before and after RTX treatment were analyzed jointly (n = 10). 811 b 813 Table 2. Memory B cell subsets that correlate with antigen-specific 812 814 815 816 817 Spearman’s two-tailed test. immunoglobulins or autoantibodies Cell subseta P Valueb Rho HV. TT-Switched IgG+ mBc with TT-IgG 0.0242 0.7184 SLE Pt. Switched IgG+ mBc with anti-dsDNA 0.0438 0.6606 SLE Pt. CD27- IgG+ mBc with anti-dsDNA 0.0234 0.7212 a All correlations for patients (Pt.) were established when data before and after RTX treatment were analyzed jointly (n = 10). b Spearman’s two-tailed test. 818 36 Table S1. Clinical features of patients with autoimmune diseases Patient Pt. 1 Age 33 Gender F Principal Concomitant Disease Concomitant Relevant Disease activity Clinical follow up diagnosis autoimmune duration immunosuppressive previous before approximately disease (years) pharmacologic pharmacologic treatment treatment treatment RA SLE nephritis (Lupus IV 6 AI PDN, HCQ, AZA, SSZ, CQ, HCQ, MMF MTX AZA, DFZ AZA RTX 6 months after RTX treatment DAS28: moderate DAS28: low SLE 60% 9/24) Pt. 2 69 F SLE Autoimmune 14 associated clinical thromobocytopenia, steroid-refractory improvement, Sjögrens’ thrombocytopenia platelet syndrome, count improvement antiphospholipid syndrome, hypothyroidism Pt. 3 26 F SLE 2 PDN, HCQ, MMF MTX SLEDAI 8: Without clinical moderate activity, improvement. renal compromise Cyclophosphamide treatment. Pt. 4 33 F RA Pt. 5 35 F SLE Antiphospholipid 1 SSZ, CQ, MTX DAS28: high 1 PDN, AZA SLEDAI DAS28: moderate 6: Clinical syndrome, moderate activity, improvement with hypothyroidism great regard to articular Pt. 6 54 F RA Hypothyroidism 8 PDN, MTX Pt. 7 46 F SLE RA 3 MTX, PDN, AZA Pt. 8 42 F RA SLE, 7 PDN, MTX, D-Pen 6 PDN, AZA, CQ CREST, Infliximab CQ articular compromise compromise DAS28: high DAS28: moderate ND ND DAS28: high DAS28: moderate hypothyroidism Pt. 9 29 F SLE RA SLE without changes Pt. 10 47 M RA 2 MTX, SSZ, CQ DAS28: high Without clinical improvement Pt. 11 a 49 F RA 3 PDN, HCQ, MTX, DAS28: moderate SSZ 60% clinical improvement Pt. 12 58 F RA 30 PDN, HCQ, LEF Etanercept, MTX DAS28: moderate ND Pt. 13 50 F RA 3 DFZ, HCQ, SSZ Etanercept, LEF DAS28: moderate Without clinical improvement Pt. 14 a 58 M RA 3 PDN, HCQ, MTX DAS28: high ND A complete flow cytometry assay could not be done for patients RTX 1, RTX 13, RTX 20, and RTX 22 at both time frames (before and after RTX treatment); therefore they were not included in the total and Ag-specific Bc analyses. MTX: Methotrexate, SSZ: Sulfasalazine, HCQ: Hydroxychloroquine, CQ: Chloroquine, PDN: Prednisolone, AZA: Azathioprine, LEF: Leflunomide, MMF: Mycophenolate, Deflazacort: DFZ, D-Penicillamine: D-Pen, ND: not done. Supplementary Figure legends. Supplementary Figure 1. RV-memory B cells gating strategies. Two comparable analysis strategies were used to dissect total and RV-Bc subsets (CD19+) based on their expression of surface markers. A representative result is shown for a HV. Naïve and three main subsets of mBc can be identified based on IgD and CD27 expression: naïve Bc (IgD+CD27-), IgM+ mBc (IgD+CD27+), switched mBc (IgD-CD27+), and CD27- mBc (IgD-CD27). A. If only CD27+ mBc are considered (naïve and CD27- mBc are excluded) five mBc subsets can be defined in terms of IgM and IgD expression: IgM+ only mBc, IgM+ mBc IgMhiIgDlow, IgM+ mBc IgMlowIgDhi, IgD+ only mBc, and switched mBc (IgM-IgD-). Total (top row plots) and RV-mBc (VLPs-GFP+) (lower row plots) were gated. B. When isotype expression is considered, naïve B cells and IgM+ mBc express IgD and IgM; switched mBc express IgG and IgA, but a subset which only expresses IgM can also be identified on the IgD-CD27+ gate: IgM+ only mBc; and CD27- mBc express IgA, IgG or IgM. Supplementary Figure 2. Comparison of other total B cell subpopulations among the study groups. Other total B cell subpopulations studied are shown for healthy volunteers (HV), patients before RTX treatment (prior-RTX) and patients after RTX treatment (after-RTX). The dotted lines represent the estimated flow cytometry detection limit of 3.5 CD19+ B cells/mL. Solid lines and error bars denote the median and interquartile range, respectively. Differences between HV (n = 10) and patients prior-RTX (n = 10) were evaluated with Mann–Whitney tests and between patients prior-RTX and patients after-RTX (n = 10) with Wilcoxon tests. All p values reported are 2-tailed. Supplementary Figure 3. Comparison of other RV and TT-specific B cell subpopulations among the study groups. Other RV- and TT-specific B cell subpopulations studied are shown for HV (n = 10), patients prior-RTX (n = 10) and patients after-RTX (n = 10). Solid lines and error bars denote the median and interquartile range, respectively. Differences between HV and patients prior-RTX were evaluated with Mann–Whitney tests and between patients prior-RTX and patients after-RTX with Wilcoxon tests. All p values reported are 2-tailed. 7. GENERAL DISCUSSION AND CONCLUSIONS RV vaccines have been introduced in the national immunization programs of approximately 40 countries by 2012 [242]. This has meant a breakthrough in the prevention of RV disease burden. In middle and high-income countries, significant decreases of 49-89% in hospitalizations due to RV GE among children under the age of five, and 17-55% reduction in all-cause GE hospitalizations, have been observed within two years after RV vaccine introduction [60]. Notably, additional benefits have been observed in older unvaccinated children and adults with an 829% reduction in GE hospitalizations in the RV season following vaccine introduction in the United States [243]. Unfortunately, and similar to what has happened with other enteric vaccines (oral polio, cholera, and typhoid), there is an important disparity in the efficacy of RV vaccines between middle (72%-83%) to high-income countries (>90%) and lowincome countries (39%-49%), where mortality is greatest [9, 10]. Many factors may contribute for the lower efficacy rates in low socio-economic settings, irrespective of the geographical zone considered: higher titers of maternal antibodies (either transplacentally transferred or those present in breast milk), oral polio vaccine interference, nutritional deficiencies (zinc, vitamin A, and vitamin D), concomitant infections with other gut microbes (viruses, tropical enteropathy, and helminthes), and differences in the gut microbiota, among others [244]. These factors are in turn associated with an impaired immune response to live oral vaccines and natural infection. Recently, a mathematical model of RV transmission and disease was developed to understand the reduced vaccine efficacy in low-income settings [245]. The model predicted 93%, 86%, and 51% prevention against severe RV GE in high, middle, and low socio-economic settings. The most important factors responsible for the lower efficacy in low-income settings were reduced immunogenicity of vaccination, probably the most modifiable factor, and reduced protection conferred by natural infection. If vaccine doses resemble the effect of primary and/or secondary natural infections, the observed higher rates of subsequent infections and persistence of severity in low-income settings are consistent with the lower vaccine efficacy and suggested decreased duration of protection [245]. Many strategies are considered to improve the immunogenicity of current vaccines [9, 245]: delaying the administration schedule (to allow waning of maternal antibodies), adding a third dose to the Rotarix scheme (it was estimated that a third dose may improve vaccine efficacy by 9% in low-income settings), and supplementing with micronutrients (to enhance immune function). Moreover, there are various candidate vaccines ongoing different clinical phases of assessment [244]. Nevertheless, an adequate immunological correlate of protection to easily 48 evaluate the effect of the mentioned interventions to the current RV vaccines, and to test the vaccines under development, has not been identified to date [242]. This work advances the RV field mainly in three ways: 1. We proposed that plasma RV-SIg might serve as a valuable correlate of protection for RV vaccines (first article). 2. Circulating RV-Bc subpopulations were thoroughly assessed in healthy adults and patients with autoimmunity and a similar distribution was found among them (second article). 3. We presented direct evidence that RV-serological memory seems to be maintained by long-lived PC, in agreement with the proposed model of independent functions and importance of mBc and PC in the immune response and protection from reinfection [34, 218] (second article). In the following pages, these conclusions will be discussed in as much as they provide starting points for further research. We confirmed [21, 22] that plasma RV-SIg can be detected in naturally infected children, but with a noticeable difference compared to the literature. It has been reported that plasma RV-SIg, in contrast to plasma RV-IgA, can be detected in the acute phase of the infection and early in the convalescence, but no later than one month after the onset of diarrhea [22]. Notwithstanding, RV-SIg was detected in the great majority of children with evidence of previous RV infection without an ongoing RV GE, which is at odds with the aforementioned result. It is possible that our ELISA assay is sensitive enough to detect very low concentrations of RV-SIg, previously undetected by other assays. Even though, in some vaccinees RV-SIg was only transiently observed. These differences between our results and those reported in the literature, and between vaccinees and children with previous natural RV infection (using the same technique) require further assessment. Therefore, to better define the best time frame for the detection of plasma RV-SIg, particularly if it is going to be used as a correlate of protection, it is necessary to determine the kinetics of RV-SIg in blood after RV vaccination. Children vaccinated with the attenuated RIX4414 human RV vaccine presented higher RV-SIg titers than placebo recipients, both after D1 and D2, and in vaccinees higher titers were observed after D2 than after D1. These significant differences between vaccinees and placebo recipients were unobserved for plasma RV-IgA [17]. In addition, a detectable boost for RV-SIg was observed in three children whereas for RV-IgA it was detected only in one child. Moreover, the frequency of protected children was significantly higher in RV-IgA- (titer < 1:100) vaccinees compared to RV-IgA- placebo recipients, which suggests that other factors are important for conferring protection from disease in vaccinees [17]. In agreement with these findings, in our trial, plasma RV-SIg seemed to be a better correlate of protection than plasma RV-IgA. RV-SIg measured after D2 also correlated with protection in vaccinees and placebo recipients analyzed jointly and, in contrast to plasma RV-IgA, the frequency of protected children was significantly higher in RV-SIg+ children (titers ≥ 1:100) than in those RV-SIg- (titer < 1:100). Furthermore, the presence of RV-SIg conferred an almost four times increase in 49 the probability to be protected against any RV GE. These results, and those reported in naturally infected children, suggest that RV-SIg is associated with protection both after vaccination and natural infection. Our studies are the first in which plasma antigen-specific SIg is evaluated as a correlate of protection after vaccination. However, given that preimmune plasma samples were unavailable, the level of vaccine induced RV-SIg is unknown. In addition, the correlation of RV-SIg with protection may be underestimated because the Rotarix commercial formulation induces higher RV-IgA seroconversion rates than the RIX4414 formulation used in the present study [246], and this may also be the case for RV-SIg. Therefore, the value of plasma RV-SIg as a correlate of protection needs to be thoroughly assessed with current RV vaccines, and RV-SIg induction by the vaccines must be addressed to add evidence for a probable mechanistic role in protection. The ELISA assay used to detect plasma RV-SIg is time-consuming and laborintensive due to its multiple steps, which increase its complexity. Additionally, it requires a relative high amount of plasma, and uses a bovine viral lysate as the RV antigen, the production of which adds labor to the process. Therefore, one of our purposes for the near future is to optimize this assay to make it adequate for largescale studies. Recently, the use of recombinant VP6 in a DELFIA assay [247], which employs lanthanide chelate europium (Eu3+)-labeled secondary antibodies, to assess the RV-IgG response showed comparable results to the conventional virus-capture ELISA. This assay is less labor intensive, uses lower sample volume, and only requires a single test dilution [247]. Furthermore, the assessment of Ab responses to recombinant viral proteins, instead of using the intact virus capsid, may be another strategy to find useful correlates of protection, as suggested for NSP4 [248]. In our previous study with the RIX4414 RV vaccine [17], circulating RV-IgDCD27+47+CCR9+ mBc measured after D1 correlated with protection from disease, although with a low correlation coefficient. Since these cells expressed intestinal homing receptors and it is considered that plasma RV-SIg reflects local mucosal immunity, a correlation of RV-SIg titers with circulating RV-mBc after vaccination was expected, but it was undetected. This can be explained, at least in part, by the fact that RV-SIg is probably a mixture of SIgM and SIgA. Another possibility is that a direct cause-and-effect relationship between RV-mBc (irrespective of their phenotype) and Abs, in this case plasma RV-SIg, is inexistent. SIgs (SIgA and SIgM) are normally detected in the systemic compartment of healthy individuals (1 – 91 years old) [145-147]. However, the mechanism by which SIgA, produced at mucosal surfaces, is transported to the circulation is undetermined [20]. Additionally, the physiological function of SIgs (structurally equipped to perform its functions mainly in the luminal side of the mucosae) in the systemic compartment remains to be established. 50 SIgA has been implicated in the pathophysiology of some autoimmune diseases, particularly IgA nephropathy and celiac disease. In patients with IgA nephropathy, a clinical association between mucosal infections and worsening of the renal condition has been reported, which suggested a role of SIgA in the disease pathogenesis [147]. Consistent with this association, SIgA levels in blood are higher in patients with IgA nephropathy than in healthy controls, and the level of serum SIgA correlates with the severity of the pathological phenotype and with clinical parameters like proteinuria and serum creatinine levels [147]. Additionally, deposits of SIgA are found in the glomerular mesangium of some patients [147, 249]. The transferrin receptor (CD71) was characterized as a novel IgA receptor in patients with IgA nephropathy [149]. It is upregulated on glomerular mesangial cells in these patients and is involved in the deposit of IgA 1 [149]. Recently, it was reported in a mouse model that IgA1, soluble CD89 (another described IgA receptor), transferrin receptor, and transglutaminase-2, as a critical factor, are needed for mesangial cell activation and disease development [250]. In patients with active celiac disease, CD71 is abnormally expressed at the apical pole of enterocytes and serves as a receptor for SIgA [150]. It is proposed that CD71 mediates the retro transport of SIgA-gliadin peptides complexes from the apical side of the enterocyte to the lamina propria. This abnormal transport would protect gliadin peptides from being normally degraded by lysosomal acid proteases [150]. Recently, direct evidence was provided in this regard: CD71-SIgA-gliadin complexes, or CD71-SIgA, are endocytosed and directed to the recycling pathway, thus, avoiding lysosomal degradation [251]. Furthermore, transglutaminase-2 seems to control CD71 endocytosis [252]. Notably, transglutaminase-2 seems essential both for IgA nephropathy and celiac disease pathogenesis. The role of antigen-specific SIgA in the induction of autoimmunity is intriguing. On the one hand, as mentioned earlier, an association between mucosal infections and worsening of renal compromise in patients with IgA nephropathy has been reported. Nevertheless, a study that directly assessed this relationship, through the challenge of IgA nephropathy patients and controls with cholera toxin subunit B via intranasal vaccination (as a neoantigen), concluded that the levels of antigenspecific SIgA were equivalent in both patients and controls [253]. On the other hand, frequent RV infections have been associated with an increased risk for developing celiac disease in genetically predisposed children [254]. Furthermore, in one of the few prospective studies concerning reactive arthritis [255], total serum SIgA and serum Yersinia-specific SIgA levels were higher in patients who developed joint symptoms compared with those who did not develop them. These precedents prompted us to explore the possibility of serum SIg as an important factor in the pathogenesis of reactive arthritis and undifferentiated 51 spondyloarthritis. Preliminary results show that patients with these diagnoses have significantly higher total SIgA concentrations than healthy controls. This constitutes one of our interests for further research, along with the role that RV infections may play in the induction of autoimmune diseases, as it is suggested by the mentioned findings in celiac disease. As mentioned before, although RV preferentially replicates in the intestine, antigenemia and viremia are frequently observed in infected children and animals, and its clinical significance has started to become evident [15, 241]. Therefore, the systemic immune response may be as important as the one originated in the intestine. Moreover, Abs are crucial for protecting infants against RV reinfection [12]. Nevertheless, how the Bc that produce these antibodies are related to the virus itself and how RV-mBc contribute to the maintenance of serological memory is still poorly understood. Thus, characterization of RV-specific mBc and the understanding of their relation with serological memory are probably crucial to identify useful correlates of protection for vaccines [31, 256]. We thoroughly assessed circulating RV-Bc subpopulations in healthy adults and patients with autoimmunity, advancing our knowledge of RV-mBc (second article). We confirmed [43, 44, 102] that in HV RV-mBc are enriched in the IgMhiIgDlow subset and endorsed that RV-mBc are also enriched in the IgMlowIgDhi and IgM+ only mBc subsets [102]. Moreover, patients with autoimmunity had a similar distribution of IgM+ mBc subpopulations. The enrichment of RV-mBc in all IgM+ mBc subsets in HV is puzzling. The IgM+ mBc population (CD27+IgD+IgM+), which has provoked so much controversy, in turn comprises IgMhiIgDlow and IgMlowIgDhi mBc. IgM+ mBc have been termed by some as “natural effector” or “innate-like” cells [181, 193, 194], since they are detected in the absence of GC [178, 181]. In contrast, there is also evidence to consider these cells as “true” mBc derived from a GC reaction [161]. These apparent contradictions may be explained by the fact that IgM+ mBc are indeed heterogeneous and may have very different origins and functions. This is fairly clear in the mouse model, in which IgMhiIgDlow cells are termed spleen marginal zone Bc, and IgMlowIgDhi are follicular Bc. In humans, this remains to be determined; however, it is thought that IgMhiIgDlow cells resemble the spleen marginal zone B cells, may use a prediversified subset of Ig genes, and participate in “innate” Ig responses to pathogens [257]. A comprehensive genetic characterization of the IgMhiIgDlow and IgMlowIgDhi subsets is lacking both in non-antigen specific mBc and antigen-specific mBc. RV seems an adequate model to study these cells, particularly because RV-mBc are enriched in them, and the VLP-GFP construct used to identify RV-Bc allows to perform fluorescence activated cell sorting of these populations. Since human CD27+IgM+ RV-mBc switch to IgG in vitro and in vivo, and significantly reduce RV antigenemia and viremia in an adoptive transfer immunodeficient mice model [102], 52 to deepen the understanding of these subsets becomes even more important; it is of primary interest for us to identify the phenotype of the cells capable of classswitching. Furthermore, given that the RV-immune response is compartmentalized, it would also be important to address and compare the genetic profile of circulating and intestinal RV-mBc subsets. Concerning IgM+ only mBc, since they are absent in X-linked hyper IgM patients, like switched mBc, it is thought that they arise from an independent diversification pathway [178], compared to IgM+ mBc cells, and that they are the bona fide IgM+ mBc [159]. In fact, IgM+ only mBc seem to come from primary GC reactions [193], then, the enrichment of RV-mBc in this subset (at the expense of switched IgA+ or IgG+ mBc) suggests that RV-mBc have undergone a less extensive maturation in GC than other mBc subpopulations. Remarkably, regardless of the described origins and phenotypic differences, to date, all IgM+ mBc subsets seem to have a similar usage of IGHJ and IGHV gene families [194]. The role of RV-IgM+ mBc subsets in the immune response against RV is incompletely understood. It is important to determine if these cells increase in an antigen-specific manner after RV vaccination –supporting their status as mBc– and to establish if they express the intestinal homing receptors 47 and CCR9– confirming that they are the product of an immune response induced in the intestine [205]. Recently, the phenotype of pneumococcus-specific Bc was analyzed in healthy adults using fluorescently labeled pneumococcal polysaccharides [258]. PPS14and PPS23F-specific Bc were significantly enriched in CD27+IgM+ mBc, like RVmBc. Unfortunately, pneumococcus-IgM+ mBc were not further characterized in terms of the other IgM+ subsets described for RV-mBc (IgM+ mBc IgMhiIgDlow and IgMlowIgDhi, and IgM+ only mBc). Notably, in splenectomized patients, circulating IgM+ mBc are absent and remain permanently depleted, in contrast to switched mBc that can be regenerated in the lymph nodes and increase with time [259]. These findings support the assumption that a great proportion of IgM+ mBc are circulating marginal zone Bc from the spleen [183]. Since RV-mBc are enriched in these cells, it would be interesting to assess RV-Bc in splenectomized patients and to evaluate the immune response to RV vaccines in such patients. Finally, regarding the relation of mBc with serological memory, we present direct evidence that despite the absence of circulating RV- and TT-mBc, after RTX treatment, the corresponding antigen-specific Abs levels remain constant, regardless of the antigen-specific isotype and subclass evaluated here (RV-IgA, RV-IgG, RV-IgG1, and TT-IgG). To our knowledge, the simultaneous study of circulating antigen-specific mBc and antigen-specific Abs of the IgA and IgG1 isotypes in patients receiving RTX has no precedents. We conclude that RV- and TT-serological memory seems to be maintained by long-lived PC unaffected by RTX. 53 Consequently, in contrast to our hypothesis, the enrichment of RV-mBc in IgM+ mBc and CD27- mBc, relevant mBc subsets in the pathogenesis of various autoimmune diseases, appears irrelevant for the relation of RV-mBc with RVserological memory. In other words, even for a pathogen like RV, with the mentioned mBc peculiarities and an apparently different relationship with serological memory (compared to that of TT-mBc and TT-IgG) [43], long-lived PC seem to be committed to the maintenance of Abs levels in resting conditions. Consistent with these findings, long-lived PC maintain antigen-specific serological memory in some mouse models [260-262] and there is a whole body of evidence [34, 263, 264] at odds with the mBc bystander activation model of the maintenance of serological memory in healthy individuals. Therefore, under normal physiological conditions, mBc and long-lived PC would accomplish different and separated, but complementary, protective functions [34, 218]. Long-lived PC are unable to sense antigens, but are derived from previous immunological encounters in which somatic hypermutation improved the Ig antigen-binding capacity. Thus, long-lived PC that produce high affinity Abs constitute a first line of defense against reinfection. Meanwhile, mBc constitute a backup measure in case Abs, and the effector mechanisms triggered by them, fail to control the antigenic challenge. Furthermore, mBc are equipped with antigenselected matured surface Igs, which allow them to launch rapid recall responses [265]. In secondary responses, mBc can accumulate mutations and develop a new Ab repertoire [198], from which new optimally adapted PC may derive, thus, improving the PC compartment and increasing the level and quality of specific Abs. Concerning autoimmune serological memory, the auto-Abs measured were significantly diminished, in contrast to pathogen-specific Abs. This suggests that, at least, an important proportion of IgM-RF, IgG-anti-CCP, and IgG-anti-dsDNA autoAbs are maintained by short-lived PC, which are probably in equilibrium with autoAg-specific mBc depleted by RTX. Notably, auto-Abs that decrease after Bc depletion therapy with RTX are still detectable [236]. It is considered that long-lived PC may be responsible for this, as well as for some auto-Abs that remain steady after treatment with RTX [266]. Therefore, it would be important to simultaneously assess auto-antigen-specific mBc and the corresponding auto-Abs. At present, this could be done making use of a peptide mimetope of DNA that allows the identification of potentially dsDNA-specific autoreactive Bc [267]. With respect to total Abs levels, RTX treatment had a small effect on total IgA and IgG levels, which probably reflects its differential effect on both auto-Abs and Abs against pathogens, and the proportion of Abs depending on long-lived and shortlived PC in the corresponding total pool. Compared to total IgA and IgG, total IgM decreased at significantly higher levels, suggesting that a high proportion of the total IgM pool may depend on short-lived PC. In support of these findings, after RTX treatment, the percentage drops in IgG-anti-dsDNA and IgG-anti-CCP were 54 significantly higher than the percentage drops in total plasma IgG (second article), as well as the decrease of IgA-RF compared to that of total IgA [39], whereas the decrease of IgM-RF and total plasma IgM was similar in this and prior studies [39]. In agreement with these results, all IgM+ mBc subsets correlated with total plasma IgM when data before and after RTX treatment were analyzed jointly. This is the first time that such correlation is described in patients with autoimmunity. The overexpression of IL-10 and CD154 detected in some patients, which is associated with a rapid PC differentiation and auto-Ab production [219-221], would explain the apparent enrichment of the total IgM pool in Abs produced by short-lived PC. However, further studies are required to address the effect of B-cell depletion therapy on pathogen-specific plasma IgM. 55 8. PERSPECTIVES 8.1 To evaluate the plasma RV-SIg kinetics in vaccinated children and to determine its value as a RV correlate of protection using the commercial formulation of current RV vaccines. 8.2 To optimize the plasma RV-SIg ELISA assay throughout the assessment of other RV antigens such as double-layered particles, and the use of peroxidase substrates that increase sensitivity. 8.3 To explore the role of SIgA and RV-SIg in the pathophysiology of reactive arthritis and other autoimmune diseases, given the importance of SIgA in the pathogenesis of celiac disease and IgA nephropathy. 8.4 To assess the genes (IGH and IGL gene segment usage, mutation load, clonality, germinal center dependence or independence status, and probable tissue of origin) used by circulating, particularly IgM+ mBc IgMhiIgDlow versus IgMlowIgDhi, and intestinal RV-mBc subsets. 8.5 To deepen the understanding of the immunological function of the different RVIgM+ mBc subsets in comparison to other antigens, such as Streptococcus pneumoniae, for which enrichment in IgM+ mBc has also been reported, in splenectomized patients. 56 9. APPENDIX 9.1 DETAILED MATERIALS AND METHODS Written informed consent was obtained from each volunteer or infant’s parents or legal guardian. Studies were approved by the Ethics Committee of the San Ignacio Hospital and Pontificia Universidad Javeriana and conducted in accordance with the guidelines of the Helsinki Declaration. 9.1.1 Subjects and sample processing: children with gastroenteritis, children vaccinated with RIX4414, and placebo recipient children Plasma samples from 36 children with acute GE from prior published studies were assessed [94, 268]. These children (14 females and 22 males; mean age: 13.5 months, range: 6 – 22; 20 breast fed and 16 not breast fed) were admitted with gastroenteritis to the pediatric emergency service or were hospitalized at the moment of sample collection. Demographic and clinical data of the children are presented in supplemental material Table S1 of the first article. The mean time of blood drawing after onset of diarrhea was 5 d (range: 1–12). Plasma and serum samples were obtained from 10 healthy adult volunteers (7 females and 3 males; mean age: 28 years, range: 25–38), without any gastrointestinal symptoms during the month previous to the blood drawing. Additionally, 4 umbilical cord blood samples taken from healthy full-term newborn infants were also included. In our previous double-blind randomized controlled study [17], children received two doses of either placebo (n = 160) or 10 6.7 focus-forming units of the attenuated RIX4414 human RV vaccine (n = 159). Vaccine and placebo groups were very similar in terms of the median age at the time of the first and second vaccination (60 and 122 days, respectively), gender (M/F 85/74 and 84/76, respectively), and percentage of breast fed at dose 1 and dose 2 (96.9% and 95%, 88.6% and 88.1%, respectively). Details about the vaccine trial and the strategy for clinical evaluation of protection were previously published [17]. Briefly, from the moment infants received their second dose of vaccine/placebo, they were contacted every 2 weeks until they were 13 months old to identify cases of GE. Of the 319 children who received two doses of vaccine/placebo, a subgroup of 119 was randomly selected for immunological assessments (50 vaccinees and 69 placebo recipients). Plasma samples from all these children, except seven placebo recipients (children in whom the informed consent form did not authorize further studies), were included in the present studies. Plasma samples were collected 14–16 days after receiving each dose of RIX4414 or placebo. 57 All plasma samples from previous studies [17, 94, 268], which had been stored at 80°C, were thawed, diluted in 50% glycerol and preserved at -20°C for use. All assays, except competitive binding assays, were blinded experiments. 9.1.2 ELISA for measuring plasma RV secretory immunoglobulin 96-well vinyl microtiter ELISA plates (Thermo Electron Corporation, Cat. No. 2401) were coated with 70 l of 1/10,000 dilution (in phosphate-buffered saline, PBS [Gibco, Cat. No. 21600-069]) of an anti-human SC monoclonal Ab (clone GA-1) (Sigma-Aldrich, Cat. No. I 6635), and incubated overnight at 4°C. After discarding this solution, 150 l of 5% blotto (5% non-fat powdered milk plus 0.1% Tween-20) was added to the plate as a blocking solution and incubated at 37°C for 1h. Then, the blotto was discarded and 70 l of serial dilutions of plasma samples in 2.5% blotto were deposited in each well. After 2 h incubation at 37°C, samples were discarded and the plates were washed three times with PBS-Tween 20 and 70 l of 1/10 dilutions in PBS of a supernatant from RF (Bovine RV strain P6[1]G6, 10 7 focus forming units/ml) virus-infected MA104 cells or the supernatant of mockinfected cells (negative control) were added and incubated at 37°C for 1h. Notably, most antibodies detected with this antigen are specific for the major capsid protein VP6, which contains group- and subgroup-specific antigenic determinants and exhibits a high level of sequence conservation [201, 269]. The wells were then washed three times and 70 l of guinea pig anti-rhesus RV hyperimmune serum diluted 1/4,000 in 2.5% blotto was added to each well and incubated for 1h at 37°C. After three washes, 70 l of biotinylated goat anti-guinea pig serum (Vector Laboratories, Cat. No. BA-7000) diluted 1/2,000 in 2.5% blotto was added to each well. After 1h of incubation at 37°C, the wells were washed three times and 70 l of peroxidase-labeled streptavidin (Kirkegaard and Perry Laboratories [KPL], Cat. No. 14-30-00) diluted 1/1,000 in 2.5% blotto was added to each well and incubated for 1h at 37°C. After three washes, plates were developed using 70 l tetramethyl benzidine substrate (Sigma-Aldrich, Cat. No. 50-76-00). The reaction was stopped by the addition of 17.5 l 2 M sulfuric acid. Absorbance was read at a wavelength of 450 nm on an ELISA plate reader (Multiskan EX; Thermo Labsystems). Serial dilutions of a pool of plasmas from children with RV-SIg was used as a positive control and a plasma from a child without evidence of previous RV infection (RVIgA-) was used as a negative control in each plate. Samples were considered positive if the optical density in the experimental well was > 0.1 optical density units and 2-fold greater than the optical density in the corresponding negative control wells. To be accepted for analysis, the titer of the positive control plasma could not differ by more than one dilution from plate to plate. A schematic representation of this ELISA is available in Figure A1 of the appendix. 58 9.1.3 ELISA for measuring total plasma secretory IgA To detect total SIgA, a sandwich ELISA was developed using a previously described approach [270]. Briefly, 96-well vinyl microtiter ELISA plates were coated with 70 l of 1/10,000 dilution of the anti-human SC monoclonal Ab or PBS (negative control) and incubated overnight at 4°C. 5% blotto was added and incubated at 37°C for 1h. Then, 70 l of serial dilutions of plasma samples were applied in each well. After 2 h incubation at 37°C, the plates were washed three times with PBS-Tween 20 and 70 l of biotin-labeled goat anti-human IgA (KPL, Cat. No. 16-10-01) diluted 1/1,000 in 2.5% blotto was added and incubated for 1h at 37°C. After three washes, 70 l of peroxidase-labeled streptavidin diluted 1/1,000 in 2.5% blotto was added and the plates were incubated for 1h at 37°C. After three washes, plates were developed and analyzed as described above for measuring plasma RV-SIg. The concentration of total SIgA in the plasma pool, used as a positive control, was interpolated from a standard curve generated with purified SIgA from human colostrum (AbD Serotec, Cat. No. PHP133). The corresponding concentration for each plasma sample tested was in turn interpolated from the plasma pool curve using a four-parameter logistic-log function [271]. A schematic representation of this ELISA is available in Figure A2 of the appendix. 9.1.4 ELISA for measuring plasma RV-IgM RV-IgM ELISA was performed as previously described [43], with minor modifications. Briefly, 96-well Immulon 2 microtiter ELISA plates (Dynex Technologies) were coated overnight at 4°C with 70 l of Goat F(ab’)2 anti-human IgM (Invitrogen, Cat. No. AHI1601) diluted 1/500 in PBS. The plates were then blocked and incubated with plasma samples diluted in 5% blotto. After five washes with PBS-Tween 20, the remaining steps of the assay continued as described above for measuring plasma RV-SIg. Samples were considered as positive using the same criteria previously described. 9.1.5 Recombinant human SC and competitive binding assays The recombinant human secretory component (rhSC) was kindly provided by Doctor Blaise Corthésy. To obtain rhSC, a expression vector pcDNA3:SC was created by inserting into XbaI/EcoRI-cut pcDNA3 plasmid (Invitrogen) the 1.85 kb fragment carrying the cDNA for human SC recovered from XbaI/EcoRI-treated plasmid pBS-hSC:End. After transfection into CHO dhfr- cells (CHO DUK-; ATCC CRL 9096) and selection in the presence of G418, clones isolated by FACS scan were tested by ELISA [272]. The clone producing the highest amount of rhSC 59 represents the source of rhSC used in the paper to ensure the activity of the capture antibody in the SIg ELISAS. Bovine serum albumin (Merck, 1120180100) (used as a negative control) or rhSC was added in 1/2 serial dilutions (starting from 6.1 μg/ml onwards) after the blocking step, and incubated for 10 min at 37°C. Next, purified SIgA was added at a concentration of 0.076 μg/ml (the concentration of SIgA present in a 1/200 dilution of the positive control plasma pool), plates were incubated for 2 h, and the assay continued as described above. A similar strategy was used for RV-SIg, using a dilution of plasma samples (1/200), either with only plasma RV-IgA or with only plasma RV-IgM, which gave a sub-saturating signal in the ELISA. After this, plates were incubated for 2 h and the assay continued as previously described. 9.1.6 Subjects, sample collection and processing: patients with autoimmune diseases and healthy volunteers Fourteen patients, twelve females and two males, nine of them diagnosed with RA and five with SLE, according to the American College of Rheumatology international criteria [273, 274], were included. All patients had moderate or high disease activity, despite treatment with disease-modifying anti-rheumatic drugs or standard immunosuppressive therapy, measured by the disease activity score of 28 joint counts (DAS28) or SLE Disease Activity Index (SLEDAI), respectively. Given the failure to standard treatment regimens, they were selected to receive RTX by their treating rheumatologist. Additional clinical manifestations considered to use RTX as the treatment of choice in patients included: lupus nephritis (n = 2), autoimmune thrombocytopenia (n = 1), overlap of RA and SLE (n = 4), and antiphospholipid syndrome (n = 2). The treatment regimen included two infusions of intravenous RTX (1,000 mg), 14 days apart, in combination with intravenous methylprednisolone (100-250 mg) [275, 276]. The median age at RTX treatment was 46 years (range 26 – 69) and the median disease duration to the time of RTX treatment was 3 years (range 1 – 30); eight patients had been diagnosed (within three years or less). Clinical follow up could be done in eleven patients within the following six months post B-cell depletion therapy. Out of these, seven patients showed subjective and objective clinical improvement. Supplementary Table S1 in the second article describes accompanying autoimmune diagnoses, concomitant and relevant previous pharmacologic treatment, baseline disease activity, and clinical follow up. Ten age and sex matched healthy volunteers were used as controls. PBMC were isolated by LymphoSep (MP Biomedicals, Solon, OH) density-gradient centrifugation from heparinized samples from ten of the fourteen patients described above, immediately before and four to six months after RTX infusion (in the remaining four patients PBMC samples were only available after RTX treatment), and from ten age and sex matched healthy controls. A complete blood count test 60 was performed for each volunteer after each blood draw, and plasma was collected and stored at −80 °C for subsequent total and antigen-specific Igs assessment and auto-Abs measurement. 9.1.7 Production of fluorescent virus like particles (VLPs) Fluorescent RV VLPs were a kind gift of Annie Charpilienne and were produced using baculovirus expression vectors, as previously described [202]. Briefly, Sf9 cells were co-infected with 2 recombinant baculoviruses at a multiplicity of infection greater than 5 PFU/cell. One baculovirus expressed RF (bovine RV) VP6 and the other a fusion protein consisting of green fluorescent protein (GFP) fused to the N terminus of RF VP2 deleted in the first 92 amino acids. Infected cultures were collected five to seven days post infection and purified by density gradient centrifugation in CsCl. The optimal concentration of the RV VLPs for labeling of specific mBc was determined using PBMC from healthy volunteers. Notably, RV VP6 is an immunodominant protein, and the majority of human RV-specific B cells bind to VP6 [102]. Additionally, the majority of RV antibodies in infected animals and humans recognize the VP6 protein on the outer shell of the VLPs [201]. 9.1.8 Biotinylated - TT antigen Tetanus Toxoid (Statens Serum Institute, Denmark) for in vitro tests was biotinylated using the EZ-Link Photoactivatable Biotin kit (Pierce Protein Biology Products, Cat. No. 29987) according to manufacturer's instructions, as previously described [43], with minor modifications. A total of 750 μg of TT protein was incubated with biotin at a molar ratio of 20 mol of dye per mole of protein, for 20 min on ice under a UV (365 nm) lamp, and then dialyzed against PBS for 18 hours to remove excess biotin, using a Slide-A-Lyzer dialysis cassette (Thermo Scientific Pierce, Cat. No. 66333). The optimal concentration of the biotinylated TT for labeling of specific mBc was determined using PBMC from healthy and recently TT vaccinated volunteers. 9.1.9 Flow cytometry assays Fresh PBMC, 4 to 6 x 106, were washed twice with PBS (Gibco-BRL, Cat. No. 70011-044) and incubated with the GFP labeled VLPs (0.9 μg/test) or without this reagent (negative control) for 45 minutes in the dark, at room temperature (RT). The cells were then washed with PBS – 1% bovine serum albumin (Merck, Cat No. 1120180100), 0.02% sodium azide (Mallinckrodt Baker, Cat No. V015-05) (staining buffer), and surface stained with Abs against CD19-allophycocyanin (APC)-H7 (SJ25C1 clone; Becton Dickinson [BD], Cat No. 643078), IgD-HorizonTM V450 (IA6-2 clone; BD, Cat. No. 561309), CD27- phycoerythrin (PE)-Cy7 (M-T271 clone; 61 BD, Cat No. 560609), goat anti-IgA-R-PE (Jackson ImmunoResearch, Cat. No. 109-115-011), IgG-APC (G18-145 clone; BD, Cat. No. 550931) and custom-made IgM-Alexa Fluor 700 (145-8 clone; BD). Biotinylated-TT, or no reagent, was also added at this step and incubated for 30 minutes in the dark, at RT. Cells were then washed with staining buffer and the biotinylated-TT was detected using streptavidin-peridinin chlorophyll protein (PerCP) (BD, Cat. No. 340130). Streptavidin-PerCP was also added to the PBMCs without biotinylated-TT to assess the background generated by this reagent (negative control). After staining, the cells were washed and resuspended in staining buffer. At least 200,000 B cells, gated on a CD19+ window, were acquired on a FACSAria (BD) or LSRFortessa (BD) flow cytometer. Application settings were used to obtain constant fluorescence intensity values among experiments run on different days and regardless of the flow cytometer used. Fluorescence minus one controls were used to determine the cut-off between positive and negative cell populations for each marker [277]. Notably, Abs against CD3/CD14-HorizonTM V500 (UCHT1 and M5E2 clones, respectively; BD, Cat. No. 561416 and 561392) were used as a dump channel in samples taken from patients after RTX treatment. However, since conclusions did not change with or without its use, the dump channel was not considered in the final analyses. Results for total and antigen-specific mBc were expressed as absolute numbers of CD19+ B cells/mL, calculated after background subtraction, based on the total lymphocyte numbers in the patient's complete blood count test results, according to the following equation: Absolute number of CD19 + B cells/mL per mBc subpopulation = (absolute number of lymphocytes in complete blood count/mL)×(percentage of CD19+ B cells in each subpopulation). Evaluable total B cell subpopulations were defined as those with 10 acquired events [278]. The frequency, in terms of CD19+ B cells, of those 10 events was calculated considering the median CD19+ events acquired after RTX treatment, and multiplied by the median absolute B cell count after RTX treatment. This value, 3.5 CD19+ B cells/mL, corresponds to the dotted lines present in each total B cell subpopulation of Figure 2 and represents the flow cytometry detection limit for total B cell subpopulations. A common detection limit could not be determined for antigen-specific mBc subsets due to the variable background. Nevertheless, the reported values correspond to antigen-specific mBc subsets with 10 acquired events, and at least two-fold greater than the observed background. Flow cytometry analysis was performed using FlowJo software version 9.6.2 for Mac (Treestar, Ashland, OR). 62 9.1.10 Measurement of total immunoglobulins (IgA, IgG and IgM) and IgM Rheumatoid Factor Plasma samples were thawed and simultaneously assessed by kinetic nephelometry on an IMMAGE® immunochemistry system (Beckman Coulter, Fullerton, CA), following the manufacturer’s instructions. Measuring ranges are as follows: IgA: 40 – 700 mg/dL (normal reference range values: 82 – 453 mg/dL); IgG: 200 – 3,600 mg/dL (normal reference range values: 751 – 1,560 mg/dL); IgM: 25 – 400 mg/dL (normal reference range values: 46 – 304 mg/dL); and IgM rheumatoid factor (RF): 20 – 800 IU/mL (negative cut off value: <20 IU/mL), with a sensitivity level reported by the manufacturer of 70-75%. 9.1.11 ELISAs for detection of RV-specific IgA, IgG, and IgG1 and TT-specific IgG in plasma RV and TT antibodies were assessed as previously described with minor modifications [43]: 96-well vinyl microtiter ELISA plates (Thermo Electron Corporation, Milford, MA) were coated with 70 l of either a supernatant from RF virus-infected MA104 cells or the supernatant of mock-infected cells (negative control) diluted 1/10 in PBS, for RV-specific ELISAs, or 0.5 μg/mL of TT or PBS (negative control), for TT-specific IgG ELISA, and incubated overnight at 4°C. After blocking with 150 l of 5% blotto during 1h at 37°C, 70 l of serial dilutions of plasma samples were deposited in each well. After 2 h incubation at 37°C, samples were discarded and the plates were washed three times with PBS-Tween 20. Depending on the type of ELISA performed, 70 l of a 1/1,000 dilution in 2.5% blotto of biotin-labeled goat anti-human IgA or IgG (KPL, Cat No. 16-10-01 and Cat. No. 16-10-06, respectively), or biotin-labeled mouse anti-human IgG1 (8c/6-39 clone, Sigma-Aldrich, Cat. No. B 6775) diluted 1,2000 in 2.5% blotto were added to each well. After three washes, 70 l of a 1/1,000 dilution of peroxidase-labeled streptavidin were added. Plates were developed and analyzed as previously described for measuring plasma RV-SIg. Pools of plasmas from children with RVIgA or RV-IgG, and from adults with TT-IgG were used as positive controls. Plasmas from a child without evidence of previous RV infection (RV-IgA-), and without RV-IgG from placental transfer of maternal IgG antibodies, and from an adult negative for TT-IgG were used as negative controls. 9.1.12 Measurement of anti-CCP and anti-dsDNA autoantibodies (IgG isotype) Plasma samples were simultaneously assessed by a fluorescence enzyme immunoassay (EliA test), following the manufacturer’s instructions, on a Phadia ImmunoCAP 100 system (Phadia AB, Uppsala, Sweden). The anti-CCP test has a measuring range of 0.4 to at least 340 U/mL, a negative cut off value of < 7 U/mL, an equivocal range of 7 – 10 U/mL, and a positive cut off value of > 10 U/mL; the 63 manufacturer’s reported clinical sensitivity and specificity are 87.8% and 96.7%, respectively. The anti-dsDNA test has a measuring range of 0.5 to at least 400 IU/mL, a negative cut off value of < 10 IU/mL, an equivocal range of 10 – 15 IU/mL, and a positive cut off value of > 15 IU/mL; the manufacturer’s reported sensitivity for active SLE is 70.8% and clinical specificity of 93.2%. 9.1.13 Statistical analyses Analyses were performed with SPSS software version 20.0 (IBM Inc.) and with GraphPad Prism version 6. Differences between groups were evaluated with nonparametric Mann–Whitney and Wilcoxon tests, as required. Correlations were evaluated with Spearman's test. When data followed a normal distribution, or were normalized, a Student’s t-test was applied. Significance was established if p < 0.05, in 1 or 2 tailed tests, if the direction of hypothesis was known or unknown, respectively. 64 9.2 Figure A1: Schematic representation of the ELISA for measuring plasma RV secretory immunoglobulin 65 9.3 Figure A2: Schematic representation of the ELISA for measuring total plasma secretory IgA 66 9.4 Relevant data not shown from the first article: “Rotavirus Specific Plasma Secretory Immunoglobulin in Children with Acute Gastroenteritis and Children Vaccinated with an Attenuated Human Rotavirus Vaccine” 9.4.1 Concentration of total SIgA in plasma and serum samples from the same adult healthy volunteers The concentration of SIgA for each sample was determined by ELISA based on a standard curve of plasma with a known SIgA concentration (14.6 g/ml). The limit of detection was 4.8 ng/ml. Lines and error bars denote the mean and SEM, respectively. Differences between groups (n = 10) were evaluated with the nonparametric Mann–Whitney test. There was no significant difference when plasma or serum samples were evaluated. 67 9.5 Relevant data not shown from the second article: “Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab” 9.5.1 RV-mBc enrichment in the CD27-IgG+ subset in healthy volunteers when the analysis was done in terms of the CD27- mBc Summary of the frequencies of three subsets of total and RV-mBc assessed by multiparametric flow cytometry and expressed in terms of CD27- mBc in healthy volunteers (n = 10). All p values reported are 2-tailed (p < 0.05, Wilcoxon test). Lines and error bars denote the median and interquartile range, respectively. 9.6 Journal paper: “Circulating human rotavirus specific CD4 T cells identified with a class II tetramer express the intestinal homing receptors α4β7 and CCR9” 68 Elsevier Editorial System(tm) for Virology Manuscript Draft Manuscript Number: VIRO-13-631R1 Title: Circulating human rotavirus specific CD4 T cells identified with a class II tetramer express the intestinal homing receptors α4β7 and CCR9 Article Type: Regular Article Section/Category: 8 Immunity Keywords: Rotavirus (RV); T cells; intestinal homing receptors; MHC class II tetramers. Corresponding Author: Dr. Juana Angel, Corresponding Author's Institution: Pontificia Universidad Javeriana First Author: Miguel H Parra Order of Authors: Miguel H Parra; Daniel Herrera; J. Mauricio Calvo-Calle; Lawrence J Stern; Carlos A Parra-López; Eugene Butcher; Manuel Franco; Juana ANGEL Abstract: Using a consensus epitope prediction approach, three rotavirus (RV) peptides that induce cytokine secretion by CD4 T cells from healthy volunteers were identified. The peptides were shown to bind HLA-DRB1*0101 and then used to generate MHC II tetramers. RV specific T cell lines specific for one of the three peptides studied were restricted by MHC class II molecules and contained T cells that bound the tetramer and secreted cytokines upon activation with the peptide. The majority of RV and Flu tetramer+ CD4 T cells in healthy volunteers expressed markers of antigen experienced T cells, but only RV specific CD4 T cells expressed intestinal homing receptors. CD4 T cells from children that received a RV vaccine, but not placebo recipients, were stained with the RV-VP6 tetramer and also expressed intestinal homing receptors. Circulating RV-specific CD4 T cells represent a unique subset that expresses intestinal homing receptors.. *Manuscript Click here to view linked References 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 1 Circulating human rotavirus specific CD4 T cells identified with a class II 2 tetramer express the intestinal homing receptors 47 and CCR9 3 4 Miguel Parra1, Daniel Herrera1, J. Mauricio Calvo-Calle2, Lawrence J. Stern2, 5 Carlos A. Parra-López3, Eugene Butcher4, Manuel Franco1, and Juana Angel1,& 6 7 1 8 Javeriana, Bogotá, Colombia. 9 2 Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Department of Pathology, University of Massachusetts Medical School, 10 Worcester, MA 01655. 11 3 12 de Colombia, Bogotá, Colombia. 13 4 14 Stanford University School of Medicine, Stanford, California , USA. Facultad de Medicina, Departamento de Microbiología, Universidad Nacional Laboratory of Immunology and Vascular Biology, Department of Pathology, 15 16 Running title: Rotavirus specific CD4 T cells express intestinal homing 17 receptors. 18 19 Keywords: Rotavirus (RV), T cells, intestinal homing receptors, MHC class II 20 tetramers 21 22 & 23 Pontificia Universidad Javeriana, Carrera 7 No. 40-62, Bogotá, Colombia. 24 Email: [email protected]. Phone: 57-1-3208320 Ext 2790. Fax: 57-1- 25 2850356. Address Correspondence to: Dr. Juana Angel. Instituto de Genética Humana, 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 27 ABSTRACT 28 Using a consensus epitope prediction approach, three rotavirus (RV) peptides 29 that induce cytokine secretion by CD4 T cells from healthy volunteers were 30 identified. The peptides were shown to bind HLA-DRB1*0101 and then used to 31 generate MHC II tetramers. RV specific T cell lines specific for one of the three 32 peptides studied were restricted by MHC class II molecules and contained T 33 cells that bound the tetramer and secreted cytokines upon activation with the 34 peptide. The majority of RV and Flu tetramer+ CD4 T cells in healthy volunteers 35 expressed markers of antigen experienced T cells, but only RV specific CD4 T 36 cells expressed intestinal homing receptors. CD4 T cells from children that 37 received a RV vaccine, but not placebo recipients, were stained with the RV- 38 VP6 tetramer and also expressed intestinal homing receptors. Circulating RV- 39 specific CD4 T cells represent a unique subset that expresses intestinal homing 40 receptors. 41 42 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 43 INTRODUCTION 44 Rotavirus (RV) is the leading worldwide cause of severe gastroenteritis in 45 children under the age of 5 years (Tate et al., 2012). Two vaccines (RotarixTM 46 and RotateqTM) have been included in national immunization programs in many 47 countries (Glass et al., 2012), but their efficacy is relatively low in some African 48 and Asian countries, where they are most needed (Angel et al., 2012). Thus, 49 improvement of current vaccines or generation of new RV vaccines is desirable; 50 however, an important drawback to this end is the lack of optimal immune 51 correlates of protection after vaccination (Angel et al., 2012). 52 The protective immune response to RV in humans and animals is mediated by 53 intestinal IgA (Blutt et al., 2012; Franco et al., 2006), which is, at least partially, 54 T cell dependent: on the one hand, in the murine model the CD4 T cells are 55 essential for the development of RV-specific intestinal IgA (Franco and 56 Greenberg, 57 immunodeficiencies get chronically infected with RV, suggesting that both arms 58 of the immune system are important in clearance of RV infection (Gilger et al., 59 1992). Our group has observed that higher frequencies of RV-specific CD8 and 60 CD4 T cells secreting IFN- circulate in symptomatically infected adults and RV- 61 exposed laboratory workers, compared with healthy volunteers. (Jaimes et al., 62 2002). In contrast, children with RV diarrhea had low or below detection levels 63 of RV-specific CD8 and CD4 T cells secreting IFN- (Jaimes et al., 2002; Mesa 64 et al., 2010; Rojas et al., 2003). Consequently, monitoring of RV-specific CD4 T 65 cells responses after vaccination may require a direct and highly sensitive 66 assay. 1997). On the other hand, children with T and/or B 4 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 67 The expression of tissue-homing receptors defines subsets of memory T cells 68 that preferentially home to the skin or gut (Butcher and Picker, 1996; Sallusto 69 and Lanzavecchia, 2009). These receptors are imprinted by dendritic cells in 70 developing T cells and promote trafficking properties based on the site-specific 71 expression of their ligands (Sigmundsdottir and Butcher, 2008). Gastrointestinal 72 associated lymphoid tissue dendritic cells metabolize food-vitamin A into 73 retinoic acid, which induces the T cells to express high levels of the gut-homing 74 receptors 47 and CCR9, predisposing the migration of the recent activated T 75 cells from the blood to the effector sites in the gut mucosa (Mavigner et al., 76 2012). The natural ligand of the 47 integrin is the mucosal addressing cell 77 adhesion molecule-1 (MAdCAM-1), which is expressed by endothelial cells of 78 the lamina propria along the entire intestine. Whereas, CCL25, the ligand of 79 CCR9, is only expressed by small intestine endothelial and epithelial cells 80 (Mavigner et al., 2012). Thus, T cells that express both markers are conditioned 81 to home to the small intestine. 82 RV predominantly replicates in mature enterocytes of the small intestine, but 83 also has a systemic dissemination (Blutt et al., 2003) and, consequently, both 84 intestinally and systemically primed T cells are expected to be generated 85 (Franco et al., 2006). Using purified subsets of peripheral blood mononuclear 86 cells (PBMC) that express the intestinal homing receptor 47, we found that 87 RV-specific CD4 T cells secreting IFN- from adult volunteers preferentially 88 express this receptor (Rojas et al., 2003). With similar studies other 89 investigators have shown that in healthy adults circulating CD4 T cells that 90 proliferate in vitro in response to RV also express 47 (Rott et al., 1997). All of 91 these studies have the drawback that subsets of T cells expressing the homing 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 92 receptor have to be purified before their identification in the functional studies, 93 which may change their phenotype. Moreover, no studies have assessed the 94 expression of CCR9 on human RV-specific T cells. 95 Recently, the use of MHC class II tetramers for characterization of CD4 T cells 96 populations (Vollers and Stern, 2008) has appeared as a new important tool to 97 characterize antigen-specific T cells against different viruses (Nastke et al., 98 2012; Nepom, 2012). Also, tetramers have been used to examine the CD4 T 99 cells responses after vaccination against influenza (Flu) (Danke and Kwok, 100 2003) and anthrax (Laughlin et al., 2007). The tetramers permit the ex vivo 101 quantification and phenotypic characterization of T cells without T cell activation. 102 In the present study, we identified the first HLA-DR1-restricted human RV- 103 specific CD4 T cell epitope, and used MHC class II tetramers to characterize 104 the phenotype of the T cells specific to this epitope. T cells specific for the RV 105 peptide tetramer, but not for a Flu virus peptide-tetramer, expressed intestinal 106 homing receptors. Moreover, antigen experienced CD4 T cells from children 107 that received a RV vaccine, but not from placebo recipients, were stained with 108 the RV tetramer and expressed intestinal homing receptors. 109 110 METHODS 111 112 Epitope prediction and peptides synthesis 113 To predict HLA-DR1 (DRB1*0101) binding epitopes, we used the sequences of 114 the RV strain KU G1P[8] form the NCBI genome databases (BAA84966, 115 BAA84967, Q82050.1, BAA84969, BAA84970, AAK15270.1, BAA84962, 116 BAA84963, BAA84964, P13842, BAA84965, BAA03847). Each potential 9-mer 6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 117 binding frame was evaluated using two independent prediction algorithms: P9 118 (Calvo-Calle et al., 2007; Hammer et al., 1994; Nastke et al., 2012; Sturniolo et 119 al., 1999) and SYFPEITHI (Schuler et al., 2007), as previously described 120 (Calvo-Calle et al., 2007; Nastke et al., 2012). Potential epitopes were selected 121 using cutoff scores of ≥1.5 for P9 and ≥29 for SYFPEITHI. Overall, 1,440 122 possible 9-mer minimal epitopes were evaluated and 39 potential epitopes, 123 scoring highly for both algorithms, were selected (Supplementary table 1), 124 extended by six residues on each side, and synthesized (Sigma-Aldrich 125 PEPscreen®) with an acetylated N-terminal and amidated C-terminal. 126 127 Subjects 128 After written informed consent was signed, blood samples were obtained from 129 52 healthy volunteers, 23 to 52 years old that, as expected, had serum 130 antibodies against RV. Frozen PBMC from 35 RV IgA seropositive vaccinated 131 children and 24 RV seronegative placebo recipient children (samples from a 132 previous study (Rojas et al., 2007)), in whom the informed consent authorized 133 further studies, were also assessed. This was a double-blind randomized 134 controlled study, in which children received two doses of either placebo (n = 135 160) or 10 136 (precursor of the RotarixTM vaccine, n = 159). The first and second doses were 137 administered at 2 and 4 months of age, respectively, and children were bled 138 14–16 days after each dose. Studies were approved by the Ethics Committee of 139 the San Ignacio Hospital and Pontificia Universidad Javeriana. 6.7 focus-forming units of the attenuated RIX4414 human RV vaccine 140 141 Human haplotype determination 7 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 142 DNA was obtained from blood samples using Illustra blood genomicPrep Mini 143 Spin Kit (G/E healthcare, UK Buckinghamshire), according to manufacturer’s 144 instructions. The HLA class II haplotype was determined using All set Gold-SSP 145 HLA DRDQ low resolution Kit (Invitrogen Corporation, Wisconsin USA), PCR- 146 based protocols, according to manufacturer’s instructions. All samples identified 147 as a DRB1*01 in low resolution were analyzed for high-resolution using the All 148 set Gold-SSP HLA DRB1*01 high-resolution Kit (Invitrogen Corporation, 149 Wisconsin USA), according to manufacturer’s instructions. (Supplementary 150 table 2). 151 152 Antigen stimulation of PBMC and intracellular cytokine staining (ICS) 153 PBMC were purified from heparinized whole-blood samples by Ficoll-Hypaque 154 gradients (Lympho Separation Medium, MP Biomedicals). The cells were 155 washed twice with RPMI containing 20 mM HEPES, 100 U of penicillin/ml, and 156 100 mg of streptomycin/ml plus 10% fetal bovine serum (FBS) (all from GIBCO, 157 Carlsbad, CA, USA) (complete medium) and re-suspended in 1ml of AIM-V 158 medium (life technologies, Carlsbad, CA, USA). PBMC (1x106 cells in a final 159 volume of 1 ml) were stimulated with the supernatant of MA104 cells infected 160 with RRV (Rhesus RV, MOI:7), the supernatant of mock-infected MA104 cells 161 (negative control), the superantigen staphylococcal enterotoxin B (SEB; Sigma, 162 St Louis, Mo, USA), peptides pools (5 peptides per pool at 1 µg/ml each) or 163 individual peptides at different concentrations. Anti-CD28 (0.5 µg/ml) and anti- 164 CD49d (0.5 µg/ml) (Both from BD Biosciences, San Jose, CA) monoclonal 165 antibodies were added to each sample as co-stimulators (Waldrop et al., 1998; 166 Waldrop et al., 1997). Antigen stimulation was done in 15 ml polystyrene tubes 8 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 167 (Becton Dickinson Falcon Labware, Franklin Lakes, N.J., USA) incubated with a 168 5° slant for 10 h at 37°C with 5% CO2. The last 5 h of the incubation included 169 brefeldin A (10 µg/ml; Sigma) to block the secretion of cytokines. At the end of 170 the incubation, the cells were washed once with PBS–0.5% bovine serum 171 albumin (Merck, Darmstadt, Germany) 0.02% sodium azide (Mallinckrodt 172 Chemicals, Paris, Ky.) (Staining Buffer). Then, a 2 mM final concentration of 173 EDTA (GIBCO, N.Y. USA) in PBS was added for 10 min to detach plastic- 174 adherent cells, and the samples were washed once more with Staining Buffer. 175 PBMC were stained with Aqua viability reagent (Invitrogen Molecular Probes, 176 Eugene, OR) in PBS for 10 min at room temperature (RT), and the cells were 177 stained with monoclonal antibodies (Mabs) against CD14-V500 and CD19- 178 V500, as a dump channel, CD3-pacific blue, CD4-PerCP-Cy5.5, and CD8-APC- 179 H7 for 20 min at RT (all from BD Biosciences, San Jose, CA). After two wash 180 steps with Staining Buffer, cells were treated with Citofix/Citoperm solution (BD 181 Biosciences, San Jose, CA) for 30 min at 4°C and washed twice with 1 ml of 182 Perm/Wash solution (BD Bioscience, San Jose, CA). Then, Mabs against IL-2- 183 FITC, IFN--PE-Cy7 and TNF--APC (all from BD Biosciences) were added and 184 incubated for 20 min at RT. Production of IL-2 and IFN- by RV stimulated T 185 cells was observed in our previous work; TNF- secretion was also evaluated to 186 make a more comprehensive analysis of multifunctional T cells (Gattinoni et al., 187 2011). Finally, the cells were washed twice with Perm/Wash, resuspended in 188 250 µl of Perm/Wash, acquired in a FACSAria flow cytometer (BD Biosciences, 189 San Jose, CA) and analyzed with FlowJo software v.9.3.2. 190 191 Peptide binding assays 9 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 192 Peptide binding to DR1 and DR4 was analyzed using an ELISA-based 193 competition assay, as previously described (Parra-López et al., 2006). Purified 194 HLA-DR1 or DR4 molecules (0.05 µM) were diluted with freshly prepared 195 binding buffer (100 mM citrate/phosphate buffer [pH 5.4], 0.15 mM NaCl, 4mM 196 EDTA, 4% NP-40, 4 mM PMSF, and 40 µg/ml for each of the following protease 197 inhibitors: soybean trypsin inhibitor, antipain, leupeptin and chymostatin) 198 containing 0.025 µM biotin-labeled hemagglutinin HA306–318, a well described 199 binding peptide from Flu hemagglutinin (PKYVKQNTLKLAT) (Roche and 200 Cresswell, 1990), and various concentrations of unlabeled competitor peptide 201 (HA306-318, 202 (YNALIYYRYNYAFDLKRWIYL) and VP6-7 (DTIRLLFQLMRPPNMTPAVNA)) in 203 a total volume of 120 µl. Peptides were diluted from stock solutions in binding 204 buffer. After 48h of incubation at RT, 100 µl were transferred to 96-well ELISA 205 microtiter plates (Immuno Modules MaxiSorp, Nunc, Denmark), which had been 206 previously coated overnight with a 10 µg/ml anti-HLA-DR Mab LB3.1, washed, 207 and subsequently blocked with PBS containing 3% bovine serum albumin. After 208 2 hours of incubation at RT, plates were washed with PBS, 0.05% Tween-20 209 and incubated for 1h with phosphatase-labeled streptavidin (KPL, Maryland, 210 USA). Captured biotin-labeled peptide/DR complexes were revealed with 4- 211 nitrophenylphosphate substrate (KPL, Maryland, USA). For determining peptide 212 binding to HLA-DR molecules a Ultramark ELISA plate reader (Bio-Rad, CA, 213 USA) with a 405 nm filter was used. Results at each concentration are 214 expressed normalized with respect to the maximum observed binding, and used 215 to calculate IC50 values. NSP2-3 (SGNVIDFNLLDQRIIWQNWYA), VP3-4 216 10 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 217 Carboxyfluorescein succinimidyl ester (CFSE) proliferation assay 218 Proliferation of cells was evaluated by CFSE staining as reported by Quah 219 (Quah and Parish, 2010; Quah et al., 2007), with some modifications. Briefly, 4- 220 10x106 fresh PBMC were resuspended in 1 ml of PBS 1X, placed in a 15 ml 221 conical tube, and stained with CFDA-SE (CellTrace™ CFSE Cell Proliferation 222 Kit). The cells were incubated 5 min at RT, protected from light, and then 223 washed 3 times with 10 ml of PBS 1X-FBS 5% at RT. Finally, the cells were 224 diluted in 1 ml of RPMI supplemented with 10% AB+ human serum (Multicell, 225 human serum AB, Wisent INC, Canada). After CFSE staining, PBMC were 226 stimulated with SEB and three RV peptides (NSP2-3, VP3-4, and VP6-7) for 5 227 days at 37°C with 5% CO2. Then, cells were harvested, washed twice with PBS 228 1X, and stained with Violet viability reagent (Invitrogen Molecular Probes, 229 Eugene, OR) in PBS for 10 min; CD3-PE, CD4-PerCP-Cy5.5 and CD8-APC-H7 230 were added and incubated for 30 min at RT. Finally, the cells were 231 resuspended in 250 µl of PBS, acquired in a FACSAria flow cytometer (BD 232 Biosciences, San Jose, CA) and analyzed with FlowJo software v.9.3.2. 233 234 T cell lines 235 T cell lines were generated from PBMC. 1-2x106 PBMC per well were incubated 236 in 24-well plates in 1 ml of RPMI 1640 supplemented with AB+ human serum 237 10% (Multicell), 100 U/ml penicillin, 100 g/ml streptomycin, 1 mM sodium 238 pyruvate, 2 mM L-glutamine, and 1 mM nonessential amino acids. Antigen- 239 specific populations were expanded by culture in the presence of NSP2-3, VP3- 240 4 or VP6-7 peptides (10 µg/ml) or RRV infected MA104 cell lysate (MOI:7). 241 After 48h of incubation at 37°C with 5% CO2, fresh T cell medium 11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 242 supplemented with 100 U/ml IL-2r (Proleukin; Chiron Corporation, Emeryville, 243 CA) was added. This last step was repeated every 2 days until the culture 244 completed 12 days. Then, autologous non-irradiated PBMC (ratio 2:1), pulsed 245 with or without peptide (10 µg/ml) for 1h, were used as source of antigen- 246 presenting cells to stimulate the T cell lines. Finally, T cell lines were evaluated 247 by ICS, as described above. In some cases, the cells were stained as described 248 below with the class II tetramer. 249 250 Class II tetramer staining of PBMC from adults and children 251 Biotinylated HLA-DR1-peptide complexes were prepared using proteins 252 produced in insect cells, as previously described (Cameron et al., 2002). Class 253 II tetramers with different peptides (HA306-318, a transferrin [TRF] control peptide 254 [RVEYHFLSPYVSRKESP (Chicz et al., 1992)], NSP2-3, VP3-4 or VP6-7) were 255 prepared with streptavidin-PE (Invitrogen, MD, USA) from a stock solution at a 256 final concentration of 1 µg diluted in 50 µl of PBS 1X. Fresh PBMC obtained 257 from 8 DR1 healthy adults were washed twice in PBS 1X and distributed in 5 ml 258 polystyrene tubes (5x106 cells/50µl per tube). Frozen PBMC of 3 vaccinated or 259 3 placebo recipient HLA-DR1 children were thawed at 37°C and washed twice 260 with a 5 ml Benzonase® (Novagen, San Diego, CA) solution pre-heated at 261 37°C. Then, the cells were distributed in 5 ml polystyrene tubes. 50 µl of 262 Dasatinib® (Bristol-Myers Squibb Company Princeton, NJ 08543 USA) solution 263 (100 µM) was added to each tube and incubated for 30 min at 37°C (Lissina et 264 al., 2009). Later, 10 µl of AB+ human serum was mixed with the cells just before 265 tetramer solution (1 µg) was added and incubated for 120 min at RT. Unlabeled 266 mouse anti-CCR9 Mab was added and incubated for 20 min at RT, then the 12 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 267 cells were washed once with PBS 1X, followed by addition of goat anti-mouse 268 antibodies (AF-488 or Pacific Blue [Invitrogen Corporation, Wisconsin USA]) 269 and incubated for 20 min at RT. The cells were washed once with PBS 1X, then 270 Aqua reagent was added and incubated for 10 min at RT; subsequently, Mabs 271 against CD14-V500 and CD19-V500, as a dump channel, CD3 (Pacific Blue or 272 AF-700), CD4-PerCP-Cy5.5, CD8-APC-H7, CD45RA (FITC or PE-Cy7), 273 CD62L-V450 or CCR7-PE-Cy7, and 47-APC (ACT-1) were added and 274 incubated for 20 min at RT. Cells were washed and resuspended in 400 µl of 275 PBS-BSA-sodium azide, acquired in a FACSAria flow cytometer (BD 276 Biosciences, San Jose, CA) and analyzed with FlowJo software v.9.3.2. 277 278 ELISA for RV-specific IgA in plasma 279 For detection of RV-specific IgA, 96-well vinyl micro titer plates were coated 280 with 70 µl of a 1:10 dilution (in PBS, pH 7.4) of supernatant from RF (bovine 281 RV) virus-infected MA104 cells or the supernatant of mock-infected MA104 cells 282 (negative control) and incubated overnight at 4°C. The wells were then blocked 283 with 150 µl of 5% nonfat powdered milk plus 0.1% Tween-20 in PBS (5% 284 BLOTTO) and the plates were incubated at 37°C for 1 h. Then, the BLOTTO 285 was discarded, and 70 µl of serial plasma dilutions in 2.5% BLOTTO were 286 deposited in each well. After 2h of incubation at 37°C, the plates were washed 287 three times with PBS-Tween-20, and 70 µl of biotin-labeled goat anti-human IgA 288 (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) diluted (1:1000) in 2.5% 289 BLOTTO was added to the plates. The plates were then incubated for 1h at 290 37°C. After three washes with PBS-Tween-20, 70 µl of streptavidin-peroxidase 291 (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) diluted (1:1000) in 2.5% 13 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 292 BLOTTO was added, and the plates were incubated for 1h at 37°C. After three 293 washes with PBS-Tween-20, the plates were developed using 70 µl of 294 tetramethyl benzidine substrate (TMB; Sigma, St. Louis, Mo.). The reaction was 295 stopped by the addition of 17.5 µl of sulfuric acid (2 M). Absorbance was read at 296 450 nm wavelength on an ELISA plate reader (Multiskan EK, Thermolab 297 Systems). Samples were considered positive if optical density (OD) in the well 298 was >0.1 OD units and were two times higher than the OD of the negative 299 control (Rojas et al., 2007). 300 301 Statistical analyses 302 Analysis was performed with GraphPad Prism version 6. Differences between 303 groups were evaluated with the nonparametric Wilcoxon test. 304 305 RESULTS 306 307 Prediction of RV epitopes 308 We used a consensus approach that combined P9 binding and SYFPEITHI 309 presentation algorithms to predict HLA-DR1-restricted T cell epitopes (Calvo- 310 Calle et al., 2007) from the KU strain of RV (Table S1). Thirty-nine 9-mer 311 sequences with high scores were selected: 11 were derived from non-structural 312 proteins and the remaining 28 were derived from structural proteins (Table S1). 313 Peptides were synthesized as 21-mers, containing the 9-mer sequence of 314 interest flanked by 6 aa residues on each side. 315 14 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 316 Screening of peptide pools and identification of individual peptides 317 recognized by CD4 T cells from healthy adults 318 The 39 peptides were organized in 8 pools of 5 peptides each (pool 8 only had 319 4 peptides) according to the algorithm score; the 5 peptides with the lowest 320 scores were arranged in pool 1, and the 4 peptides with highest scores were 321 joined in the pool 8. We expected that HLA-DR1-peptides selected would be 322 recognized by CD4 T cells from individuals of other MHC haplotypes, because 323 of the broadly specific “promiscuous” peptide binding motifs characteristic of 324 most human MHC class II protein, that give rise to the concept of “MHC class II 325 supertypes” (Greenbaum et al., 2011). For this reason, all 18 volunteers 326 selected for our screening experiments expressed MHC haplotypes belonging 327 to the DR-1 supertype (Table S2) (Greenbaum et al., 2011). 328 PBMC of 18 healthy volunteers were obtained and CD4 T cell responses to 329 pools of peptides were evaluated by ex-vivo ICS of IFN- and IL-2. CD4 T cells 330 from 4 volunteers (HA-02; HA-04; HA-05 and HA-06) responded against the 331 peptide pools: cells from volunteer HA-06 recognized pools 7 and 8 (Fig. 1A), 332 cells from volunteer HA-05 recognized pool 5 (CD4 IL-2+: 0,0232%), and cells 333 from volunteers HA-02 (CD4 IL-2+: 0,0208%) and HA-04 (CD4 IL-2+: 1,284%) 334 recognized pool 7 (data not shown). Positive pools were deconvoluted to 335 individual peptides using the same assay. Fig. 1B shows the frequency of cells 336 from volunteer HA-06 producing IL-2 in response to peptides from pools 7 and 337 8. Three peptides (VP6-7, NSP2-3, and VP3-4) were found to induce IL-2 338 production by CD4 T cells from the HLA-DR1-volunteers: VP6-7 induced IL-2 339 production in cells from volunteers HA-06 (Fig. 1B), HA-02, and HA-04; and 340 also IFN- production in cells from HA-06 (data not shown). In addition, VP3-4 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 341 induced IL-2 production in cells from volunteer HA-06 (Fig. 1B), and NSP2-3 in 342 cells from HA-04 (data not shown). No response was seen to individual 343 peptides of pool 5 from volunteer HA-05 (data not shown). 344 The percentage of cells producing IL-2 in response to VP6-7 peptide used to 345 stimulate PBMC from the volunteers HA-06 (Fig. 1C), HA-02, and HA-04 (data 346 not shown) was dose dependent. A similar result was obtained stimulating cells 347 from volunteer HA-06 with VP3-4 peptide (Fig. 1C), but no dose effect was 348 observed with cells from volunteer HA-04 stimulated with NSP2-3 (data not 349 shown). 350 351 RV peptides bind HLA-DR1 molecules 352 To evaluate if the initial 9-mer sequences defined using prediction algorithms 353 bind to recombinant DR1 and DR4 MHC molecules, the 9 aa core of the 354 peptides NSP2-3, VP3-4 and VP6-7, with 1aa addition at both ends, were 355 synthetized and tested for HLA-DR1 and HLA-DR4 binding in a competition 356 binding assay with a biotinylated high affinity DR1- and DR4-binding peptide 357 from Flu haemagglutinin HA306–318 (Fig. 2). Compared to HA peptide (IC50 96 358 nM), VP6-7 (IC50 2 nM) and NSP2-3 (IC50 15 nM) peptides bound to the HLA- 359 DR1 molecules with relatively higher affinity and VP3-4 peptide bound with 360 similar affinity (IC50 73 nM). In contrast, all RV peptides show low affinity binding 361 to the HLA-DR4 molecules (IC50 from 0.8 M to 55 M) (Fig. 2). Based on these 362 results, DR1 tetramers were synthetized with the RV peptides NSP2-3, VP3-4, 363 and VP6-7. 364 365 RV peptide VP6-7 is recognized by RRV specific T cell lines 16 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 366 To evaluate if the selected peptides were processed and presented after viral 367 infection, RRV-T cell lines were derived from two HLA-DR1 healthy volunteers 368 (HA-02 and HA-41) and stained with the three RV DR1-tetramers. RRV-T cell 369 lines derived from both volunteers only stained with VP6-7-tetramers (Fig. 3A 370 and data not shown). In addition, after restimulation of RRV-T cell lines from 371 volunteers HA-02 and HA-52 with RRV and VP6-7 peptide, CD4 T cells 372 producing TNF- and/or IFN- were identified in both cases (data not shown). 373 Only one of these cell lines produced cytokines after restimulation with NSP2-3 374 and neither of them after restimulation with the VP3-4 peptide (data not shown). 375 376 RV peptides are presented to CD4 T cells in the context of HLA-DR 377 molecules 378 To determine if the three RV peptides were presented in the context of HLA-DR 379 molecules, peptide specific T cell lines from two individuals (HA-02 380 [DRB1*01:01] 381 corresponding or control peptides in the absence or presence of LB3.1 or SPV- 382 L3 antibodies (directed against HLA-DR or HLA-DQ molecules, respectively) 383 and IFN- production was evaluated by intracellular cytokine staining. The 384 frequency of CD4 T cells specific for VP6-7, NSP2-3 and VP3-4 producing IFN- 385 decreased in the presence of LB3.1, but not in the presence of SPV-L3 (Fig. 386 3B and data not shown): IFN- production of VP3-4-T cell line from HA-02 387 volunteer was reduced approximately 55% in the presence of LB3.1 and only 388 6% in the presence of SPV-L3 (Fig. 3B). From volunteer HA-06, only a VP6-7 389 specific T cell line was obtained and the response of these cells was also 390 specifically inhibited by LB3.1 (data not shown). These results provide and HA-06 [DRB1*01:02]) were restimulated with the 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 391 additional evidence that RV peptides are presented in the context of HLA-DR 392 molecules, as indicated by tetramer staining. 393 394 VP6-7-MHC class II tetramers recognize functional peptide-specific CD4 T 395 cells in T cell lines 396 To provide additional evidence that VP6-7-tetramers recognize functional VP6- 397 7-specific CD4 T cells, T cell lines from two volunteers (HA-02 and HA-19) were 398 stained with tetramers (TRF or VP6-7) and restimulated with VP6-7 peptide or 399 DMSO (as negative control), and the production of IFN- and TNF- was 400 evaluated by intracellular cytokine staining. When the VP6-7-T cell line from 401 HA-02 was restimulated with VP6-7 peptide almost 70% of the VP6-7-tetramer 402 positive CD4 T cells produced cytokines (TNF- and/or IFN-), whereas in the 403 control stimulated T cell line only a low number (10%) of tetramer positive cells 404 produced cytokines (Fig. 3C). Similar results were obtained with a VP6-7- T cell 405 line derived from HA-19 volunteer (data not shown). 406 407 CD4 T cells from DR1 healthy adults proliferate and produce cytokines 408 after stimulation with RV peptides. 409 Fresh PBMC from eight DRB1*0101 (HA-02, HA-15, HA-19, HA-23, HA-25, HA- 410 41, HA-51 and HA-52) and two DRB1*0102 healthy volunteers (HA-04 and HA- 411 06) were stimulated with the three RV peptides and evaluated 10h later by 412 intracellular cytokine staining (IL-2, TNF- and IFN-), and 5 days later for 413 proliferation using CFSE staining. Five DRB1*0101 (HA-15, HA-19, HA-29, HA- 414 51 and HA-52) and one DRB1*0102 (HA-04) healthy adults had detectable 415 levels of cytokine producing CD4 T cells (Table 1). CD4 T cells from HA-15 and 18 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 416 HA-19 produced IL-2 after stimulation with VP6-7. CD4 T cells from HA-51 and 417 HA-52 produced TNF- after stimulation with VP6-7. Cells from HA-29 418 responded to VP3-4 stimulation producing TNF- and cells from HA-04 419 responded to VP3-4 producing TNF- and to VP6-7 producing IFN- (Table 1). 420 CD4 T cells of HA-02 proliferated in response to the three RV peptides (NSP2- 421 3, VP3-4, and VP6-7), whereas CD4 T cells obtained from HA-19 and HA-23 422 only proliferated to NSP2-3 stimulus. Thus, although approximately 60% of DR1 423 individuals have peptide-specific T cells detectable by intracellular cytokine 424 staining or proliferation, these responses do not seem to occur simultaneously. 425 426 Antigen experienced CD4 T cells of healthy volunteers stained with VP6-7- 427 tetramer are enriched in the populations expressing the intestinal homing 428 receptors 429 Fresh PBMC from the same eight DRB1*0101 healthy donors described above 430 were stimulated with the three RV peptides in order to generate specific T cell 431 lines. Specific T cell lines for VP6-7 were obtained in all eight individuals and 432 specific T cell lines for NSP2-3 and VP3-4 each in four individuals (Table 2). T 433 cell lines from three volunteers (HA-02, HA-51 and HA-52) were expanded with 434 three peptides; T cell lines from two volunteers (HA-15 and HA-19) were 435 expanded with two peptides and T cell lines from three volunteers only 436 recognized VP6-7 (Table 2). 437 To compare the phenotype of RV- and Flu-specific T cells of the volunteers in 438 which T cell lines were expanded, PBMC were stained with the TRF-, Flu-, and 439 the corresponding RV-peptide tetramers (Figs 4A and 4B). The relative 440 numbers of the CD4 T cells that stained with the tetramers VP6-7 and Flu 19 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 441 (medians of 27/6.0x105 and 45/6.0x105 CD4 T cells, respectively) were higher 442 than those stained with the TRF-tetramer (median of 9/6.0x105 CD4 T cells) 443 (Wilcoxon test p=0.011 and p=0.003, respectively). Most of the CD4 T cells 444 stained with VP6-7- and Flu-tetramers (medians of 63.5% and 67.05%, 445 respectively) showed a phenotype of antigen experienced cells (CD62L 446 CD45RA 447 in the frequencies of these cells (Table 2, Fig. 4C). Antigen experienced CD4 T 448 cells stained with VP6-7-tetramer were enriched in the populations expressing 449 the intestinal homing receptors: 47 CCR9 and 47 CCR9 (Table 2, Figs 450 4B and 4D). In contrast, antigen experienced CD4 T cells stained with Flu- 451 tetramer were enriched in the 47 CCR9 population (Table 2, Figs 4B and 452 4D). 453 RV-tetramer 454 populations expressing the intestinal homing receptors 455 To evaluate if RV vaccination induced the expansion of RV-CD4 T cells of 456 children, PBMC from three HLA-DR1-vaccinated and three HLA-DR1-placebo 457 recipient children, obtained two weeks after the second dose of the RIX4414 458 human attenuated RV vaccine or placebo (Rojas et al., 2007), were stained with 459 the VP6-7- or control TRF-tetramers, and the same panel of markers previously 460 used in adults. Because of the limited amount of sample available from 461 vaccinated children only direct PBMC staining and not T cell line experiments 462 were performed. The vaccinated, but not placebo recipient children, had 463 detectable serum levels of RV-specific IgA after two doses of RV vaccine (data 464 not shown). In vaccinated children and placebo recipient children from 40-71% 465 and 0-8%, respectively, of VP6-7-tetramer+ cells had the phenotype of antigen- +/- + - - and CD62L CD45RA ) and no statistical differences were observed + - + + + - - CD4 T cells in vaccinated children are enriched in the 20 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 466 experienced cells (data not shown). In both groups of children the CD4 T cells 467 stained with the TRF-tetramer only 0-30% of cells had this phenotype (data not 468 shown). In vaccinated children, VP6-7 antigen experienced CD4 T cells were 469 detected at low frequencies (0.001-0.1%). In all 3 cases, most of the antigen 470 experienced CD4 tetramer T cells expressed 47, and in two children (Fig. 471 5A, two top panels), most cells expressed both, 47 and CCR9, homing 472 receptors. In vaccinated children the TRF-tetramer (Fig. 5A, left panels) stained 473 from 4 to 10 times less antigen experienced cells than the VP6-7-tetramer (from 474 <0.0001-0.01%). In placebo recipients (Fig. 5B), VP6-7- and TRF-tetramers 475 detected antigen experienced CD4 T cells at similar low levels (<0.0001- 476 0.003%). + 477 21 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 478 DISCUSSION 479 We have identified a RV CD4 T cell epitope (VP6-7) and shown that HLA-DR1 480 tetramers loaded with this peptide, but not a Flu peptide, expressed intestinal 481 homing receptors (Fig. 4). Moreover, studies with a low number of vaccinated 482 children showed that this type of reagent might be useful to monitor the RV CD4 483 T cell response in vaccine trials (Fig. 5). 484 Of 39 predicted epitopes, three peptides were identified by screening of PBMC 485 from healthy adults by intracellular cytokine staining; all of them also bound to 486 HLA-DRB1*0101 molecules (Figs. 1 and 2). The VP6-7 peptide is probably 487 processed and presented after RV infection, since it was recognized by a 488 rotavirus-T cell line (Fig. 3A). Moreover, peptide specific T cell lines were DR- 489 MHC restricted (Fig. 3B) and VP6-7-tetramers were recognized by cells of 490 vaccinated but not placebo recipient children (Fig. 5), characterizing this peptide 491 as a RV epitope. This epitope overlaps totally with one previously found in mice 492 (Baños et al., 1997) and partially with a VP6 epitope found in Rhesus 493 macaques (Zhao et al., 2008), which suggests that this region is particularly 494 prone to be recognized by CD4 T cells. Although a RV specific class II restricted 495 human T cell epitope had been previously described (Honeyman et al., 2010), 496 our studies are the first to characterize epitope specific CD4 T cells with 497 tetramers. 498 HLA supertypes are defined as a set of HLA (class I or II) associated with 499 largely overlapping peptide/binding repertoires. Recently, three different class II 500 DR supertypes were classified (main DR, DR4 and DRB3) (Greenbaum et al., 501 2011), and all of the healthy adults volunteers for our screening experiments 502 were selected for having the main DR supertype, which includes HLA-DR1 and 22 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 503 many other class II molecules. Contrary to our expectations, only HLA-DR1 504 healthy adults recognized three peptides. However, in one DRB1*0102 505 individual VP6-7 T cell line were generated and their stimulation was inhibited 506 by an anti-DR monoclonal antibody, suggesting that at this level promiscuity for 507 HLA binding exists. The levels of promiscuity of viral epitopes varies between 508 studies from low (Kwok et al., 2008; Nepom, 2012) to moderate (Roti et al., 509 2008). Further studies are necessary to clarify the reasons for these 510 differences. 511 Ex vivo tetramer staining of PBMC from healthy adults showed that CD4 T cells 512 specific for the VP6-7 peptide expressed intestinal homing receptors. This result 513 is in agreement with our previous report, in which we observed that RV-specific 514 IFN- secreting CD4 T cells from adult volunteers preferentially express the 515 intestinal homing receptor α4β7 (Rojas et al., 2003). The present findings 516 extend these results by showing that RV-tetramer 517 (CD62L CD45RA 518 CCR9 and, thus, are prone to home to the small intestine. Compared to total 519 non-antigen specific T cells, VP6-7 specific T cells are enriched approximately 520 10 times in CCR9 expressing cells (Figs 4A and 4B), indicating that this is 521 indeed a unique subset. Further studies are necessary to determine if these 522 circulating dual 47 and CCR9 expressing RV-specific T cells have a unique 523 TCR repertoire. 524 The generation of RRV- or RV peptide-specific T cell lines support the results 525 obtained with ex vivo tetramer staining. Characterization of T cell lines 526 expanded with RRV showed that VP6-7 and NSP2-3 are processed and 527 presented by infected cells (Fig. 3A and data not shown). However, peptide- + - +/- + antigen experienced - and CD62L CD45RA ) CD4 T cells express both 47 and 23 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 528 specific T cell lines were obtained after stimulation of PBMC with all three 529 peptides (Table 1). Moreover, responses of T cell lines specific for the three 530 peptides generated from PBMC obtained from an HLA-DRB1*0101 healthy 531 adult were significantly blocked with an antibody against DR and poorly against 532 an antibody to DQ molecules (Fig. 3B and data not shown), suggesting that the 533 VP6-7 epitope and the two candidate RV-epitopes (NSP2-3 and VP3-4) were 534 presented in the context of HLA-DR molecules. T cell lines expanded with virus 535 lysate preparations might select clonotypes associated with immunodominant 536 peptides over low frequency and/or slowly growing clonotypes (Nastke et al., 537 2012). Thus, in some of the experiments with the RRV-T cell lines the 538 responses to the NSP2-3 and VP3-4 candidate epitopes might have been 539 masked. 540 The simultaneous staining of the majority of cytokine secreting cells from a 541 VP6-7 T cell line with the VP6-7 tetramer (Fig. 3C) supports the specificity of the 542 tetramer staining. Moreover, they show that most cells stained with the tetramer 543 are functional. A correlation between cells staining with the tetramer and those 544 producing cytokines ex vivo is difficult to establish, because of the low or 545 inexistent level of cytokine secreting cells specific for the RV peptides (Table 1). 546 However, the capacity of the tetramers to identify specific T cells ex vivo seems 547 more sensitive than the intracellular cytokine staining and proliferation assays 548 (Table 1) and, thus, more suited to vaccine studies in children. Nonetheless, it is 549 possible that some of the cells stained with the tetramer might be secreting 550 cytokines not evaluated. 551 Staining of cells from vaccinated and placebo recipient children with the VP6-7 552 tetramer showed that VP6-7-specific CD4 T cells could be expanded after RV 24 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 553 vaccination. Although the numbers of cells observed in the vaccinated children 554 were low (Fig. 5A), they were all, as expected, 47 and in two cases they also 555 expressed CCR9. The cells used in the present study had been frozen over 556 seven years (Rojas et al., 2007), and it is expected that studies with fresh cells 557 may permit to obtain more cells to study an increase in the sensitivity of the 558 assay. Further studies are necessary to confirm that CD4 T cells from HLA-DR1 559 vaccinated children recognize the RV epitope we have identified. 560 In conclusion, we have shown that CD4 T cells specific for a RV epitope 561 express intestinal homing receptors, which supports the hypothesis that cells 562 primed in peripheral compartments may constitute a separate lineage (Sallusto 563 and Lanzavecchia, 2009). We also describe MHC tetramers that could be used 564 to analyze RV-specific CD4 T cell responses in vaccine studies. Similar studies 565 in the context of other MHC haplotypes are needed to expand the number of 566 tetramers available to monitor the CD4 T cell response to RV vaccines and, 567 hopefully, develop better correlates of protection. 568 25 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 569 ACKNOWLEDGMENTS 570 This work was financed by grants from Colciencias 1203-408-20481 and the 571 Pontificia Universidad Javeriana (ID5195). LJS and JMCC received support 572 from NIH grant U19-AI057319 and EB funding from R37-AI047822 and RC1- 573 AI087257 also from the NIH, which funded Ab production. Miguel Parra was 574 funded by a scholarship from Colciencias. 575 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 576 References 577 Angel, J., Franco, M.A., Greenberg, H.B., 2012. Rotavirus immune responses 578 and correlates of protection. Curr Opin in Virol 2,419-425. 579 Baños, D.M., Lopez, S., Arias, C.F., Esquivel, F.R., 1997. Identification of a T- 580 helper cell epitope on the rotavirus VP6 protein. J Virol 71, 419-426. 581 Blutt, S.E., Kirkwood, C.D., Parreno, V., Warfield, K.L., Ciarlet, M., Estes, M.K., 582 Bok, K., Bishop, R.F., Conner, M.E., 2003. Rotavirus antigenaemia and 583 viraemia: a common event? Lancet 362, 1445-1449. 584 Blutt, S.E., Miller, A.D., Salmon, S.L., Metzger, D.W., Conner, M.E., 2012. IgA is 585 important for clearance and critical for protection from rotavirus infection. 586 Mucosal Immunol 5, 712-719. 587 Butcher, E.C., Picker, L.J., 1996. Lymphocyte homing and homeostasis. 588 Science 272, 60-66. 589 Calvo-Calle, J.M., Strug, I., Nastke, M.-D., Baker, S.P., Stern, L.J., 2007. 590 Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or 591 infection. PLoS Pathog 3, 1511-1529. 592 Cameron, T.O., Norris, P.J., Patel, A., Moulon, C., Rosenberg, E.S., Mellins, 593 E.D., Wedderburn, L.R., Stern, L.J., 2002. Labeling antigen-specific CD4(+) T 594 cells with class II MHC oligomers. J Immunol Methods 268, 51-69. 595 Chicz, R.M., Urban, R.G., Lane, W.S., Gorga, J.C., Stern, L.J., Vignali, D.A., 596 Strominger, J.L., 1992. Predominant naturally processed peptides bound to 597 HLA-DR1 are derived from MHC-related molecules and are heterogeneous in 598 size. Nature 358, 764-768. 599 Danke, N.A., Kwok, W.W., 2003. HLA class II-restricted CD4+ T cell responses 600 directed against influenza viral antigens postinfluenza vaccination. J Immunol 601 171, 3163-3169. 602 Franco, M.A., Angel, J., Greenberg, H.B., 2006. Immunity and correlates of 603 protection for rotavirus vaccines. Vaccine 24, 2718-2731. 604 Franco, M.A., Greenberg, H.B., 1997. Immunity to rotavirus in T cell deficient 605 mice. Virology 238, 169-179. 606 Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, 607 J.R., Gostick, E., Yu, Z., Carpenito, C., Wang, E., Douek, D.C., Price, D.A., 608 June, C.H., Marincola, F.M., Roederer, M., Restifo, N.P., 2011. A human 27 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 609 memory T cell subset with stem cell-like properties. Nature Medicine 17, 1290- 610 1297. 611 Gilger, M.A., Matson, D.O., Conner, M.E., Rosenblatt, H.M., Finegold, M.J., 612 Estes, M.K., 1992. Extraintestinal rotavirus infections in children with 613 immunodeficiency. J Pediatr 120, 912-917. 614 Glass, R.I., Parashar, U., Patel, M., Tate, J., Jiang, B., Gentsch, J., 2012. The 615 control of rotavirus gastroenteritis in the United States. Trans Am Clin Climatol 616 Assoc 123, 36-53. 617 Greenbaum, J., Sidney, J., Chung, J., Brander, C., Peters, B., Sette, A., 2011. 618 Functional classification of class II human leukocyte antigen (HLA) molecules 619 reveals seven different supertypes and a surprising degree of repertoire sharing 620 across supertypes. Immunogenetics 63, 325-335. 621 Hammer, J., Bono, E., Gallazzi, F., Belunis, C., Nagy, Z., Sinigaglia, F., 1994. 622 Precise prediction of major histocompatibility complex class II-peptide 623 interaction based on peptide side chain scanning. J Exp Med 180, 2353-2358. 624 Honeyman, M.C., Stone, N.L., Falk, B.A., Nepom, G., Harrison, L.C., 2010. 625 Evidence for Molecular Mimicry between Human T Cell Epitopes in Rotavirus 626 and Pancreatic Islet Autoantigens. J Immunol 184, 2204-2210. 627 Jaimes, M.C., Rojas, O.L., González, A.M., Cajiao, I., Charpilienne, A., Pothier, 628 P., Kohli, E., Greenberg, H.B., Franco, M.A., Angel, J., 2002. Frequencies of 629 virus-specific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon 630 after acute natural rotavirus infection in children and adults. J Virol 76, 4741- 631 4749. 632 Kwok, W.W., Yang, J., James, E., Bui, J., Huston, L., Wiesen, A.R., Roti, M., 633 2008. The anthrax vaccine adsorbed vaccine generates protective antigen 634 (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T 635 cells. Infect Immun 76, 4538-4545. 636 Laughlin, E.M., Miller, J.D., James, E., Fillos, D., Ibegbu, C.C., Mittler, R.S., 637 Akondy, R., Kwok, W., Ahmed, R., Nepom, G., 2007. Antigen-specific CD4+ T 638 cells recognize epitopes of protective antigen following vaccination with an 639 anthrax vaccine. Infect Immun 75, 1852-1860. 640 Lissina, A., Ladell, K., Skowera, A., Clement, M., Edwards, E., Seggewiss, R., 641 van den Berg, H.A., Gostick, E., Gallagher, K., Jones, E., Melenhorst, J.J., 642 Godkin, A.J., Peakman, M., Price, D.A., Sewell, A.K., Wooldridge, L., 2009. 28 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 643 Protein kinase inhibitors substantially improve the physical detection of T-cells 644 with peptide-MHC tetramers. J Immunol Methods 340, 11-24. 645 Mavigner, M., Cazabat, M., Dubois, M., L’faqihi, F.-E., Requena, M., Pasquier, 646 C., Klopp, P., Amar, J., Alric, L., Barange, K., Vinel, J.-P., Marchou, B., Massip, 647 P., Izopet, J., Delobel, P., 2012. Altered CD4+ T cell homing to the gut impairs 648 mucosal immune reconstitution in treated HIV-infected individuals. J. Clin. 649 Invest. 122, 62-69. 650 Mesa, M.C., Gutiérrez, L., Duarte-Rey, C., Angel, J., Franco, M.A., 2010. A 651 TGF-beta mediated regulatory mechanism modulates the T cell immune 652 response to rotavirus in adults but not in children. Virology 399, 77-86. 653 Nastke, M.-D., Becerra, A., Yin, L., Dominguez-Amorocho, O., Gibson, L., 654 Stern, L.J., Calvo-Calle, J.M., 2012. Human CD4+ T Cell Response to Human 655 Herpesvirus 6. J Virol 86, 4776-4792. 656 Nepom, G.T., 2012. MHC Class II Tetramers. J Immunol 188, 2477-2482. 657 Parra-López, C., Calvo-Calle, J.M., Cameron, T.O., Vargas, L.E., Salazar, L.M., 658 Patarroyo, M.E., Nardin, E., Stern, L.J., 2006. Major histocompatibility complex 659 and T cell interactions of a universal T cell epitope from Plasmodium falciparum 660 circumsporozoite protein. J Biol Chem 281, 14907-14917. 661 Quah, B.J.C., Parish, C.R., 2010. The use of carboxyfluorescein diacetate 662 succinimidyl ester (CFSE) to monitor lymphocyte proliferation. JoVE. 663 Quah, B.J.C., Warren, H.S., Parish, C.R., 2007. Monitoring lymphocyte 664 proliferation in vitro and in vivo with the intracellular fluorescent dye 665 carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2, 2049-2056. 666 Roche, P.A., Cresswell, P., 1990. High-affinity binding of an influenza 667 hemagglutinin-derived peptide to purified HLA-DR. J Immunol 144, 1849-1856. 668 Rojas, O.L., Caicedo, L., Guzmán, C., Rodríguez, L.-S., Castañeda, J., Uribe, 669 L., Andrade, Y., Pinzón, R., Narváez, C.F., Lozano, J.M., De Vos, B., Franco, 670 M.A., Angel, J., 2007. Evaluation of circulating intestinally committed memory B 671 cells in children vaccinated with attenuated human rotavirus vaccine. Viral 672 Immunol 20, 300-311. 673 Rojas, O.L., González, A.M., González, R., Pérez-Schael, I., Greenberg, H.B., 674 Franco, M.A., Angel, J., 2003. Human rotavirus specific T cells: quantification by 675 ELISPOT and expression of homing receptors on CD4+ T cells. Virology 314, 676 671-679. 29 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 677 Roti, M., Yang, J., Berger, D., Huston, L., James, E.A., Kwok, W.W., 2008. 678 Healthy human subjects have CD4+ T cells directed against H5N1 influenza 679 virus. J Immunol 180, 1758-1768. 680 Rott, L.S., Rosé, J.R., Bass, D., Williams, M.B., Greenberg, H.B., Butcher, E.C., 681 1997. Expression of mucosal homing receptor alpha4beta7 by circulating CD4+ 682 cells with memory for intestinal rotavirus. J Clin Invest 100, 1204-1208. 683 Sallusto, F., Lanzavecchia, A., 2009. Heterogeneity of CD4+ memory T cells: 684 functional modules for tailored immunity. Eur. J. Immunol. 39, 2076-2082. 685 Schuler, M.M., Nastke, M.-D., Stevanovikć, S., 2007. SYFPEITHI: database for 686 searching and T-cell epitope prediction. Methods Mol Biol 409, 75-93. 687 Sigmundsdottir, H., Butcher, E.C., 2008. Environmental cues, dendritic cells and 688 the programming of tissue-selective lymphocyte trafficking. Nat Immunol 9, 981- 689 987. 690 Sturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., 691 Braxenthaler, M., Gallazzi, F., Protti, M.P., Sinigaglia, F., Hammer, J., 1999. 692 Generation of tissue-specific and promiscuous HLA ligand databases using 693 DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17, 555-561. 694 Tate, J.E., Burton, A.H., Boschi-Pinto, C., Steele, A.D., Duque, J., Parashar, 695 U.D., 2012. 2008 estimate of worldwide rotavirus-associated mortality in 696 children younger than 5 years before the introduction of universal rotavirus 697 vaccination programmes: a systematic review and meta-analysis. Lancet Infect 698 Dis 12, 136-141. 699 Vollers, S.S., Stern, L.J., 2008. Class II major histocompatibility complex 700 tetramer staining: progress, problems, and prospects. Immunology 123, 305- 701 313. 702 Waldrop, S.L., Davis, K.A., Maino, V.C., Picker, L.J., 1998. Normal human 703 CD4+ memory T cells display broad heterogeneity in their activation threshold 704 for cytokine synthesis. J Immunol 161, 5284-5295. 705 Waldrop, S.L., Pitcher, C.J., Peterson, D.M., Maino, V.C., Picker, L.J., 1997. 706 Determination of antigen-specific memory/effector CD4+ T cell frequencies by 707 flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism 708 in HIV-associated immunodeficiency. J Clin Invest 99, 1739-1750. 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 709 Zhao, W., Pahar, B., Sestak, K., 2008. Identification of Rotavirus VP6-Specific 710 CD4+ T Cell Epitopes in a G1P[8] Human Rotavirus-Infected Rhesus Macaque. 711 Virology (Auckl) 1, 9-15. 712 713 714 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 715 FIG. LEGENDS 716 Fig. 1. CD4 T cells from one healthy adult recognize peptide pools and 717 individual RV peptides. PBMC from HA-06 were stimulated with peptide pools 718 (A), or individual peptides (B), at a concentration of 1 µg/ml or with different 719 doses (C) during 10h at 37oC and for the last 5h, 1 µg/ml of brefeldin A was 720 added. The frequencies of T cells producing IL-2 and IFN- were evaluated by 721 intracellular cytokine staining. SEB was used as a positive control. Responses 722 were considered positive if the number of IL-2 or IFN--producing CD4 T cells 723 was at least twice that of the DMSO control and above 0.02% (dashed lines). In 724 the experiments shown T cells did not produce IFN- 725 726 Fig. 2. RV peptides bind HLA-DR1 but not HLA-DR4. Competition binding 727 assays for RV (NSP2-3, VP3-4, and VP6-7) and Flu (HA306-318) peptides were 728 performed. The graphics show inhibition of binding of the biotinylated HA 306-318 729 peptide to HLA-DR1 (A) and HLA-DR4 (B) by increasing amounts of RV and flu 730 peptides. Results were analyzed using GraphPad Prism Software version 6. 731 732 Fig. 3. Response of RRV and peptide specific T cell lines. (A) A RRV-T cell 733 line was obtained from a healthy adult (HA-02), then restimulated with RRV, 734 NSP2-3, VP3-4 or VP6-7, and finally stained with the TFR-tetramer or the 735 corresponding RV-tetramers. Left panel: RRV-T cell line restimulated with RRV 736 and stained with the TRF-tetramer. Middle panel: RRV-T cell line restimulated 737 with NSP2-3 peptide and stained with the NSP2-3-tetramer. Right panel: RRV-T 738 cell line restimulated with VP6-7 peptide and stained with the VP6-7-tetramer. 739 This T cell line only recognizes the VP6-7 tetramer. (B). A VP3-4 specific T cell 32 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 740 line from HA-02 was restimulated with DMSO (upper left panel), VP1-4 as a 741 control peptide (upper right panel), or VP3-4 in the absence (upper center 742 panel) or in the presence of an isotype control antibody (lower left panel), LB3.1 743 (lower center panel), or SPV-L3 (lower right panel) antibodies, which are 744 directed against HLA-DR or HLA-DQ molecules, respectively, and the 745 frequencies of cells producing IFN- were evaluated by intracellular cytokine 746 staining. (C) A VP6-7 specific T cell line from HA-02 was stimulated with DMSO 747 (left panels) or VP6-7 (middle and right panels) for 6h at 37oC and stained with 748 the VP6-7-tetramer (upper right and left panels) or TRF-tetramer (upper center 749 panels). Tetramer cells were evaluated by ICS for TNF- and IFN- production 750 (lower panels). Numbers inside all graphics represent percentages of 751 populations. Responses were considered positive if the frecuency of TNF- 752 and/or IFN--producing CD4 T cells was at least twice that of the DMSO control 753 stimulated cells. + 754 + 755 Fig. 4. Phenotype and expression of homing receptors of CD4 tetramer T 756 cells of healthy adults. Fresh PBMC were obtained from HLA-DRB1*0101 757 healthy adults and stained with the Flu-tetramer (left panels), the TRF-tetramer 758 (center panels) or the VP6-7-tetramer (right panels) and antibodies against 759 differentiation markers and intestinal homing receptors. After gating on live CD3 760 T cells, total (A) or tetramer (B) CD4 T cells (top panels) were analyzed to 761 identify antigen experienced T cells CD62L CD45RA 762 (middle panels). The expression of 47 and CCR9 intestinal homing receptors 763 was evaluated in antigen experienced cells (lower panels). Numbers in + - +/- + - and CD62L CD45RA 33 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 764 parenthesis in the lower row dot plots indicate number of events. Results from 765 the eight volunteers for antigen experienced T cells VP6-7-tetramer and Flu- 766 tetramer cells (C) and the expression of intestinal homing receptors (D) are 767 summarized. Statistically significant differences determined with the Wilcoxon 768 test are shown. + + 769 - 770 Fig. 5. Expression of homing receptors on antigen experienced (CD62L 771 CD45RA 772 placebo recipient children. Frozen PBMC from HLA-DRB1*0101 RV 773 vaccinated (A) or placebo recipient children (B) were stained as in Fig. 4 with 774 the TRF-tetramer (left panels) and VP6-7-tetramer (right panels). Dot plots 775 show the expression of 47 and CCR9 intestinal homing receptors of CD4- 776 tetramer 777 parenthesis in the dot plots indicate number of events. +/- + + - and CD62L CD45RA ) CD4 T cells from RV vaccinated and antigen experienced cells from individual children. Numbers in 778 34 Figure Click here to download Figure: figuras 221213.pdf Figure 1 A. 16 14 12 % CD4-IL2+ 10 8 1.5 1.0 SEB DMSO 1 2 3 4 5 6 7 8 NSP1-4 0.0 VP4-5 0.5 Peptide pool number B. 20 18 14 12 10 0.05 0.04 0.03 0.02 NSP2-3 NSP1-5 VP6-7 NSP6-1 VP3-3 VP2-3 VP3-4 DMSO 0.00 SEB 0.01 C. 100 DMSO SEB VP1-1 VP3-4 VP6-7 10 1 % CD4-IL2+ % CD4-IL2+ 16 0.1 0.01 0.0 0.5 Peptide Concentration ug/ml 1.0 Figure 2 % HA-Bio Peptide A. B. 120 120 110 110 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 100 101 102 103 Peptide Concentration (nM) 104 105 0 100 HA peptide VP3-4a VP6-7a NSP2-3a 101 102 103 Peptide Concentration (nM) 104 105 Figure 3 ! C. D. CD4 Tet VP6-7+ CD4 Tet Flu+ % CD4 Tetramer+ cells ! Figure 4 100 100 90 90 80 80 70 70 60 60 50 50 40 40 30 30 20 20 10 10 0 CD4 Tet+Antigen Exp. 0 p=0.0078 p=0.0195 p=0.0039 !4"7+CCR9+ !4"7+ CCR9- !4"7-CCR9- !4"7-CCR9+ Figure 5 B. A. TRF Tetramer VP6-7 Tetramer TRF Tetramer CHP-1 CHV-2 CHP-2 CHV-3 CHP-3 α4β7 α4β7 CHV-1 CCR9 CCR9 VP6-7 Tetramer Tables Table 1. Cytokine production and proliferation of CD4 T cells after stimulation with RV peptides. Healthy Adult Peptide Stimulus HA-02 NSP2-3 - + VP3-4 - + VP6-7 - + NSP2-3 HA-15 HA-19 HA-23 HA-29 HA-41 HA-51 HA-52 HA-04* HA-06* CD4 T cytokine production CD4 T proliferation - - VP3-4 - - VP6-7 IL-2(+) - NSP2-3 - + VP3-4 - - VP6-7 IL-2(+) - NSP2-3 - + VP3-4 - - VP6-7 - - NSP2-3 - - VP3-4 TNF-α(+) - VP6-7 - - NSP2-3 - - VP3-4 - - VP6-7 - - NSP2-3 - N.D. VP3-4 - N.D. VP6-7 TNF-α(+) N.D. NSP2-3 - N.D. VP3-4 - N.D. VP6-7 TNF-α(+) N.D. NSP2-3 - N.D. VP3-4 TNF-α(+) N.D. VP6-7 IFN-γ(+) N.D. NSP2-3 - - VP3-4 - - VP6-7 - - *HLA DRB1 0102 Healthy volunteer. N.D. Not Done. +, at least two-times background values. + Table 2. Ex vivo phenotyping of Tetramer CD4 T cells of DRB1*0101 healthy adults with RV peptide specific TCLs. + Healthy Adult Peptide Tetramer #Tet /6.0x105 + CD4 T cells HA-02 TRF 8 54.5 HA-15 HA-19 HA-23 HA-29 HA-41 HA-51 HA-52 % Antigen % α4β7(+) experienced CCR9(-) # T cells* % α4β7(+) CCR9(+)# % α4β7(-) CCR9(-)# % α4β7(-) CCR9(+)# 33.3 33.3 33.3 0 FLU 36 68.4 42.3 7.69 50 0 NSP2-3 10 53.8 85.7 14.3 0 0 VP3-4 16 61.1 54.5 9.09 27.3 9.09 VP6-7 28 85.7 63.3 26.7 3.33 6.67 TRF 4 0 ¥ ¥ ¥ ¥ FLU 30 83.3 25 12.5 62.5 0 VP3-4 16 23.1 50 0 50 0 VP6-7 22 63.2 63.6 27.3 9.09 0 TRF 10 85.7 8.33 33.3 33.3 25 FLU 24 65.7 21.7 0 78.3 0 NSP2-3 18 48.1 30.8 7.69 61.5 0 VP6-7 26 64.1 28 4 64 4 TRF 8 57.1 25 25 50 0 FLU 60 91.2 32.7 3.85 61.5 1.92 VP6-7 24 87 75 15 10 0 TRF 14 50 0 50 50 0 FLU 48 59.3 6.25 12.5 81.2 0 VP6-7 32 38.9 57.1 14.3 28.6 0 TRF 3 100 33.3 0 66.7 0 FLU 42 97.1 3.03 0 90.9 6.06 VP6-7 25 67.3 50 0 50 0 TRF 98 36.7 44.8 20.7 27.6 6.9 FLU 155 40.6 50.7 15.5 31 2.82 NSP2-3 63 31.7 34.6 30.8 26.9 7.69 VP3-4 54 37.5 45.8 12.5 29.2 8.33 VP6-7 50 41.5 58.8 23.5 5.88 11.8 TRF 72 27.3 66.7 0 33.3 0 FLU 284 25.4 40.3 8.06 50 1.61 NSP2-3 140 17 55.6 11.1 27.8 5.56 VP3-4 149 22.6 35.7 0 57.1 7.14 VP6-7 134 16.5 31.2 25 43.7 0 +/- + - - * Antigen experienced cells are CD62L ,CD45RA and CD62L CD45RA (Figure 4B). # Percentages correspond to antigen experienced cells. ¥, No antigen experienced cells were identified. Supplementary Material (To be Published) Click here to download Supplementary Material (To be Published): Suplementary tables 201213.docx 10. REFERENCES 1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, S WCGR: 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis 2012, 12:136-141. 2. De la Hoz F, Alvis N, Narváez J, Cediel N, Gamboa O, Velandia M: Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. Vaccine 2010, 28:3856-3864. 3. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Gentsch JR, Stockman LJ, Curns AT, Griffin M, Weinberg GA, Hall CB, et al: Active, populationbased surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008, 122:1235-1243. 4. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI: Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572. 5. Who: Meeting of the Strategic Advisory Group of Experts on immunization, October 2009--Conclusions and recommendations. Biologicals 2010, 38:170-177. 6. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD: Realworld impact of rotavirus vaccination. Pediatr Infect Dis J 2011, 30:S1-5. 7. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI: Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 2009, 200 Suppl 1:S39-48. 8. Ward RL, McNeal MM, Steele AD: Why does the world need another rotavirus vaccine? Ther Clin Risk Manag 2008, 4:49-63. 9. Serazin AC, Shackelton LA, Wilson C, Bhan MK: Improving the performance of enteric vaccines in the developing world. Nat Immunol 2010, 11:769-773. 10. Ángel J, Franco MA, Greenberg HB: Rotavirus immune responses and correlates of protection. Curr Opin Virol 2012, 2:419-425. 11. Velázquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL, Glass RI, Pickering LK, Ruiz-Palacios GM: Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000, 182:1602-1609. 69 12. Franco MA, Ángel J, Greenberg HB: Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006, 24:2718-2731. 13. Ángel J, Franco MA, Greenberg HB: Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol 2007, 5:529539. 14. Blutt SE, Conner ME: Rotavirus: to the gut and beyond! Curr Opin Gastroenterol 2007, 23:39-43. 15. Blutt SE, Matson DO, Crawford SE, Staat MA, Azimi P, Bennett BL, Piedra PA, Conner ME: Rotavirus antigenemia in children is associated with viremia. PLoS Med 2007, 4:e121. 16. Jaimes MC, Rojas OL, Kunkel EJ, Lazarus NH, Soler D, Butcher EC, Bass D, Ángel J, Franco MA, Greenberg HB: Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J Virol 2004, 78:10967-10976. 17. Rojas OL, Caicedo L, Guzmán C, Rodríguez LS, Castañeda J, Uribe L, Andrade Y, Pinzón R, Narváez CF, Lozano JM, et al: Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Viral Immunol 2007, 20:300-311. 18. Ward RL, Clark HF, Offit PA: Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 2010, 202 Suppl:S72-79. 19. Grauballe PC, Hjelt K, Krasilnikoff PA, Schiotz PO: ELISA for rotavirusspecific secretory IgA in human sera. Lancet 1981, 2:588-589. 20. Mantis NJ, Rol N, Corthesy B: Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011, 4:603-611. 21. Hjelt K, Grauballe PC, Schiotz PO, Andersen L, Krasilnikoff PA: Intestinal and serum immune response to a naturally acquired rotavirus gastroenteritis in children. J Pediatr Gastroenterol Nutr 1985, 4:60-66. 22. Hjelt K, Grauballe PC, Andersen L, Schiotz PO, Howitz P, Krasilnikoff PA: Antibody response in serum and intestine in children up to six months after a naturally acquired rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1986, 5:74-80. 70 23. Blutt SE, Miller AD, Salmon SL, Metzger DW, Conner ME: IgA is important for clearance and critical for protection from rotavirus infection. Mucosal Immunol 2012, 5:712-719. 24. Franco MA, Greenberg HB: Immunity to rotavirus infection in mice. J Infect Dis 1999, 179 Suppl 3:S466-469. 25. Velázquez F, Matson D, Calva J, Guerrero M, Morrow A, Carter-Campbell S, Glass R, Estes M, Pickering L, Ruiz-Palacios G: Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028. 26. Kapikian AZ, Wyatt RG, Levine MM, Yolken RH, VanKirk DH, Dolin R, Greenberg HB, Chanock RM: Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis 1983, 147:95-106. 27. Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, Walker MC, Schiff GM: Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989, 159:79-88. 28. Marcelin G, Miller AD, Blutt SE, Conner ME: Immune mediators of rotavirus antigenemia clearance in mice. J Virol 2011, 85:7937-7941. 29. Gilger MA, Matson DO, Conner ME, Rosenblatt HM, Finegold MJ, Estes MK: Extraintestinal rotavirus infections in children with immunodeficiency. J Pediatr 1992, 120:912-917. 30. Amanna IJ, Carlson NE, Slifka MK: Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915. 31. Hofer T, Muehlinghaus G, Moser K, Yoshida T, H EM, Hebel K, Hauser A, Hoyer B, E OL, Dorner T, et al: Adaptation of humoral memory. Immunol Rev 2006, 211:295-302. 32. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB: Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81:215-228. 33. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A: Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010, 10:193-200. 71 34. Amanna IJ, Hammarlund E, Lewis MW, Slifka MK: Impact of infection or vaccination on pre-existing serological memory. Hum Immunol 2012, 73:1082-1086. 35. Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202. 36. Traggiai E, Puzone R, Lanzavecchia A: Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003, 21 Suppl 2:S35-37. 37. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmstrom V, Trollmo C: Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74. 38. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581. 39. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146-2154. 40. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC: B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006, 54:3612-3622. 41. Parez N, Garbarg-Chenon A, Fourgeux C, Le Deist F, Servant-Delmas A, Charpilienne A, Cohen J, Schwartz-Cornil I: The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins. J Virol 2004, 78:12489-12496. 42. Kallewaard NL, McKinney BA, Gu Y, Chen A, Prasad BV, Crowe JE, Jr.: Functional maturation of the human antibody response to rotavirus. J Immunol 2008, 180:3980-3989. 43. Rojas OL, Narváez CF, Greenberg HB, Ángel J, Franco MA: Characterization of rotavirus specific B cells and their relation with serological memory. Virology 2008, 380:234-242. 72 44. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE, Jr.: Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. J Immunol 2008, 180:3279-3288. 45. Rodríguez-Bayona B, Ramos-Amaya A, Pérez-Venegas JJ, Rodríguez C, Brieva JA: Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients. Arthritis Res Ther 2010, 12:R108. 46. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE: Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009, 11:R84. 47. Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, Dorner T: Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2002, 46:2160-2171. 48. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I: A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633. 49. Greenberg HB, Estes MK: Rotaviruses: from vaccination. Gastroenterology 2009, 136:1939-1951. 50. Periz J, Celma C, Jing B, Pinkney JN, Roy P, Kapanidis AN: Rotavirus mRNAS are released by transcript-specific channels in the doublelayered viral capsid. Proc Natl Acad Sci U S A 2013, 110:12042-12047. 51. Trask SD, Ogden KM, Patton JT: Interactions among capsid proteins orchestrate rotavirus particle functions. Curr Opin Virol 2012, 2:373-379. 52. Hoshino Y, Kapikian AZ: Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr 2000, 18:5-14. 53. Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Banyai K, Brister JR, Buesa J, Esona MD, Estes MK, Gentsch JR, et al: Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol 2011, 156:1397-1413. 73 pathogenesis to 54. Dennehy PH: Rotavirus vaccines: an overview. Clin Microbiol Rev 2008, 21:198-208. 55. Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Hall CB, Chappell J, Bernstein DI, Curns AT, et al: Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013, 368:11211130. 56. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al: Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 382:209-222. 57. Cáceres DC, Peláez D, Sierra N, Estrada E, Sánchez L: Burden of rotavirus-related disease among children under five, Colombia, 2004. Rev Panam Salud Publica 2006, 20:9-21. 58. Pitzer VE, Viboud C, Simonsen L, Steiner C, Panozzo CA, Alonso WJ, Miller MA, Glass RI, Glasser JW, Parashar UD, Grenfell BT: Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325:290-294. 59. Curns AT, Panozzo CA, Tate JE, Payne DC, Patel MM, Cortese MM, Parashar UD: Remarkable postvaccination spatiotemporal changes in United States rotavirus activity. Pediatr Infect Dis J 2011, 30:S54-55. 60. Patel MM, Glass R, Desai R, Tate JE, Parashar UD: Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis 2012, 12:561-570. 61. Santos N, Hoshino Y: Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005, 15:29-56. 62. Todd S, Page NA, Duncan Steele A, Peenze I, Cunliffe NA: Rotavirus strain types circulating in Africa: Review of studies published during 1997-2006. J Infect Dis 2010, 202 Suppl:S34-42. 63. Ciarlet M, Crawford SE, Cheng E, Blutt SE, Rice DA, Bergelson JM, Estes MK: VLA-2 (alpha2beta1) integrin promotes rotavirus entry into cells but is not necessary for rotavirus attachment. J Virol 2002, 76:11091123. 74 64. Greenberg HB, Estes MK: Fields Virology, Chapter 45: Rotaviruses Sixth Edition edn: Lippincott Williams & Wilkins; 2013. 65. Arnold MM, Sen A, Greenberg HB, Patton JT: The Battle between Rotavirus and Its Host for Control of the Interferon Signaling Pathway. PLoS Pathog 2013, 9:e1003064. 66. Ramig RF: Systemic rotavirus infection. Expert Rev Anti Infect Ther 2007, 5:591-612. 67. Kawashima H, Ishii C, Ioi H, Nishimata S, Kashiwagi Y, Takekuma K: Transaminase in rotavirus gastroenteritis. Pediatr Int 2012, 54:86-88. 68. Akelma AZ, Kutukoglu I, Koksal T, Cizmeci MN, Kanburoglu MK, Catal F, Mete E, Bozkaya D, Namuslu M: Serum transaminase elevation in children with rotavirus gastroenteritis: seven years' experience. Scand J Infect Dis 2013, 45:362-367. 69. Ramig RF: Pathogenesis of intestinal and systemic rotavirus infection. J Virol 2004, 78:10213-10220. 70. Lynch M, Shieh WJ, Tatti K, Gentsch JR, Ferebee-Harris T, Jiang B, Guarner J, Bresee JS, Greenwald M, Cullen S, et al: The pathology of rotavirus-associated deaths, using new molecular diagnostics. Clin Infect Dis 2003, 37:1327-1333. 71. Hagbom M, Sharma S, Lundgren O, Svensson L: Towards a human rotavirus disease model. Curr Opin Virol 2012, 2:408-418. 72. Lundgren O, Peregrin AT, Persson K, Kordasti S, Uhnoo I, Svensson L: Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science 2000, 287:491-495. 73. Hagbom M, Istrate C, Engblom D, Karlsson T, Rodriguez-Diaz J, Buesa J, Taylor JA, Loitto VM, Magnusson KE, Ahlman H, et al: Rotavirus stimulates release of serotonin (5-HT) from human enterochromaffin cells and activates brain structures involved in nausea and vomiting. PLoS Pathog 2011, 7:e1002115. 74. Eiden J, Lederman HM, Vonderfecht S, Yolken R: T-cell-deficient mice display normal recovery from experimental rotavirus infection. J Virol 1986, 57:706-708. 75. Offit PA: Host factors associated with protection against rotavirus disease: the skies are clearing. J Infect Dis 1996, 174 Suppl 1:S59-64. 75 76. Wilkins C, Gale M, Jr.: Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010, 22:41-47. 77. Broquet AH, Hirata Y, McAllister CS, Kagnoff MF: RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium. J Immunol 2011, 186:1618-1626. 78. Sen A, Pruijssers AJ, Dermody TS, García-Sastre A, Greenberg HB: The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J Virol 2011, 85:37173732. 79. Deal EM, Jaimes MC, Crawford SE, Estes MK, Greenberg HB: Rotavirus structural proteins and dsRNA are required for the human primary plasmacytoid dendritic cell IFNalpha response. PLoS Pathog 2010, 6:e1000931. 80. Pott J, Stockinger S, Torow N, Smoczek A, Lindner C, McInerney G, Backhed F, Baumann U, Pabst O, Bleich A, Hornef MW: Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. PLoS Pathog 2012, 8:e1002670. 81. Douagi I, McInerney GM, Hidmark AS, Miriallis V, Johansen K, Svensson L, Karlsson Hedestam GB: Role of interferon regulatory factor 3 in type I interferon responses in rotavirus-infected dendritic cells and fibroblasts. J Virol 2007, 81:2758-2768. 82. Rodríguez LS, Barreto A, Franco MA, Ángel J: Immunomodulators released during rotavirus infection of polarized caco-2 cells. Viral Immunol 2009, 22:163-172. 83. Rodríguez LS, Narváez CF, Rojas OL, Franco MA, Ángel J: Human myeloid dendritic cells treated with supernatants of rotavirus infected Caco-2 cells induce a poor Th1 response. Cell Immunol 2012, 272:154161. 84. Franco MA, Greenberg HB: Immunity to rotavirus in T cell deficient mice. Virology 1997, 238:169-179. 85. Jaimes MC, Rojas OL, González AM, Cajiao I, Charpilienne A, Pothier P, Kohli E, Greenberg HB, Franco MA, Ángel J: Frequencies of virusspecific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol 2002, 76:4741-4749. 76 86. Rojas OL, González AM, González R, Pérez-Schael I, Greenberg HB, Franco MA, Ángel J: Human rotavirus specific T cells: quantification by ELISPOT and expression of homing receptors on CD4+ T cells. Virology 2003, 314:671-679. 87. Jiang B, Snipes-Magaldi L, Dennehy P, Keyserling H, Holman RC, Bresee J, Gentsch J, Glass RI: Cytokines as mediators for or effectors against rotavirus disease in children. Clin Diagn Lab Immunol 2003, 10:995-1001. 88. Totterdell BM, Banatvala JE, Chrystie IL, Ball G, Cubitt WD: Systemic lymphoproliferative responses to rotavirus. J Med Virol 1988, 25:37-44. 89. Yasukawa M, Nakagomi O, Kobayashi Y: Rotavirus induces proliferative response and augments non-specific cytotoxic activity of lymphocytes in humans. Clin Exp Immunol 1990, 80:49-55. 90. Offit PA, Hoffenberg EJ, Pia ES, Panackal PA, Hill NL: Rotavirus-specific helper T cell responses in newborns, infants, children, and adults. J Infect Dis 1992, 165:1107-1111. 91. Offit PA, Hoffenberg EJ, Santos N, Gouvea V: Rotavirus-specific humoral and cellular immune response after primary, symptomatic infection. J Infect Dis 1993, 167:1436-1440. 92. Makela M, Marttila J, Simell O, Ilonen J: Rotavirus-specific T-cell responses in young prospectively followed-up children. Clin Exp Immunol 2004, 137:173-178. 93. Narváez CF, Ángel J, Franco MA: Interaction of rotavirus with human myeloid dendritic cells. J Virol 2005, 79:14526-14535. 94. Mesa MC, Gutiérrez L, Duarte-Rey C, Ángel J, Franco MA: A TGF-beta mediated regulatory mechanism modulates the T cell immune response to rotavirus in adults but not in children. Virology 2010, 399:77-86. 95. Seder RA, Darrah PA, Roederer M: T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258. 96. Miller AD, Blutt SE, Conner ME: FoxP3 regulatory T cells are not important for rotavirus clearance or the early antibody response to rotavirus. Microbes Infect 2013:1-6. 77 97. Kim B, Feng N, Narvaez CF, He XS, Eo SK, Lim CW, Greenberg HB: The influence of CD4+ CD25+ Foxp3+ regulatory T cells on the immune response to rotavirus infection. Vaccine 2008, 26:5601-5611. 98. Nepom GT: MHC class II tetramers. J Immunol 2012, 188:2477-2482. 99. Nastke MD, Becerra A, Yin L, Domínguez-Amorocho O, Gibson L, Stern LJ, Calvo-Calle JM: Human CD4+ T cell response to human herpesvirus 6. J Virol 2012, 86:4776-4792. 100. Williams MB, Rose JR, Rott LS, Franco MA, Greenberg HB, Butcher EC: The memory B cell subset responsible for the secretory IgA response and protective humoral immunity to rotavirus expresses the intestinal homing receptor, alpha4beta7. J Immunol 1998, 161:4227-4235. 101. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272:104-107. 102. Narváez CF, Feng N, Vásquez C, Sen A, Ángel J, Greenberg HB, Franco MA: Human rotavirus-specific IgM Memory B cells have differential cloning efficiencies and switch capacities and play a role in antiviral immunity in vivo. J Virol 2012, 86:10829-10840. 103. Uhnoo I, Dharakul T, Riepenhoff-Talty M, Ogra PL: Immunological aspects of interaction between rotavirus and the intestine in infancy. Immunol Cell Biol 1988, 66 ( Pt 2):135-145. 104. Hjelt K, Grauballe PC, Paerregaard A, Nielsen OH, Krasilnikoff PA: Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J Med Virol 1987, 21:39-47. 105. Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF: Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 1992, 30:1678-1684. 106. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK: Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993, 167:577-583. 107. Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, Jaffar S, Gomara MI, Gray JJ, Brown DW, et al: Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011, 365:337-346. 78 108. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ: More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005, 192 Suppl 1:S36-43. 109. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22. 110. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33. 111. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al: Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298. 112. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, González A, Malespin O, Amador JJ, Umaña J, et al: Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301:2243-2251. 113. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, et al: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623. 114. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, doubleblind, placebo-controlled trial. Lancet 2010, 376:606-614. 115. Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, Cook JR, Koch G, Heaton P: Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007, 11 Suppl 2:S29-35. 116. Ward RL, Kirkwood CD, Sander DS, Smith VE, Shao M, Bean JA, Sack DA, Bernstein DI: Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 8912. J Infect Dis 2006, 194:1729-1736. 79 117. Midthun K, Pang LZ, Flores J, Kapikian AZ: Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates. J Clin Microbiol 1989, 27:2799-2804. 118. Wood D, Group WHOIC: WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005. Vaccine 2005, 23:5478-5487. 119. Cheuvart B, Neuzil, K.M., Steele, D., Cunliffe, N., Madhi, S.A., Karkada, N., Han, H.H., Vinals, C.: Correlates of efficacy for human rotavirus vaccines: Value of anti-rotavirus immunoglobulin A antibody concentrations. 10th International Rotavirus Symposium 2012. 120. Cheuvart B, Neuzil KM, Steele AD, Cunliffe N, Madhi SA, Karkada N, Htay Han H, Vinals C: Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: Analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother 2013, 10. 121. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U: A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013, 208:284-294. 122. Brandtzaeg P: Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009, 70:505-515. 123. Neutra MR, Mantis NJ, Kraehenbuhl JP: Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001, 2:10041009. 124. Rescigno M: Intestinal dendritic cells. Adv Immunol 2010, 107:109-138. 125. Cerutti A: The regulation of IgA class switching. Nat Rev Immunol 2008, 8:421-434. 126. Rimoldi M, Chieppa M, Salucci V, Avogadri F, Sonzogni A, Sampietro GM, Nespoli A, Viale G, Allavena P, Rescigno M: Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005, 6:507-514. 127. Cerutti A, Rescigno M: The biology of intestinal immunoglobulin A responses. Immunity 2008, 28:740-750. 80 128. Pabst O: New concepts in the generation and functions of IgA. Nat Rev Immunol 2012, 12:821-832. 129. Vossenkamper A, Blair PA, Safinia N, Fraser LD, Das L, Sanders TJ, Stagg AJ, Sanderson JD, Taylor K, Chang F, et al: A role for gut-associated lymphoid tissue in shaping the human B cell repertoire. J Exp Med 2013, 210:1665-1674. 130. Asano M, Komiyama K: Polymeric immunoglobulin receptor. J Oral Sci 2011, 53:147-156. 131. Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P: Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J Exp Med 1999, 190:915-922. 132. Brandtzaeg P: Gate-keeper function of the intestinal epithelium. Benef Microbes 2013, 4:67-82. 133. Cao AT, Yao S, Gong B, Elson CO, Cong Y: Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis. J Immunol 2012, 189:4666-4673. 134. Corthesy B, Kraehenbuhl JP: Antibody-mediated protection of mucosal surfaces. Curr Top Microbiol Immunol 1999, 236:93-111. 135. Brandtzaeg P: Secretory IgA: Designed for Anti-Microbial Defense. Front Immunol 2013, 4:222. 136. Corthesy B: Role of secretory IgA in infection and maintenance of homeostasis. Autoimmun Rev 2013, 12:661-665. 137. Brandtzaeg P: Human secretory immunoglobulins. 4. Quantitation of free secretory piece. Acta Pathol Microbiol Scand B Microbiol Immunol 1971, 79:189-203. 138. Hutchings AB, Helander A, Silvey KJ, Chandran K, Lucas WT, Nibert ML, Neutra MR: Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J Virol 2004, 78:947-957. 139. Apter FM, Michetti P, Winner LS, 3rd, Mack JA, Mekalanos JJ, Neutra MR: Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio 81 cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun 1993, 61:5279-5285. 140. Corthesy B: Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol 2013, 4:185. 141. Walter J, Ley R: The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 2011, 65:411-429. 142. Macpherson AJ, Uhr T: Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004, 303:16621665. 143. Diana J, Moura IC, Vaugier C, Gestin A, Tissandie E, Beaudoin L, Corthesy B, Hocini H, Lehuen A, Monteiro RC: Secretory IgA induces tolerogenic dendritic cells through SIGNR1 dampening autoimmunity in mice. J Immunol 2013, 191:2335-2343. 144. Daniels JA, Lederman HM, Maitra A, Montgomery EA: Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol 2007, 31:1800-1812. 145. Brandtzaeg P: Human secretory immunoglobulins. V. Occurrence of secretory piece in human serum. J Immunol 1971, 106:318-323. 146. Kvale D, Brandtzaeg P: An enzyme-linked immunosorbent assay for differential quantitation of secretory immunoglobulins of the A and M isotypes in human serum. J Immunol Methods 1986, 86:107-114. 147. Zhang JJ, Xu LX, Liu G, Zhao MH, Wang HY: The level of serum secretory IgA of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Nephrol Dial Transplant 2008, 23:207-212. 148. Corthesy B: Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J Immunol 2007, 178:27-32. 149. Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC: Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001, 194:417-425. 150. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, Lebreton C, Menard S, Candalh C, Ben-Khalifa K, Dugave C, Tamouza H, van Niel G, et al: 82 Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008, 205:143-154. 151. Hjelt K, Grauballe PC, Nielsen OH, Schiotz PO, Krasilnikoff PA: Rotavirus antibodies in the mother and her breast-fed infant. J Pediatr Gastroenterol Nutr 1985, 4:414-420. 152. Rahman MM, Yamauchi M, Hanada N, Nishikawa K, Morishima T: Local production of rotavirus specific IgA in breast tissue and transfer to neonates. Arch Dis Child 1987, 62:401-405. 153. Corthesy B, Benureau Y, Perrier C, Fourgeux C, Parez N, Greenberg H, Schwartz-Cornil I: Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol 2006, 80:10692-10699. 154. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE: Identification and characterization of circulating human transitional B cells. Blood 2005, 105:4390-4398. 155. Kurosaki T, Aiba Y, Kometani K, Moriyama S, Takahashi Y: Unique properties of memory B cells of different isotypes. Immunol Rev 2010, 237:104-116. 156. Good KL, Avery DT, Tangye SG: Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol 2009, 182:890-901. 157. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF: Expression of BCMA, TACI, and BAFFR in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103:689-694. 158. Tangye SG, Avery DT, Deenick EK, Hodgkin PD: Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol 2003, 170:686694. 159. Lanzavecchia A, Sallusto F: Human B cell memory. Curr Opin Immunol 2009, 21:298-304. 160. Pérez-Andrés M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, Vogt RF, Jr., Marti GE, Rawstron AC, Van Zelm MC, et al: Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010, 78 Suppl 1:S47-60. 83 161. Seifert M, Kuppers R: Molecular footprints of a germinal center derivation of human IgM+(IgD+)CD27+ B cells and the dynamics of memory B cell generation. J Exp Med 2009, 206:2659-2669. 162. Klein U, Rajewsky K, Kuppers R: Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-1689. 163. Chen K, Cerutti A: New insights into the enigma of immunoglobulin D. Immunol Rev 2010, 237:160-179. 164. Fecteau JF, Cote G, Neron S: A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 2006, 177:3728-3736. 165. Odegard VH, Schatz DG: Targeting of somatic hypermutation. Nat Rev Immunol 2006, 6:573-583. 166. Orthwein A, Di Noia JM: Activation induced deaminase: how much and where? Semin Immunol 2012, 24:246-254. 167. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD: Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994, 180:329-339. 168. Maurer D, Fischer GF, Fae I, Majdic O, Stuhlmeier K, Von Jeney N, Holter W, Knapp W: IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J Immunol 1992, 148:3700-3705. 169. Dunn-Walters DK, Isaacson PG, Spencer J: Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells. J Exp Med 1995, 182:559-566. 170. Klein U, Kuppers R, Rajewsky K: Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 1997, 89:1288-1298. 171. Agematsu K, Nagumo H, Yang FC, Nakazawa T, Fukushima K, Ito S, Sugita K, Mori T, Kobata T, Morimoto C, Komiyama A: B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997, 27:2073-2079. 84 172. Agematsu K: Memory B cells and CD27. Histol Histopathol 2000, 15:573576. 173. Richards SJ, Morgan GJ, Hillmen P: Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells. Blood 2000, 96:3522-3528. 174. Himmelmann A, Gautschi O, Nawrath M, Bolliger U, Fehr J, Stahel RA: Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD(+)CD27(+) memory B cells. Br J Haematol 2001, 114:400405. 175. Shi Y, Agematsu K, Ochs HD, Sugane K: Functional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol 2003, 108:128-137. 176. Tangye SG, Good KL: Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 2007, 179:13-19. 177. Fecteau JF, Neron S: CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J Immunol 2003, 171:4621-4629. 178. Weller S, Faili A, García C, Braun MC, Le Deist FF, de Saint Basile GG, Hermine O, Fischer A, Reynaud CA, Weill JC: CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A 2001, 98:1166-1170. 179. Cattoretti G, Buttner M, Shaknovich R, Kremmer E, Alobeid B, Niedobitek G: Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood 2006, 107:3967-3975. 180. Pillai S, Cariappa A: The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 2009, 9:767-777. 181. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, et al: Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004, 104:3647-3654. 182. Cerutti A, Cols M, Puga I: Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013, 13:118-132. 85 183. Rosado MM, Gesualdo F, Marcellini V, Di Sabatino A, Corazza GR, Smacchia MP, Nobili B, Baronci C, Russo L, Rossi F, et al: Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies. Eur J Immunol 2013, 43:2659-2670. 184. Aranburu A, Ceccarelli S, Giorda E, Lasorella R, Ballatore G, Carsetti R: TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol 2010, 185:7293-7301. 185. Weller S, Bonnet M, Delagreverie H, Israel L, Chrabieh M, Marodi L, Rodríguez-Gallego C, Garty BZ, Roifman C, Issekutz AC, et al: IgM+IgD+CD27+ B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients. Blood 2012, 120:4992-5001. 186. Griffin DO, Holodick NE, Rothstein TL: Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 2011, 208:67-80. 187. Pérez-Andrés M, Grosserichter-Wagener C, Teodosio C, van Dongen JJ, Orfao A, van Zelm MC: The nature of circulating CD27+CD43+ B cells. J Exp Med 2011, 208:2565-2566. 188. Descatoire M, Weill JC, Reynaud CA, Weller S: A human equivalent of mouse B-1 cells? J Exp Med 2011, 208:2563-2564. 189. Griffin DO, Holodick NE, Rothstein TL: Human B1 cells are CD3-: A reply to "A human equivalent of mouse B-1 cells?" and "The nature of circulating CD27+CD43+ B cells". J Exp Med 2011, 208:2566-2569. 190. Verbinnen B, Covens K, Moens L, Meyts I, Bossuyt X: Human CD20+CD43+CD27+CD5- B cells generate antibodies to capsular polysaccharides of Streptococcus pneumoniae. J Allergy Clin Immunol 2012, 130:272-275. 191. Covens K, Verbinnen B, Geukens N, Meyts I, Schuit F, Van Lommel L, Jacquemin M, Bossuyt X: Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood 2013, 121:5176-5183. 192. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I: Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009, 45:144-158. 86 193. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, He B, Biermann K, Lange JF, van der Burg M, et al: Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011, 118:2150-2158. 194. Wu YC, Kipling D, Dunn-Walters DK: The relationship between CD27 negative and positive B cell populations in human peripheral blood. Front Immunol 2011, 2:81. 195. Taylor JJ, Pape KA, Jenkins MK: A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 2012, 209:597-606. 196. Schena F, Volpi S, Faliti CE, Penco F, Santi S, Proietti M, Schenk U, Damonte G, Salis A, Bellotti M, et al: Dependence of immunoglobulin class switch recombination in B cells on vesicular release of ATP and CD73 ectonucleotidase activity. Cell Rep 2013, 3:1824-1831. 197. Kaji T, Ishige A, Hikida M, Taka J, Hijikata A, Kubo M, Nagashima T, Takahashi Y, Kurosaki T, Okada M, et al: Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J Exp Med 2012, 209:2079-2097. 198. Kaji T, Furukawa K, Ishige A, Toyokura I, Nomura M, Okada M, Takahashi Y, Shimoda M, Takemori T: Both mutated and unmutated memory B cells accumulate mutations in the course of the secondary response and develop a new antibody repertoire optimally adapted to the secondary stimulus. Int Immunol 2013. 199. Leyendeckers H, Odendahl M, Lohndorf A, Irsch J, Spangfort M, Miltenyi S, Hunzelmann N, Assenmacher M, Radbruch A, Schmitz J: Correlation analysis between frequencies of circulating antigen-specific IgGbearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 1999, 29:1406-1417. 200. Kuklin NA, Rott L, Feng N, Conner ME, Wagner N, Muller W, Greenberg HB: Protective intestinal anti-rotavirus B cell immunity is dependent on alpha 4 beta 7 integrin expression but does not require IgA antibody production. J Immunol 2001, 166:1894-1902. 201. Youngman KR, Franco MA, Kuklin NA, Rott LS, Butcher EC, Greenberg HB: Correlation of tissue distribution, developmental phenotype, and intestinal homing receptor expression of antigen-specific B cells during the murine anti-rotavirus immune response. J Immunol 2002, 168:2173-2181. 87 202. Charpilienne A, Nejmeddine M, Berois M, Parez N, Neumann E, Hewat E, Trugnan G, Cohen J: Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem 2001, 276:29361-29367. 203. Johansen K, Granqvist L, Karlen K, Stintzing G, Uhnoo I, Svensson L: Serum IgA immune response to individual rotavirus polypeptides in young children with rotavirus infection. Arch Virol 1994, 138:247-259. 204. González AM, Jaimes MC, Cajiao I, Rojas OL, Cohen J, Pothier P, Kohli E, Butcher EC, Greenberg HB, Ángel J, Franco MA: Rotavirus-specific B cells induced by recent infection in adults and children predominantly express the intestinal homing receptor alpha4beta7. Virology 2003, 305:93-105. 205. Butcher EC, Williams M, Youngman K, Rott L, Briskin M: Lymphocyte trafficking and regional immunity. Adv Immunol 1999, 72:209-253. 206. Ray PG, Kelkar SD: Measurement of antirotavirus IgM/IgA/IgG responses in the serum samples of Indian children following rotavirus diarrhoea and their mothers. J Med Virol 2004, 72:416-423. 207. Weitkamp JH, Kallewaard N, Kusuhara K, Bures E, Williams JV, LaFleur B, Greenberg HB, Crowe JE, Jr.: Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires. J Immunol 2003, 171:4680-4688. 208. Weitkamp JH, Lafleur BJ, Greenberg HB, Crowe JE, Jr.: Natural evolution of a human virus-specific antibody gene repertoire by somatic hypermutation requires both hotspot-directed and randomly-directed processes. Hum Immunol 2005, 66:666-676. 209. Di Niro R, Mesin L, Raki M, Zheng NY, Lund-Johansen F, Lundin KE, Charpilienne A, Poncet D, Wilson PC, Sollid LM: Rapid generation of rotavirus-specific human monoclonal antibodies from small-intestinal mucosa. J Immunol 2010, 185:5377-5383. 210. Weitkamp JH, Kallewaard NL, Bowen AL, Lafleur BJ, Greenberg HB, Crowe JE, Jr.: VH1-46 is the dominant immunoglobulin heavy chain gene segment in rotavirus-specific memory B cells expressing the intestinal homing receptor alpha4beta7. J Immunol 2005, 174:3454-3460. 211. Benckert J, Schmolka N, Kreschel C, Zoller MJ, Sturm A, Wiedenmann B, Wardemann H: The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest 2011, 121:1946-1955. 88 212. Ahmed R, Gray D: Immunological memory and protective immunity: understanding their relation. Science 1996, 272:54-60. 213. Dunning AJ: A model for immunological correlates of protection. Stat Med 2006, 25:1485-1497. 214. Zhang J, Jacobi AM, Wang T, Berlin R, Volpe BT, Diamond B: Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun 2009, 33:270-274. 215. Uysal H, Nandakumar KS, Kessel C, Haag S, Carlsen S, Burkhardt H, Holmdahl R: Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010, 233:9-33. 216. Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstrom V, Feldmann M, Venables PJ: Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54. 217. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM: Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009, 68:1011-1016. 218. Amanna IJ, Slifka MK: Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138. 219. Tangye SG, Avery DT, Hodgkin PD: A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J Immunol 2003, 170:261-269. 220. Peng H, Wang W, Zhou M, Li R, Pan HF, Ye DQ: Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus. Clin Rheumatol 2013, 32:1255-1266. 221. Peters AL, Stunz LL, Bishop GA: CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009, 21:293-300. 222. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F: Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750. 223. Davidson A, Diamond B: Autoimmune diseases. N Engl J Med 2001, 345:340-350. 89 224. Dorner T, Radbruch A, Burmester GR: B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009, 5:433-441. 225. Sanz I, Lee FE: B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337. 226. Bluml S, McKeever K, Ettinger R, Smolen J, Herbst R: B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013, 15 Suppl 1:S4. 227. Kazkaz H, Isenberg D: Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004, 4:398-402. 228. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during antiCD20 antibody immunotherapy. J Exp Med 2004, 199:1659-1669. 229. Stevenson FK, Stevenson GT: Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood 2012, 119:36593667. 230. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, Aul C: Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002, 69:95-100. 231. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, et al: A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007, 357:545-552. 232. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, et al: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806. 233. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: Bcell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44:1542-1545. 234. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H: Rituximab treatment in 90 patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005, 52:2740-2750. 235. Sailler L: Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks. Clin Rev Allergy Immunol 2008, 34:103-110. 236. Leandro MJ: B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013, 15 Suppl 1:S3. 237. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620. 238. Wu YC, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK: High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 2010, 116:1070-1078. 239. Bende RJ, van Maldegem F, Triesscheijn M, Wormhoudt TA, Guijt R, van Noesel CJ: Germinal centers in human lymph nodes contain reactivated memory B cells. J Exp Med 2007, 204:2655-2665. 240. Seifert M, Steimle-Grauer SA, Goossens T, Hansmann ML, Brauninger A, Kuppers R: A model for the development of human IgD-only B cells: Genotypic analyses suggest their generation in superantigen driven immune responses. Mol Immunol 2009, 46:630-639. 241. Hemming M, Huhti L, Rasanen S, Salminen M, Vesikari T: Rotavirus Antigenemia in Children is Associated with More Severe Clinical Manifestations of Acute Gastroenteritis. Pediatr Infect Dis J 2013. 242. Parashar U, Steele D, Neuzil K, Quadros C, Tharmaphornpilas P, Serhan F, Santosham M, Patel M, Glass R: Progress with rotavirus vaccines: summary of the Tenth International Rotavirus Symposium. Expert Rev Vaccines 2013, 12:113-117. 243. Lopman BA, Payne DC, Tate JE, Patel MM, Cortese MM, Parashar UD: Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Curr Opin Virol 2012, 2:434-442. 244. Babji S, Kang G: Rotavirus vaccination in developing countries. Curr Opin Virol 2012, 2:443-448. 91 245. Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, Gambhir M, Atchison C, Grenfell BT, Edmunds WJ, et al: Understanding reduced rotavirus vaccine efficacy in low socio-economic settings. PLoS One 2012, 7:e41720. 246. Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B: Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005, 24:807-816. 247. Kavanagh O, Zeng XL, Ramani S, Mukhopadhya I, Crawford SE, Kang G, Estes MK: A time-resolved immunoassay to measure serum antibodies to the rotavirus VP6 capsid protein. J Virol Methods 2013, 189:228-231. 248. Vizzi E, Calvino E, Gonzalez R, Perez-Schael I, Ciarlet M, Kang G, Estes MK, Liprandi F, Ludert JE: Evaluation of serum antibody responses against the rotavirus nonstructural protein NSP4 in children after rhesus rotavirus tetravalent vaccination or natural infection. Clin Diagn Lab Immunol 2005, 12:1157-1163. 249. Oortwijn BD, Rastaldi MP, Roos A, Mattinzoli D, Daha MR, van Kooten C: Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007, 22:3191-3195. 250. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, Tamouza H, Jamin A, Bex-Coudrat J, Gestin A, et al: Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 2012, 209:793-806. 251. Abed J, Lebreton C, Champier G, Cuvillier A, Cogne M, Meresse B, Dugave C, Garfa-Traore M, Corthésy B, Cerf-Bensussan N, Heyman M: Abnormal apical-to-basal transport of dietary ovalbumin by secretory IgA stimulates a mucosal Th1 response. Mucosal Immunol 2013. 252. Lebreton C, Menard S, Abed J, Moura IC, Coppo R, Dugave C, Monteiro RC, Fricot A, Traore MG, Griffin M, et al: Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 2012, 143:698-707 e691-694. 253. Eijgenraam JW, Oortwijn BD, Kamerling SW, de Fijter JW, van den Wall Bake AW, Daha MR, van Kooten C: Secretory immunoglobulin A (IgA) responses in IgA nephropathy patients after mucosal immunization, as part of a polymeric IgA response. Clin Exp Immunol 2008, 152:227-232. 92 254. Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, Taki I, Norris JM, Erlich HA, Eisenbarth GS, Rewers M: Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006, 101:2333-2340. 255. Granfors K, Toivanen A: IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis. Ann Rheum Dis 1986, 45:561-565. 256. Nanan R, Heinrich D, Frosch M, Kreth HW: Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory Blymphocytes. Vaccine 2001, 20:498-504. 257. Reynaud CA, Descatoire M, Dogan I, Huetz F, Weller S, Weill JC: IgM memory B cells: a mouse/human paradox. Cell Mol Life Sci 2012, 69:1625-1634. 258. Khaskhely N, Mosakowski J, Thompson RS, Khuder S, Smithson SL, Westerink MA: Phenotypic analysis of pneumococcal polysaccharidespecific B cells. J Immunol 2012, 188:2455-2463. 259. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, Berner R, Peters A, Boehm T, Plebani A, et al: Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003, 197:939-945. 260. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, Tedder TF: Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008, 180:361-371. 261. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ: Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 2008, 105:4802-4807. 262. Huang H, Benoist C, Mathis D: Rituximab specifically depletes shortlived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A 2010, 107:4658-4663. 263. Di Genova G, Roddick J, McNicholl F, Stevenson FK: Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood 2006, 107:2806-2813. 264. Richard K, Pierce SK, Song W: The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J Immunol 2008, 181:1746-1752. 93 265. Shlomchik MJ, Weisel F: Germinal center selection and the development of memory B and plasma cells. Immunol Rev 2012, 247:52-63. 266. Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A: Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011, 7:170-178. 267. Zhang J, Jacobi AM, Mackay M, Aranow C, Wang T, Chinnasamy P, Diamond B: Identification of DNA-reactive B cells in patients with systemic lupus erythematosus. J Immunol Methods 2008, 338:79-84. 268. Mesa MC, Rodríguez LS, Franco MA, Ángel J: Interaction of rotavirus with human peripheral blood mononuclear cells: plasmacytoid dendritic cells play a role in stimulating memory rotavirus specific T cells in vitro. Virology 2007, 366:174-184. 269. Tang B, Gilbert JM, Matsui SM, Greenberg HB: Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis. Virology 1997, 237:89-96. 270. Oortwijn BD, van der Boog PJ, Roos A, van der Geest RN, de Fijter JW, Daha MR, van Kooten C: A pathogenic role for secretory IgA in IgA nephropathy. Kidney Int 2006, 69:1131-1138. 271. Plikaytis BD, Turner SH, Gheesling LL, Carlone GM: Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol 1991, 29:1439-1446. 272. Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthesy B: Secretory component: a new role in secretory IgAmediated immune exclusion in vivo. Immunity 2002, 17:107-115. 273. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588. 274. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725. 275. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, et al: 2012 update of 94 the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639. 276. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, et al: EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008, 67:195-205. 277. Perfetto SP, Chattopadhyay PK, Roederer M: Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004, 4:648-655. 278. Campana D: Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:1083-1098, vii. 95